{ "version": "2.2", "instance": { "gnft-20230630.htm gnft-20230630_d2.htm": { "nsprefix": "gnft", "nsuri": "http://www.genfit.com/20230630", "dts": { "inline": { "local": [ "gnft-20230630.htm", "gnft-20230630_d2.htm" ] }, "schema": { "local": [ "gnft-20230630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "calculationLink": { "local": [ "gnft-20230630_cal.xml" ] }, "definitionLink": { "local": [ "gnft-20230630_def.xml" ] }, "labelLink": { "local": [ "gnft-20230630_lab.xml" ] }, "presentationLink": { "local": [ "gnft-20230630_pre.xml" ] } }, "keyStandard": 236, "keyCustom": 83, "axisStandard": 23, "axisCustom": 2, "memberStandard": 33, "memberCustom": 72, "hidden": { "total": 40, "http://xbrl.sec.gov/dei/2023": 40 }, "contextCount": 361, "entityCount": 1, "segmentCount": 111, "elementCount": 1198, "unitCount": 12, "baseTaxonomies": { "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full": 869, "http://xbrl.sec.gov/dei/2023": 40 }, "report": { "R1": { "role": "http://www.genfit.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": null, "uniqueAnchor": null }, "R2": { "role": "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "longName": "0000003 - Statement - Consolidated Statements of Financial Position", "shortName": "Consolidated Statements of Financial Position", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-2", "name": "ifrs-full:CashAndCashEquivalents", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "gnft:DisclosureOfCashAndCashEquivalentsAndShortTermDepositsClassifiedAsCashAndCashEquivalentsExplanatoryTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "ifrs-full:Inventories", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "unique": true } }, "R3": { "role": "http://www.genfit.com/role/ConsolidatedStatementsofOperations", "longName": "0000004 - Statement - Consolidated Statements of Operations", "shortName": "Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:RevenueFromRenderingOfServices", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:ProfitLossFromOperatingActivities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "unique": true } }, "R4": { "role": "http://www.genfit.com/role/ConsolidatedStatementsofOtherComprehensiveLoss", "longName": "0000005 - Statement - Consolidated Statements of Other Comprehensive Loss", "shortName": "Consolidated Statements of Other Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:ProfitLoss", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "unique": true } }, "R5": { "role": "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows", "longName": "0000006 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:ProfitLoss", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "unique": true } }, "R6": { "role": "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity", "longName": "0000008 - Statement - Consolidated Statements of Changes in Equity", "shortName": "Consolidated Statements of Changes in Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-7", "name": "ifrs-full:NumberOfSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "ifrs-full:NumberOfSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.genfit.com/role/Statementoffinancialpositioncurrentnoncurrent", "longName": "0000009 - Statement - Statement of financial position, current/non-current", "shortName": "Statement of financial position, current/non-current", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": null }, "R8": { "role": "http://www.genfit.com/role/Statementofcashflowsindirectmethod", "longName": "0000010 - Statement - Statement of cash flows, indirect method", "shortName": "Statement of cash flows, indirect method", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": null }, "R9": { "role": "http://www.genfit.com/role/TheCompany", "longName": "0000012 - Disclosure - The Company", "shortName": "The Company", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-4", "name": "gnft:DisclosureOfCompanyInformationExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "gnft:DisclosureOfCompanyInformationExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriod", "longName": "0000013 - Disclosure - Major Events in the Period and Events After the Period", "shortName": "Major Events in the Period and Events After the Period", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-4", "name": "gnft:DisclosureOfMajorEventsInThePeriodAndEventsAfterThePeriodExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": null }, "R11": { "role": "http://www.genfit.com/role/BasisofPresentation", "longName": "0000014 - Disclosure - Basis of Presentation", "shortName": "Basis of Presentation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.genfit.com/role/SummaryofSignificantAccountingPolicies", "longName": "0000015 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-4", "name": "gnft:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": null }, "R13": { "role": "http://www.genfit.com/role/Operatingsegments", "longName": "0000016 - Disclosure - Operating segments", "shortName": "Operating segments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.genfit.com/role/FinancialRisksManagement", "longName": "0000017 - Disclosure - Financial Risks Management", "shortName": "Financial Risks Management", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.genfit.com/role/CashandCashEquivalents", "longName": "0000018 - Disclosure - Cash and Cash Equivalents", "shortName": "Cash and Cash Equivalents", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents", "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents", "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.genfit.com/role/IntangibleAssets", "longName": "0000019 - Disclosure - Intangible Assets", "shortName": "Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.genfit.com/role/TradeandOtherReceivables", "longName": "0000021 - Disclosure - Trade and Other Receivables", "shortName": "Trade and Other Receivables", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.genfit.com/role/OtherFinancialAssets", "longName": "0000022 - Disclosure - Other Financial Assets", "shortName": "Other Financial Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-4", "name": "gnft:DisclosureOfOtherFinancialAssetsExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "gnft:DisclosureOfOtherFinancialAssetsExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.genfit.com/role/OtherAssets", "longName": "0000023 - Disclosure - Other Assets", "shortName": "Other Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:DisclosureOfOtherAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:DisclosureOfOtherAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.genfit.com/role/LoansandBorrowings", "longName": "0000024 - Disclosure - Loans and Borrowings", "shortName": "Loans and Borrowings", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:DisclosureOfBorrowingsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:DisclosureOfBorrowingsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.genfit.com/role/FairValueofFinancialInstruments", "longName": "0000025 - Disclosure - Fair Value of Financial Instruments", "shortName": "Fair Value of Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:DisclosureOfFairValueMeasurementExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:DisclosureOfFairValueMeasurementExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.genfit.com/role/TradeandOtherPayables", "longName": "0000026 - Disclosure - Trade and Other Payables", "shortName": "Trade and Other Payables", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory", "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory", "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.genfit.com/role/DeferredIncomeandRevenue", "longName": "0000027 - Disclosure - Deferred Income and Revenue", "shortName": "Deferred Income and Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:DisclosureOfDeferredIncomeExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:DisclosureOfDeferredIncomeExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.genfit.com/role/Provisions", "longName": "0000028 - Disclosure - Provisions", "shortName": "Provisions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:DisclosureOfProvisionsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:DisclosureOfProvisionsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.genfit.com/role/EmployeeBenefits", "longName": "0000029 - Disclosure - Employee Benefits", "shortName": "Employee Benefits", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-4", "name": "gnft:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": null }, "R26": { "role": "http://www.genfit.com/role/Equity", "longName": "0000030 - Disclosure - Equity", "shortName": "Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c-4", "name": "gnft:DisclosureOfDetailedInformationAboutShareCapitalTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "gnft:DisclosureOfDetailedInformationAboutShareCapitalTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.genfit.com/role/OperatingIncome", "longName": "0000031 - Disclosure - Operating Income", "shortName": "Operating Income", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.genfit.com/role/OperatingExpense", "longName": "0000032 - Disclosure - Operating Expense", "shortName": "Operating Expense", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.genfit.com/role/FinancialIncomeandExpenses", "longName": "0000034 - Disclosure - Financial Income and Expenses", "shortName": "Financial Income and Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "29", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": null }, "R30": { "role": "http://www.genfit.com/role/IncomeTax", "longName": "0000035 - Disclosure - Income Tax", "shortName": "Income Tax", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "30", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": null }, "R31": { "role": "http://www.genfit.com/role/EarningsLossPerShare", "longName": "0000036 - Disclosure - Earnings (Loss) Per Share", "shortName": "Earnings (Loss) Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "31", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.genfit.com/role/LitigationandContingentLiabilities", "longName": "0000037 - Disclosure - Litigation and Contingent Liabilities", "shortName": "Litigation and Contingent Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "32", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.genfit.com/role/RelatedParties", "longName": "0000038 - Disclosure - Related Parties", "shortName": "Related Parties", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "33", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": null }, "R34": { "role": "http://www.genfit.com/role/Commitments", "longName": "0000040 - Disclosure - Commitments", "shortName": "Commitments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "34", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:DisclosureOfCommitmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": null }, "R35": { "role": "http://www.genfit.com/role/Cashflowstatement", "longName": "0000041 - Disclosure - Cash flow statement", "shortName": "Cash flow statement", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "35", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:DisclosureOfCashFlowStatementExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:DisclosureOfCashFlowStatementExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesPolicies", "longName": "0000042 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "36", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "unique": true } }, "R37": { "role": "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesTables", "longName": "0000044 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.genfit.com/role/OperatingsegmentsTables", "longName": "0000045 - Disclosure - Operating segments (Tables)", "shortName": "Operating segments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c-4", "name": "gnft:DisclosureOfNonCurentAssetsByGeographicalAreaTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "gnft:DisclosureOfNonCurentAssetsByGeographicalAreaTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.genfit.com/role/FinancialRisksManagementTables", "longName": "0000046 - Disclosure - Financial Risks Management (Tables)", "shortName": "Financial Risks Management (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "c-4", "name": "gnft:SensitivityOfCashAndCashEquivalentsAndExpensesToVariationOfTenPercentOfTheUSDollarsAgainstTheEuroExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "gnft:SensitivityOfCashAndCashEquivalentsAndExpensesToVariationOfTenPercentOfTheUSDollarsAgainstTheEuroExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.genfit.com/role/CashandCashEquivalentsTables", "longName": "0000047 - Disclosure - Cash and Cash Equivalents (Tables)", "shortName": "Cash and Cash Equivalents (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "c-4", "name": "gnft:DisclosureOfCashAndCashEquivalentsAndShortTermDepositsClassifiedAsCashAndCashEquivalentsExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "gnft:DisclosureOfCashAndCashEquivalentsAndShortTermDepositsClassifiedAsCashAndCashEquivalentsExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.genfit.com/role/IntangibleAssetsTables", "longName": "0000048 - Disclosure - Intangible Assets (Tables)", "shortName": "Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.genfit.com/role/TradeandOtherReceivablesTables", "longName": "0000050 - Disclosure - Trade and Other Receivables (Tables)", "shortName": "Trade and Other Receivables (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "c-4", "name": "gnft:DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "gnft:DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.genfit.com/role/OtherFinancialAssetsTables", "longName": "0000051 - Disclosure - Other Financial Assets (Tables)", "shortName": "Other Financial Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "c-4", "name": "gnft:DisclosureOfDetailedInformationAboutOtherFinancialAssetsExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": null }, "R44": { "role": "http://www.genfit.com/role/LoansandBorrowingsTables", "longName": "0000052 - Disclosure - Loans and Borrowings (Tables)", "shortName": "Loans and Borrowings (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "44", "firstAnchor": { "contextRef": "c-4", "name": "gnft:DisclosureOfDetailedInformationAboutBondsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "gnft:DisclosureOfDetailedInformationAboutBondsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.genfit.com/role/FairValueofFinancialInstrumentsTables", "longName": "0000053 - Disclosure - Fair Value of Financial Instruments (Tables)", "shortName": "Fair Value of Financial Instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "45", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.genfit.com/role/TradeandOtherPayablesTables", "longName": "0000054 - Disclosure - Trade and Other Payables (Tables)", "shortName": "Trade and Other Payables (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "46", "firstAnchor": { "contextRef": "c-4", "name": "gnft:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "gnft:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.genfit.com/role/OtherprovisionscontingentliabilitiesandcontingentassetsTables", "longName": "0000055 - Disclosure - Other provisions, contingent liabilities and contingent assets (Tables)", "shortName": "Other provisions, contingent liabilities and contingent assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "47", "firstAnchor": { "contextRef": "c-4", "name": "gnft:DisclosureOfChangeInProvisionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "gnft:DisclosureOfChangeInProvisionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.genfit.com/role/OperatingIncomeTables", "longName": "0000058 - Disclosure - Operating Income (Tables)", "shortName": "Operating Income (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "48", "firstAnchor": { "contextRef": "c-4", "name": "gnft:DisclosureOfOtherIncomeExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "gnft:DisclosureOfOtherIncomeExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.genfit.com/role/OperatingExpenseTables", "longName": "0000059 - Disclosure - Operating Expense (Tables)", "shortName": "Operating Expense (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "49", "firstAnchor": { "contextRef": "c-4", "name": "gnft:DisclosureOfOperatingExpensesAndOtherOperatingIncomeExpensesExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "gnft:DisclosureOfOperatingExpensesAndOtherOperatingIncomeExpensesExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.genfit.com/role/FinancialIncomeandExpensesTables", "longName": "0000061 - Disclosure - Financial Income and Expenses (Tables)", "shortName": "Financial Income and Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "50", "firstAnchor": { "contextRef": "c-4", "name": "gnft:DisclosureOfDetailedInformationAboutFinancialIncomeAndExpensesExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": null }, "R51": { "role": "http://www.genfit.com/role/EarningsLossPerShareTables", "longName": "0000063 - Disclosure - Earnings (Loss) Per Share (Tables)", "shortName": "Earnings (Loss) Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "51", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:EarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:EarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails", "longName": "0000068 - Disclosure - Major Events in the Period and Events After the Period - Acquisition of the Clinical-stage Biopharmaceutical Company Versantis (Details)", "shortName": "Major Events in the Period and Events After the Period - Acquisition of the Clinical-stage Biopharmaceutical Company Versantis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-2", "name": "ifrs-full:CurrentTaxLiabilitiesCurrent", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": null }, "R53": { "role": "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "longName": "0000069 - Disclosure - Major Events in the Period and Events After the Period - Additional Information (Details)", "shortName": "Major Events in the Period and Events After the Period - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:ExpenseOfRestructuringActivities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-359", "name": "gnft:RevenueRemainingPerformanceObligationVariableConsiderationAmount", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "unique": true } }, "R54": { "role": "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodSignatureofaLicensingandPartnershipAgreementwithIpsenDetails", "longName": "0000070 - Disclosure - Major Events in the Period and Events After the Period - Signature of a Licensing and Partnership Agreement with Ipsen (Details)", "shortName": "Major Events in the Period and Events After the Period - Signature of a Licensing and Partnership Agreement with Ipsen (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-2", "name": "ifrs-full:NumberOfSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "gnft:DisclosureOfDetailedInformationAboutShareCapitalTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": null }, "R55": { "role": "http://www.genfit.com/role/BasisofPresentationDetails", "longName": "0000071 - Disclosure - Basis of Presentation (Details)", "shortName": "Basis of Presentation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-2", "name": "ifrs-full:Equity", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": null }, "R56": { "role": "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofApplicableExchangeRatesUsedtoTranslateFinancialStatementsDetails", "longName": "0000072 - Disclosure - Summary of Significant Accounting Policies - Summary of Applicable Exchange Rates Used to Translate Financial Statements (Details)", "shortName": "Summary of Significant Accounting Policies - Summary of Applicable Exchange Rates Used to Translate Financial Statements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-91", "name": "ifrs-full:AverageForeignExchangeRate", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "gnft:AverageForeignExchangeRateUSDEuro", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "unique": true } }, "R57": { "role": "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails", "longName": "0000073 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)", "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-4", "name": "gnft:NumberOfSegment", "unitRef": "bond", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "gnft:ResearchTaxCreditCarryforwardPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "unique": true } }, "R58": { "role": "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofUSDollaragainstEuroDetails", "longName": "0000076 - Disclosure - Financial Risks Management - Sensitivity of Group's Cash and Cash Equivalents and Expenses to Variation 10% of US Dollar against Euro (Details)", "shortName": "Financial Risks Management - Sensitivity of Group's Cash and Cash Equivalents and Expenses to Variation 10% of US Dollar against Euro (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:CashAndCashEquivalents", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "gnft:DisclosureOfCashAndCashEquivalentsAndShortTermDepositsClassifiedAsCashAndCashEquivalentsExplanatoryTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ifrs-full:AverageForeignExchangeRate", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "unique": true } }, "R59": { "role": "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofCHFagainstEuroDetails", "longName": "0000077 - Disclosure - Financial Risks Management - Sensitivity of Group's Cash and Cash Equivalents and Expenses to Variation 10% of CHF against Euro (Details)", "shortName": "Financial Risks Management - Sensitivity of Group's Cash and Cash Equivalents and Expenses to Variation 10% of CHF against Euro (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-82", "name": "ifrs-full:CashAndCashEquivalents", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "gnft:SensitivityOfCashAndCashEquivalentsAndExpensesToVariationOfTenPercentOfTheCHFAgainstTheEuroExplanatoryTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": null }, "R60": { "role": "http://www.genfit.com/role/FinancialRisksManagementSummaryofCashCashEquivalentsandFinancialAssetsDetails", "longName": "0000078 - Disclosure - Financial Risks Management - Summary of Cash, Cash Equivalents and Financial Assets (Details)", "shortName": "Financial Risks Management - Summary of Cash, Cash Equivalents and Financial Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-2", "name": "ifrs-full:CashAndCashEquivalents", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "gnft:DisclosureOfCashAndCashEquivalentsAndShortTermDepositsClassifiedAsCashAndCashEquivalentsExplanatoryTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-93", "name": "ifrs-full:CashAndCashEquivalents", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "gnft:DisclosureOfCashCashEquivalentsAndFinancialAssetsExplanatoryTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "unique": true } }, "R61": { "role": "http://www.genfit.com/role/FinancialRisksManagementAdditionalInformationDetails", "longName": "0000079 - Disclosure - Financial Risks Management - Additional Information (Details)", "shortName": "Financial Risks Management - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-4", "name": "gnft:FluctuationInCurrencyUSDToEUR", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "1", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "gnft:FluctuationInCurrencyUSDToEUR", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "1", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.genfit.com/role/CashandCashEquivalentsSummaryofCashandCashEquivalentsDetails", "longName": "0000080 - Disclosure - Cash and Cash Equivalents - Summary of Cash and Cash Equivalents (Details)", "shortName": "Cash and Cash Equivalents - Summary of Cash and Cash Equivalents (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-2", "name": "ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "gnft:DisclosureOfCashAndCashEquivalentsAndShortTermDepositsClassifiedAsCashAndCashEquivalentsExplanatoryTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "gnft:DisclosureOfCashAndCashEquivalentsAndShortTermDepositsClassifiedAsCashAndCashEquivalentsExplanatoryTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails", "longName": "0000081 - Disclosure - Intangible Assets - Schedule of Variations in Intangible Assets (Details)", "shortName": "Intangible Assets - Schedule of Variations in Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "unique": true } }, "R64": { "role": "http://www.genfit.com/role/PropertyPlantandEquipmentSummaryofVariationsinTangibleAssetsDetails", "longName": "0000082 - Disclosure - Property, Plant and Equipment - Summary of Variations in Tangible Assets (Details)", "shortName": "Property, Plant and Equipment - Summary of Variations in Tangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:PropertyPlantAndEquipment", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": null }, "R65": { "role": "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails", "longName": "0000083 - Disclosure - Property, Plant and Equipment - Additional Information (Details)", "shortName": "Property, Plant and Equipment - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-2", "name": "ifrs-full:PropertyPlantAndEquipment", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": null }, "R66": { "role": "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails", "longName": "0000084 - Disclosure - Trade and Other Receivables - Summary of Trade and Other Receivables (Details)", "shortName": "Trade and Other Receivables - Summary of Trade and Other Receivables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-2", "name": "ifrs-full:TradeReceivables", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "ifrs-full:TradeReceivables", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.genfit.com/role/TradeandOtherReceivablesAdditionalInformationDetails", "longName": "0000085 - Disclosure - Trade and Other Receivables - Additional Information (Details)", "shortName": "Trade and Other Receivables - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-2", "name": "gnft:ResearchTaxCredit", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "gnft:DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatoryTextBlock", "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": null }, "R68": { "role": "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails", "longName": "0000086 - Disclosure - Other Financial Assets - Summary of Other Financial Assets (Details)", "shortName": "Other Financial Assets - Summary of Other Financial Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-2", "name": "ifrs-full:InvestmentAccountedForUsingEquityMethod", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "ifrs-full:InvestmentAccountedForUsingEquityMethod", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.genfit.com/role/OtherFinancialAssetsAdditionalInformationDetails", "longName": "0000087 - Disclosure - Other Financial Assets - Additional Information (Details)", "shortName": "Other Financial Assets - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-2", "name": "ifrs-full:OtherFinancialAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "gnft:NumberOfSharesRecordedAsDeductionFromEquity", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "unique": true } }, "R70": { "role": "http://www.genfit.com/role/OtherAssetsAdditionalInformationDetails", "longName": "0000088 - Disclosure - Other Assets - Additional Information (Details)", "shortName": "Other Assets - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-2", "name": "ifrs-full:OtherCurrentNonfinancialAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": null }, "R71": { "role": "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "longName": "0000089 - Disclosure - Loans and Borrowings - Additional Information (Details)", "shortName": "Loans and Borrowings - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-26", "name": "gnft:IncreaseDecreaseThroughCapitalIncrease", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-192", "name": "gnft:ConversionOfConvertibleInstrumentsAsAPercentageOfShareCapital", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "unique": true } }, "R72": { "role": "http://www.genfit.com/role/LoansandBorrowingsSummaryofBondsDetails", "longName": "0000090 - Disclosure - Loans and Borrowings - Summary of Bonds (Details)", "shortName": "Loans and Borrowings - Summary of Bonds (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c-184", "name": "gnft:BuybackOfDebtInstrumentsNumberOfInstruments", "unitRef": "oceane", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": null }, "R73": { "role": "http://www.genfit.com/role/LoansandBorrowingsSummaryofConvertibleBondsDetails", "longName": "0000091 - Disclosure - Loans and Borrowings - Summary of Convertible Bonds (Details)", "shortName": "Loans and Borrowings - Summary of Convertible Bonds (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c-2", "name": "ifrs-full:CurrentNotesAndDebenturesIssuedAndCurrentPortionOfNoncurrentNotesAndDebenturesIssued", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "gnft:DisclosureOfConvertibleLoansTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": null }, "R74": { "role": "http://www.genfit.com/role/LoansandBorrowingsSummaryofOtherLoansandBorrowingsDetails", "longName": "0000092 - Disclosure - Loans and Borrowings - Summary of Other Loans and Borrowings (Details)", "shortName": "Loans and Borrowings - Summary of Other Loans and Borrowings (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c-2", "name": "ifrs-full:OtherBorrowings", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": null }, "R75": { "role": "http://www.genfit.com/role/LoansandBorrowingsSummaryofRefundableandConditionalAdvancesDetails", "longName": "0000093 - Disclosure - Loans and Borrowings - Summary of Refundable and Conditional Advances (Details)", "shortName": "Loans and Borrowings - Summary of Refundable and Conditional Advances (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c-2", "name": "gnft:RefundableAndConditionalAdvancesNetBookValue", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "gnft:DisclosureOfDetailedInformationAboutRefundableAndConditionalAdvancesExplanatoryTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": null }, "R76": { "role": "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails", "longName": "0000094 - Disclosure - Loans and Borrowings - Summary of Bank Loans (Details)", "shortName": "Loans and Borrowings - Summary of Bank Loans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c-241", "name": "gnft:FacilitySize", "unitRef": "facilitysize", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-233", "name": "ifrs-full:BorrowingsMaturity", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "unique": true } }, "R77": { "role": "http://www.genfit.com/role/LoansandBorrowingsSummaryofMaturitiesofFinancialLiabilitiesDetails", "longName": "0000095 - Disclosure - Loans and Borrowings - Summary of Maturities of Financial Liabilities (Details)", "shortName": "Loans and Borrowings - Summary of Maturities of Financial Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c-2", "name": "gnft:RefundableAndConditionalAdvances", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": null }, "R78": { "role": "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails", "longName": "0000096 - Disclosure - Fair Value of Financial Instruments - Summary of Financial Assets And Liabilities Carrying Values By Category And Fair Values (Details)", "shortName": "Fair Value of Financial Instruments - Summary of Financial Assets And Liabilities Carrying Values By Category And Fair Values (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "c-2", "name": "ifrs-full:FinancialAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "gnft:DisclosureOfCashCashEquivalentsAndFinancialAssetsExplanatoryTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-334", "name": "ifrs-full:FinancialAssetsAtFairValue", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "unique": true } }, "R79": { "role": "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails", "longName": "0000097 - Disclosure - Trade and Other Payables - Schedule of Trade and Other Payables (Details)", "shortName": "Trade and Other Payables - Schedule of Trade and Other Payables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "c-2", "name": "ifrs-full:TradeAndOtherPayablesToTradeSuppliers", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "gnft:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": null }, "R80": { "role": "http://www.genfit.com/role/TradeandOtherPayablesAdditionalInformationDetails", "longName": "0000098 - Disclosure - Trade and Other Payables - Additional Information (Details)", "shortName": "Trade and Other Payables - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "c-2", "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "gnft:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "gnft:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true } }, "R81": { "role": "http://www.genfit.com/role/DeferredIncomeandRevenueDetails", "longName": "0000099 - Disclosure - Deferred Income and Revenue (Details)", "shortName": "Deferred Income and Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:Revenue", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-348", "name": "ifrs-full:CurrentContractLiabilitiesForPerformanceObligationsSatisfiedOverTime", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "unique": true } }, "R82": { "role": "http://www.genfit.com/role/ProvisionsAdditionalInformationDetails", "longName": "0000100 - Disclosure - Provisions - Additional Information (Details)", "shortName": "Provisions - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "c-2", "name": "gnft:ProvisionForCharges", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "gnft:DisclosureOfChangeInProvisionTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "gnft:ProvisionForCharges", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "gnft:DisclosureOfChangeInProvisionTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true } }, "R83": { "role": "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails", "longName": "0000101 - Disclosure - Employee Benefits - Additional Information (Details)", "shortName": "Employee Benefits - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "c-2", "name": "ifrs-full:CurrentProvisions", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": null }, "R84": { "role": "http://www.genfit.com/role/EquityAdditionalInformationDetails", "longName": "0000105 - Disclosure - Equity - Additional Information (Details)", "shortName": "Equity - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "c-4", "name": "gnft:ShareholderPaidInAndRegisteredPeriodForDoubleVotingRights", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "gnft:ShareholderPaidInAndRegisteredPeriodForDoubleVotingRights", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true } }, "R85": { "role": "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails", "longName": "0000106 - Disclosure - Operating Income - Additional Information (Details)", "shortName": "Operating Income - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:Revenue", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "gnft:RevenueAndOtherIncome", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "unique": true } }, "R86": { "role": "http://www.genfit.com/role/OperatingIncomeScheduleofOtherIncomeDetails", "longName": "0000107 - Disclosure - Operating Income - Schedule of Other Income (Details)", "shortName": "Operating Income - Schedule of Other Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:OtherIncome", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "gnft:DisclosureOfOtherIncomeExplanatoryTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": null }, "R87": { "role": "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails", "longName": "0000108 - Disclosure - Operating Expense - Summary of Operating Expenses and Other Operating Income (Details)", "shortName": "Operating Expense - Summary of Operating Expenses and Other Operating Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:ResearchAndDevelopmentExpense", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "gnft:DisclosureOfOperatingExpensesAndOtherOperatingIncomeExpensesExplanatoryTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "gnft:ReorganizationAndRestructuringExpenses", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "gnft:DisclosureOfOperatingExpensesAndOtherOperatingIncomeExpensesExplanatoryTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "unique": true } }, "R88": { "role": "http://www.genfit.com/role/OperatingExpenseAdditionalInformationDetails", "longName": "0000109 - Disclosure - Operating Expense - Additional Information (Details)", "shortName": "Operating Expense - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:AverageNumberOfEmployees", "unitRef": "employee", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": null }, "R89": { "role": "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails", "longName": "0000110 - Disclosure - Operating Expense - Summary of Employee Expenses and Number of Employees (Details)", "shortName": "Operating Expense - Summary of Employee Expenses and Number of Employees (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:WagesAndSalaries", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfInformationAboutEmployeesExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:WagesAndSalaries", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfInformationAboutEmployeesExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true } }, "R90": { "role": "http://www.genfit.com/role/FinancialIncomeandExpensesSummaryofFinancialIncomeandExpensesDetails", "longName": "0000119 - Disclosure - Financial Income and Expenses - Summary of Financial Income and Expenses (Details)", "shortName": "Financial Income and Expenses - Summary of Financial Income and Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:Revenue", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ifrs-full:RevenueFromInterest", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "gnft:DisclosureOfDetailedInformationAboutFinancialIncomeAndExpensesExplanatoryTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "unique": true } }, "R91": { "role": "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "longName": "0000121 - Disclosure - Income Tax - Breakdown of Deferred Taxes by Nature (Details)", "shortName": "Income Tax - Breakdown of Deferred Taxes by Nature (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "91", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:ProfitLoss", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": null }, "R92": { "role": "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails", "longName": "0000122 - Disclosure - Income Tax - Schedule of Effective Tax Rate (Details)", "shortName": "Income Tax - Schedule of Effective Tax Rate (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "92", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:ProfitLoss", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": null }, "R93": { "role": "http://www.genfit.com/role/IncomeTaxNarrativeDetails", "longName": "0000123 - Disclosure - Income Tax - Narrative (Details)", "shortName": "Income Tax - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "93", "firstAnchor": { "contextRef": "c-2", "name": "ifrs-full:CurrentTaxLiabilitiesCurrent", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": null }, "R94": { "role": "http://www.genfit.com/role/EarningsLossPerShareSummaryofEarningsLossPerShareDetails", "longName": "0000124 - Disclosure - Earnings (Loss) Per Share - Summary of Earnings (Loss) Per Share (Details)", "shortName": "Earnings (Loss) Per Share - Summary of Earnings (Loss) Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "94", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:ProfitLoss", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:WeightedAverageShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:EarningsPerShareExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "unique": true } }, "R95": { "role": "http://www.genfit.com/role/RelatedPartiesAdditionalInformationDetails", "longName": "0000125 - Disclosure - Related Parties - Additional Information (Details)", "shortName": "Related Parties - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "95", "firstAnchor": { "contextRef": "c-356", "name": "gnft:NumberOfCoFoundersHoldShareCapitalOfRelatedParty", "unitRef": "co-founder", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-356", "name": "gnft:NumberOfCoFoundersHoldShareCapitalOfRelatedParty", "unitRef": "co-founder", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true } }, "R96": { "role": "http://www.genfit.com/role/CommitmentsAdditionalInformationDetails", "longName": "0000129 - Disclosure - Commitments - Additional Information (Details)", "shortName": "Commitments - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "96", "firstAnchor": { "contextRef": "c-4", "name": "gnft:RentalPaymentObligationUnderLeaseAgreement", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "gnft:RentalPaymentObligationUnderLeaseAgreement", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true } }, "R97": { "role": "http://www.genfit.com/role/CashflowstatementDetails", "longName": "0000130 - Disclosure - Cash flow statement (Details)", "shortName": "Cash flow statement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "97", "firstAnchor": { "contextRef": "c-4", "name": "gnft:AccruedPropertyPlantAndEquipment", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "gnft:AccruedPropertyPlantAndEquipment", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true, "unique": true } }, "R9999": { "role": "http://xbrl.sec.gov/role/uncategorizedFacts", "longName": "Uncategorized Items - _IXDS", "shortName": "Uncategorized Items - _IXDS", "isDefault": "false", "groupType": "", "subGroupType": "", "menuCat": "Cover", "order": "98", "firstAnchor": { "contextRef": "c-360", "name": "ifrs-full:EstimatedFinancialEffectOfContingentAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "gnft-20230630_d2.htm", "first": true }, "uniqueAnchor": null } }, "tag": { "gnft_BuybackOfDebtInstrumentPerInstrument": { "xbrltype": "perShareItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "BuybackOfDebtInstrumentPerInstrument", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Buyback price per bond", "label": "Buyback Of Debt Instrument Per Instrument", "documentation": "Buyback of debt instrument, per instrument." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Shell Company Report", "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r317" ] }, "gnft_IncreaseDecreaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "IncreaseDecreaseAxis", "presentation": [ "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase Decrease [Axis]", "label": "Increase Decrease [Axis]", "documentation": "Increase Decrease" } } }, "auth_ref": [] }, "gnft_RevenueFromContractsWithCustomersNumberOfPerformanceObligations": { "xbrltype": "integerItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "RevenueFromContractsWithCustomersNumberOfPerformanceObligations", "presentation": [ "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Performance Obligations", "label": "Revenue From Contracts With Customers, Number Of Performance Obligations", "documentation": "Revenue From Contracts With Customers, Number Of Performance Obligations" } } }, "auth_ref": [] }, "gnft_BondsConvertibleOrExchangeableIntoNewOrExistingSharesOCEANEMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "BondsConvertibleOrExchangeableIntoNewOrExistingSharesOCEANEMember", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails", "http://www.genfit.com/role/FinancialIncomeandExpensesAdditionalInformationDetails", "http://www.genfit.com/role/FinancialRisksManagementAdditionalInformationDetails", "http://www.genfit.com/role/IncomeTaxNarrativeDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBondsDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofConvertibleBondsDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OCEANE", "label": "Bonds Convertible Or Exchangeable Into New Or Existing Shares O C E A N E [Member]", "documentation": "Bonds convertible or exchangeable into new or existing shares (OCEANE)." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r320" ] }, "ifrs-full_IncreaseDecreaseThroughOtherChangesNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughOtherChangesNetDefinedBenefitLiabilityAsset", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in net defined benefit liability (asset) resulting from other changes", "label": "Increase (decrease) in net defined benefit liability (asset) resulting from other changes" } }, "en": { "role": { "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r342" ] }, "gnft_DebtUnitFairValue": { "xbrltype": "decimalItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DebtUnitFairValue", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Buyback (EUR per bond)", "label": "Debt Unit Fair Value", "documentation": "Debt Unit Fair Value" } } }, "auth_ref": [] }, "gnft_CEOGrossNegligenceSeverancePayDescription": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "CEOGrossNegligenceSeverancePayDescription", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CEO gross negligence severance pay description", "label": "C E O Gross Negligence Severance Pay Description", "documentation": "CEO gross negligence severance pay description." } } }, "auth_ref": [] }, "gnft_PercentageOfExercisableInstrumentsRelatingToNI4DiagnosticsTechnology": { "xbrltype": "percentItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "PercentageOfExercisableInstrumentsRelatingToNI4DiagnosticsTechnology", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsParentheticalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of exercisable instruments relating to NI4 diagnostics technology", "label": "Percentage Of Exercisable Instruments Relating To N I4 Diagnostics Technology", "documentation": "Percentage of exercisable instruments relating to the ni4 diagnostics technology." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Registration Statement", "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r312" ] }, "gnft_AttendanceAndOtherRemunerationPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "AttendanceAndOtherRemunerationPayment", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersScheduleofDirectorsFeesandOtherCompensationDueandPaidtoNonExecutiveDirectorsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amounts paid", "label": "Attendance And Other Remuneration Payment", "documentation": "Attendance and other remuneration payment." } } }, "auth_ref": [] }, "gnft_DisclosureOfCashCashEquivalentsAndFinancialAssetsExplanatoryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DisclosureOfCashCashEquivalentsAndFinancialAssetsExplanatoryTextBlock", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagementTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Cash, Cash Equivalents and Financial Assets", "label": "Disclosure Of Cash Cash Equivalents And Financial Assets Explanatory [Text Block]", "documentation": "Disclosure of cash, cash equivalents and financial assets." } } }, "auth_ref": [] }, "ifrs-full_CashTransferred": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashTransferred", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash transferred", "label": "Cash transferred" } }, "en": { "role": { "documentation": "The fair value, at acquisition date, of cash transferred as consideration in a business combination. [Refer: Business combinations [member]]" } } }, "auth_ref": [ "r222" ] }, "gnft_BuybackOfDebtInstrumentsNumberOfInstruments": { "xbrltype": "integerItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "BuybackOfDebtInstrumentsNumberOfInstruments", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBondsDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of debt instruments issued", "label": "Buyback Of Debt Instruments, Number Of Instruments", "documentation": "Buyback Of Debt Instruments, Number Of Instruments" } } }, "auth_ref": [] }, "gnft_RefundableAndConditionalAdvancesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "RefundableAndConditionalAdvancesMember", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofOtherLoansandBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Refundable And Conditional Advances [Member]", "label": "Refundable And Conditional Advances [Member]", "documentation": "Refundable and conditional advances." } } }, "auth_ref": [] }, "gnft_DisclosureOfBasisOfPresentationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DisclosureOfBasisOfPresentationAbstract", "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Basis Of Presentation [Abstract]", "label": "Disclosure Of Basis Of Presentation [Abstract]", "documentation": "Disclosure of basis of presentation." } } }, "auth_ref": [] }, "gnft_ShortTermDepositsAndGuarantees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ShortTermDepositsAndGuarantees", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short Term Deposits And Guarantees", "label": "Short Term Deposits And Guarantees", "documentation": "Short-term deposits and guarantees." } } }, "auth_ref": [] }, "gnft_OutstandingLoans": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "OutstandingLoans", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bank loan outstanding", "label": "Outstanding Loans", "documentation": "Outstanding loans." } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) through share-based payment transactions, equity", "label": "Increase (decrease) through share-based payment transactions, equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } } }, "auth_ref": [ "r5" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/OtherFinancialAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Axis]", "label": "Investment, Name [Axis]" } } }, "auth_ref": [] }, "gnft_BorrowingsTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "BorrowingsTerm", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings, Term", "label": "Borrowings, Term", "documentation": "Borrowings, Term" } } }, "auth_ref": [] }, "ifrs-full_CategoriesOfRelatedPartiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CategoriesOfRelatedPartiesAxis", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersAdditionalInformationDetails", "http://www.genfit.com/role/CompensationofCorporateOfficersScheduleofDirectorsFeesandOtherCompensationDueandPaidtoNonExecutiveDirectorsDetails", "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails", "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails", "http://www.genfit.com/role/RelatedPartiesAdditionalInformationDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Categories of related parties [axis]", "label": "Categories of related parties [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r101" ] }, "ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughTransfersAndOtherChangesEquity", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity", "http://www.genfit.com/role/ConsolidatedStatementsofOperations", "http://www.genfit.com/role/EquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) through other changes, equity", "negatedTerseLabel": "Increase (decrease) through other changes, equity", "label": "Increase (decrease) through other changes, equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Equity]" } } }, "auth_ref": [ "r6" ] }, "gnft_BondsAtOriginMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "BondsAtOriginMember", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBondsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bonds at origin", "label": "Bonds At Origin [Member]", "documentation": "Bonds At Origin" } } }, "auth_ref": [] }, "gnft_ExpenseRelatingToResolutionOfDispute": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ExpenseRelatingToResolutionOfDispute", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expense relating to resolution of dispute", "label": "Expense Relating To Resolution Of Dispute", "documentation": "Expense Relating To Resolution Of Dispute" } } }, "auth_ref": [] }, "gnft_TaxEffectOfAdjustmentsWithoutTaxIncidence": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "TaxEffectOfAdjustmentsWithoutTaxIncidence", "crdr": "debit", "calculation": { "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax benefit arising from previously unrecognised tax loss, tax credit or temporary difference of prior period used to reduce current tax expense", "negatedTerseLabel": "Tax Effect Of Adjustments Without Tax Incidence", "label": "Tax Effect Of Adjustments Without Tax Incidence", "documentation": "Tax Effect Of Adjustments Without Tax Incidence" } } }, "auth_ref": [] }, "gnft_DebtInstrumentsFairValuePerInstrument": { "xbrltype": "perShareItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DebtInstrumentsFairValuePerInstrument", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of a new amended OCEANE", "label": "Debt Instruments Fair Value Per Instrument", "documentation": "Debt Instruments, fair value per instrument." } } }, "auth_ref": [] }, "gnft_DepositsAndGuaranteesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DepositsAndGuaranteesMember", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deposits And Guarantees [Member]", "label": "Deposits And Guarantees [Member]", "documentation": "Deposits and guarantees." } } }, "auth_ref": [] }, "gnft_BondsConvertibleOrExchangeableIntoNewOrExistingSharesOCEANE2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "BondsConvertibleOrExchangeableIntoNewOrExistingSharesOCEANE2022Member", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "O C E A N E 2022", "label": "Bonds Convertible Or Exchangeable Into New Or Existing Shares O C E A N E 2022 [Member]", "documentation": "Bonds Convertible Or Exchangeable Into New Or Existing Shares O C E A N E 2022" } } }, "auth_ref": [] }, "gnft_EmployeesAndOfficersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "EmployeesAndOfficersMember", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employees and Officers", "label": "Employees And Officers [Member]", "documentation": "Employees and officers." } } }, "auth_ref": [] }, "gnft_BorrowingsDeadlineDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "BorrowingsDeadlineDomain", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings Deadline [Domain]", "label": "Borrowings Deadline [Domain]", "documentation": "Borrowings Deadline [Domain]" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification", "label": "Increase (decrease) through transfers, intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The increase (decrease) in intangible assets other than goodwill resulting from transfers. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r349" ] }, "ifrs-full_ChangesInEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ChangesInEquity", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in equity", "label": "Increase (decrease) in equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity. [Refer: Equity]" } } }, "auth_ref": [ "r6" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Accounting Standard", "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r317" ] }, "ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughTreasuryShareTransactions", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) through treasury share transactions, equity", "label": "Increase (decrease) through treasury share transactions, equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from treasury share transactions. [Refer: Equity; Treasury shares]" } } }, "auth_ref": [ "r6" ] }, "gnft_FluctuationInCurrencyUSDToEUR": { "xbrltype": "percentItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "FluctuationInCurrencyUSDToEUR", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fluctuation in currency (in percent)", "label": "Fluctuation In Currency, USD to EUR", "documentation": "Fluctuation In Currency, USD to EUR" } } }, "auth_ref": [] }, "gnft_SOC2021Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "SOC2021Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SO C2021 [Member]", "label": "SO C2021 [Member]", "documentation": "SO C2021" } } }, "auth_ref": [] }, "gnft_RawMaterialsAndConsumablesUsedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "RawMaterialsAndConsumablesUsedMember", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials & consumables used", "label": "Raw Materials And Consumables Used [Member]", "documentation": "Raw materials and consumables used." } } }, "auth_ref": [] }, "gnft_DisclosureOfNonCurentAssetsByGeographicalAreaTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DisclosureOfNonCurentAssetsByGeographicalAreaTableTextBlock", "presentation": [ "http://www.genfit.com/role/OperatingsegmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of non-curent assets by geographical area", "label": "Disclosure of non-curent assets by geographical area [Table Text Block]", "documentation": "Disclosure of non-curent assets by geographical area" } } }, "auth_ref": [] }, "dei_ContactPersonnelName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "ContactPersonnelName", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Contact Personnel Name", "label": "Contact Personnel Name", "documentation": "Name of contact personnel" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "presentation": [ "http://www.genfit.com/role/BasisofPresentation" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Disclosure of basis of preparation of financial statements [text block]" } }, "en": { "role": { "documentation": "The disclosure of the basis used for the preparation of the financial statements." } } }, "auth_ref": [ "r323" ] }, "ifrs-full_OtherNoncurrentPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherNoncurrentPayables", "crdr": "credit", "calculation": { "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails": { "parentTag": "ifrs-full_NoncurrentPayables", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.genfit.com/role/TradeandOtherPayablesAdditionalInformationDetails", "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other non-current payables", "terseLabel": "Other non-current payables", "label": "Other non-current payables" } }, "en": { "role": { "documentation": "The amount of non-current payables that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r332" ] }, "gnft_NumberOfDebtInstrumentsIssuedSubjectToConversion": { "xbrltype": "integerItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "NumberOfDebtInstrumentsIssuedSubjectToConversion", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New O C E AN E shares (in shares)", "label": "Number Of Debt Instruments Issued Subject To Conversion", "documentation": "Number Of Debt Instruments Issued Subject To Conversion" } } }, "auth_ref": [] }, "gnft_ObligationsUnderLeasesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ObligationsUnderLeasesMember", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofOtherLoansandBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Obligations Under Leases [Member]", "label": "Obligations Under Leases [Member]", "documentation": "Obligations under leases." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfBorrowingsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfBorrowingsExplanatory", "presentation": [ "http://www.genfit.com/role/LoansandBorrowings" ], "lang": { "en-us": { "role": { "terseLabel": "Loans and Borrowings", "label": "Disclosure of borrowings [text block]" } }, "en": { "role": { "documentation": "The disclosure of borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r323" ] }, "ifrs-full_OtherNoncurrentReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherNoncurrentReceivables", "crdr": "debit", "calculation": { "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails": { "parentTag": "ifrs-full_NoncurrentReceivables", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current receivables", "label": "Other non-current receivables" } }, "en": { "role": { "documentation": "The amount of non-current other receivables. [Refer: Other receivables]" } } }, "auth_ref": [ "r274" ] }, "ifrs-full_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AssetsAbstract", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [abstract]" } } }, "auth_ref": [] }, "gnft_DisclosureOfOtherIncomeTable": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DisclosureOfOtherIncomeTable", "presentation": [ "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails", "http://www.genfit.com/role/OperatingIncomeScheduleofOtherIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Other Income [Table]", "label": "Disclosure Of Other Income [Table]", "documentation": "Disclosure of other income." } } }, "auth_ref": [] }, "gnft_DisclosureOfChangeInProvisionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DisclosureOfChangeInProvisionTextBlock", "presentation": [ "http://www.genfit.com/role/OtherprovisionscontingentliabilitiesandcontingentassetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of change in provision", "label": "Disclosure of change in provision [Text Block]", "documentation": "Disclosure of change in provision" } } }, "auth_ref": [] }, "ifrs-full_ProfitLossFromOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProfitLossFromOperatingActivities", "crdr": "credit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofOperations": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Operating income (loss)", "label": "Profit (loss) from operating activities" } }, "en": { "role": { "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r284", "r337" ] }, "dei_ContactPersonnelFaxNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "ContactPersonnelFaxNumber", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Contact Personnel Fax Number", "label": "Contact Personnel Fax Number", "documentation": "Fax Number of contact personnel." } } }, "auth_ref": [ "r317" ] }, "ifrs-full_Assets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "Total - Assets", "label": "Assets" } }, "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r24", "r178", "r179", "r180", "r254", "r258" ] }, "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfCashAndCashEquivalentsExplanatory", "presentation": [ "http://www.genfit.com/role/CashandCashEquivalents" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Disclosure of cash and cash equivalents [text block]" } }, "en": { "role": { "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r323" ] }, "gnft_InterestRateYearsAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "InterestRateYearsAxis", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Years [Axis]", "label": "Interest Rate Years [Axis]", "documentation": "Interest Rate Years" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfCashFlowStatementExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfCashFlowStatementExplanatory", "presentation": [ "http://www.genfit.com/role/Cashflowstatement" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of cash flow statement [text block]", "label": "Disclosure of cash flow statement [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for a statement of cash flows." } } }, "auth_ref": [ "r151" ] }, "gnft_AccruedExpensesClinicalTrialsBasedOnExchangeRateNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "AccruedExpensesClinicalTrialsBasedOnExchangeRateNet", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/TradeandOtherPayablesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses related to clinical trials based on the exchange rate, net", "label": "Accrued Expenses, Clinical Trials Based On Exchange Rate, Net", "documentation": "Accrued Expenses, Clinical Trials Based On Exchange Rate, Net" } } }, "auth_ref": [] }, "ifrs-full_OtherOperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherOperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofOperations": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0, "order": 4.0 }, "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails": { "parentTag": "gnft_ResearchAndDevelopmentExpenseGeneralAndAdministrativeExpenseMarketingAndMarketAccessExpenseAndOtherOperatingIncomeAndExpense", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofOperations", "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other operating income (expense)", "label": "Other operating income (expense)" } }, "en": { "role": { "documentation": "The amount of operating income (expense) that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r337" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "gnft_PercentageOfDiscountOfBondDebtAtEffectiveInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "PercentageOfDiscountOfBondDebtAtEffectiveInterestRate", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/FinancialIncomeandExpensesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proportion of discount of bond debt at effective interest rate (as a percent)", "label": "Percentage Of Discount Of Bond Debt At Effective Interest Rate", "documentation": "Percentage of discount of bond debt at effective interest rate." } } }, "auth_ref": [] }, "ifrs-full_OtherPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherPayables", "crdr": "credit", "calculation": { "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails": { "parentTag": "ifrs-full_TradeAndOtherPayables", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.genfit.com/role/TradeandOtherPayablesAdditionalInformationDetails", "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other payables", "label": "Other payables" } }, "en": { "role": { "documentation": "Amounts payable that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r332" ] }, "gnft_ThirdYearMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ThirdYearMember", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Third Year", "label": "Third Year [Member]", "documentation": "Third Year" } } }, "auth_ref": [] }, "gnft_CEOCorporateContractNonCompeteIndemnityCompensationEligibilityPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "CEOCorporateContractNonCompeteIndemnityCompensationEligibilityPeriod", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CEO Corporate Contract Non-Compete Indemnity Compensation Eligibility Period", "label": "C E O Corporate Contract Non Compete Indemnity Compensation Eligibility Period", "documentation": "CEO corporate contract non-compete indemnity compensation eligibility period." } } }, "auth_ref": [] }, "gnft_ReversalImpairmentOfRightsRelatedOfLeasedPremisesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ReversalImpairmentOfRightsRelatedOfLeasedPremisesMember", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reversal Impairment Of Rights Related Of Leased Premises", "label": "Reversal Impairment Of Rights Related Of Leased Premises [Member]", "documentation": "Reversal Impairment Of Rights Related Of Leased Premises" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalAbstract", "lang": { "en-us": { "role": { "terseLabel": "Disclosure of classes of share capital [abstract]", "label": "Disclosure of classes of share capital [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Profit (loss) on disposal of investments and changes in value of investments", "label": "Profit (loss) on disposal of investments and changes in value of investments" } }, "en": { "role": { "documentation": "The profit (loss) on disposal of investments and changes in the value of investments. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r105" ] }, "gnft_DescriptionOfExercisePeriodForShareBasedPaymentArrangement": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DescriptionOfExercisePeriodForShareBasedPaymentArrangement", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercice period", "label": "Description Of Exercise Period For Share Based Payment Arrangement", "documentation": "Description of exercise period for share based payment arrangement." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalLineItems", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of classes of share capital [line items]", "label": "Disclosure of classes of share capital [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "gnft_DisclosureOfMajorEventsInThePeriodAndEventsAfterThePeriodExplanatoryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DisclosureOfMajorEventsInThePeriodAndEventsAfterThePeriodExplanatoryTextBlock", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriod", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Major Events in the Period and Events After the Period", "label": "Disclosure Of Major Events In The Period And Events After The Period Explanatory [Text Block]", "documentation": "Disclosure Of Major Events In The Period And Events After The Period." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalTable", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of classes of share capital [table]", "label": "Disclosure of classes of share capital [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to classes of share capital." } } }, "auth_ref": [ "r38" ] }, "gnft_ExchangeRateUSDEuroUsedForVersantisAcquisitionConversion": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ExchangeRateUSDEuroUsedForVersantisAcquisitionConversion", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange Rate USD Euro used for Versantis acquisition conversion", "label": "Exchange Rate USD Euro used for Versantis acquisition conversion", "documentation": "Exchange Rate USD Euro used for Versantis acquisition conversion" } } }, "auth_ref": [] }, "gnft_FinancialInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "FinancialInvestmentsMember", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial investments", "label": "Financial investments [Member]", "documentation": "Financial investments" } } }, "auth_ref": [] }, "ifrs-full_OtherProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherProvisions", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other provisions", "label": "Other provisions" } }, "en": { "role": { "documentation": "The amount of provisions other than provisions for employee benefits. [Refer: Provisions]" } } }, "auth_ref": [ "r33", "r120" ] }, "ifrs-full_DisclosureOfCommitmentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfCommitmentsExplanatory", "presentation": [ "http://www.genfit.com/role/Commitments", "http://www.genfit.com/role/Statementoffinancialpositioncurrentnoncurrent" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments", "label": "Disclosure of commitments [text block]" } }, "en": { "role": { "documentation": "The disclosure of commitments." } } }, "auth_ref": [ "r323" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "gnft_ClassesOfDisclosureAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ClassesOfDisclosureAxis", "presentation": [ "http://www.genfit.com/role/OperatingExpenseAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of Disclosure [Axis]", "label": "Classes of Disclosure [Axis]", "documentation": "Classes of Disclosure" } } }, "auth_ref": [] }, "gnft_DisclosureOfMajorEventsInThePeriodAndEventsAfterThePeriodTable": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DisclosureOfMajorEventsInThePeriodAndEventsAfterThePeriodTable", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodSignatureofaLicensingandPartnershipAgreementwithIpsenDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Major Events In The Period And Events After The Period [Table]", "label": "Disclosure Of Major Events In The Period And Events After The Period [Table]", "documentation": "Disclosure of major events in the period and events after the period." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Country", "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "gnft_ForeignExchangeRatesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ForeignExchangeRatesLineItems", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagementAdditionalInformationDetails", "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofCHFagainstEuroDetails", "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofUSDollaragainstEuroDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Exchange Rates [Line Items]", "label": "Foreign Exchange Rates [Line Items]", "documentation": "Foreign exchange rates line items." } } }, "auth_ref": [] }, "ifrs-full_OtherProvisionsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherProvisionsMember", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/OperatingExpenseAdditionalInformationDetails", "http://www.genfit.com/role/ProvisionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other provisions [member]", "label": "Other provisions [member]" } }, "en": { "role": { "documentation": "This member stands for provisions other than provisions for employee benefits. It also represents the standard value for the 'Classes of other provisions' axis if no other member is used. [Refer: Provisions]" } } }, "auth_ref": [ "r123" ] }, "ifrs-full_PropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails": { "parentTag": "gnft_TotalAcquiredAssets", "weight": 1.0, "order": 2.0 }, "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentSummaryofVariationsinTangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Property, plant and equipment" } }, "en": { "role": { "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]" } } }, "auth_ref": [ "r11", "r73" ] }, "ifrs-full_DisclosureOfContingentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfContingentLiabilitiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Disclosure of contingent liabilities [abstract]", "label": "Disclosure of contingent liabilities [abstract]" } } }, "auth_ref": [] }, "gnft_SOUS20172Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "SOUS20172Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "S O U S20172 [Member]", "label": "S O U S20172 [Member]", "documentation": "SO US 2017-2." } } }, "auth_ref": [] }, "ifrs-full_PropertyPlantAndEquipmentByOperatingLeaseStatusAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PropertyPlantAndEquipmentByOperatingLeaseStatusAxis", "presentation": [ "http://www.genfit.com/role/OperatingExpenseAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment by operating lease status [axis]", "label": "Property, plant and equipment by operating lease status [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r195" ] }, "ifrs-full_OtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherReceivables", "crdr": "debit", "calculation": { "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails": { "parentTag": "ifrs-full_TradeAndOtherReceivables", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesAdditionalInformationDetails", "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other receivables", "label": "Other receivables" } }, "en": { "role": { "documentation": "The amount receivable by the entity that it does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r274" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "ifrs-full_PropertyPlantAndEquipmentNotSubjectToOperatingLeasesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PropertyPlantAndEquipmentNotSubjectToOperatingLeasesMember", "presentation": [ "http://www.genfit.com/role/OperatingExpenseAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment not subject to operating leases [member]", "label": "Property, plant and equipment not subject to operating leases [member]" } }, "en": { "role": { "documentation": "This member stands for property, plant and equipment that is not subject to operating leases. Operating lease is a lease that does not transfer substantially all the risks and rewards incidental to ownership of an underlying asset. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r195" ] }, "ifrs-full_PropertyPlantAndEquipmentByOperatingLeaseStatusMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PropertyPlantAndEquipmentByOperatingLeaseStatusMember", "presentation": [ "http://www.genfit.com/role/OperatingExpenseAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment by operating lease status [member]", "label": "Property, plant and equipment by operating lease status [member]" } }, "en": { "role": { "documentation": "This member stands for all property, plant and equipment when disaggregated by the operating lease status by a lessor. It also represents the standard value for the 'Property, plant and equipment by operating lease status' axis if no other member is used. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r195" ] }, "gnft_BIOTECHAVENIRMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "BIOTECHAVENIRMember", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersScheduleofDirectorsFeesandOtherCompensationDueandPaidtoNonExecutiveDirectorsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "B I O T E C H A V E N I R [Member]", "label": "B I O T E C H A V E N I R [Member]", "documentation": "BIOTECH AVENIR." } } }, "auth_ref": [] }, "gnft_DisclosureOfDetailedInformationAboutBondsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DisclosureOfDetailedInformationAboutBondsTableTextBlock", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Bonds", "label": "Disclosure Of Detailed Information About Bonds [Table Text Block]", "documentation": "Disclosure Of Detailed Information About Bonds" } } }, "auth_ref": [] }, "gnft_AmountsForgoRelatedPartyTransactions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "AmountsForgoRelatedPartyTransactions", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amounts forgo, related party transactions", "label": "Amounts Forgo Related Party Transactions", "documentation": "Amounts forgo related party transactions." } } }, "auth_ref": [] }, "gnft_ExistingTurnoverRateAssumption": { "xbrltype": "percentItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ExistingTurnoverRateAssumption", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Existing turnover rate", "label": "Existing Turnover Rate Assumption", "documentation": "Existing turnover rate assumption." } } }, "auth_ref": [] }, "ifrs-full_PropertyPlantAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PropertyPlantAndEquipmentMember", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/OperatingExpenseAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentSummaryofVariationsinTangibleAssetsDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment [member]", "label": "Property, plant and equipment [member]" } }, "en": { "role": { "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r74", "r285", "r300" ] }, "gnft_DescriptionOfExpectedLifeShareWarrantsGranted": { "xbrltype": "durationItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DescriptionOfExpectedLifeShareWarrantsGranted", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected life", "label": "Description Of Expected Life Share Warrants Granted", "documentation": "Description of expected life share warrants granted." } } }, "auth_ref": [] }, "ifrs-full_CurrentValueAddedTaxPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentValueAddedTaxPayables", "crdr": "credit", "calculation": { "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentPayables", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.genfit.com/role/TradeandOtherPayablesAdditionalInformationDetails", "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current value added tax payables", "label": "Current value added tax payables" } }, "en": { "role": { "documentation": "The amount of current value added tax payables. [Refer: Value added tax payables]" } } }, "auth_ref": [ "r335" ] }, "gnft_EricBACLETMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "EricBACLETMember", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersScheduleofDirectorsFeesandOtherCompensationDueandPaidtoNonExecutiveDirectorsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Eric B A C L E T [Member]", "label": "Eric B A C L E T [Member]", "documentation": "Eric BACLET." } } }, "auth_ref": [] }, "gnft_LicenceFeesAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "LicenceFeesAxis", "presentation": [ "http://www.genfit.com/role/DeferredIncomeandRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "licence fees [Axis]", "label": "licence fees [Axis]", "documentation": "licence fees" } } }, "auth_ref": [] }, "gnft_NumberOfQuarterlyPayments": { "xbrltype": "integerItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "NumberOfQuarterlyPayments", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of quarterly payments,", "label": "Number Of Quarterly Payments", "documentation": "Number Of Quarterly Payments" } } }, "auth_ref": [] }, "gnft_SOUS2017Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "SOUS2017Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "SO US 2017", "label": "S O U S2017 [Member]", "documentation": "SO US 2017." } } }, "auth_ref": [] }, "gnft_SOUS2020Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "SOUS2020Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "S O U S2020 [Member]", "label": "S O U S2020 [Member]", "documentation": "SO US 2020." } } }, "auth_ref": [] }, "gnft_ConditionalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ConditionalMember", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conditional", "label": "Conditional [Member]", "documentation": "Conditional." } } }, "auth_ref": [] }, "gnft_BorrowingsRecognizedUsingEffectiveInterestRateLessThanAYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "BorrowingsRecognizedUsingEffectiveInterestRateLessThanAYear", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings, recognized using effective interest rate, less than a year", "label": "Borrowings, Recognized Using Effective Interest Rate, Less Than A Year", "documentation": "Borrowings, Recognized Using Effective Interest Rate, Less Than A Year" } } }, "auth_ref": [] }, "ifrs-full_CurrentValueAddedTaxReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentValueAddedTaxReceivables", "crdr": "debit", "calculation": { "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current value added tax receivables", "label": "Current value added tax receivables" } }, "en": { "role": { "documentation": "The amount of current value added tax receivables. [Refer: Value added tax receivables]" } } }, "auth_ref": [ "r333" ] }, "gnft_AGAS20161Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "AGAS20161Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "A G A S20161 [Member]", "label": "A G A S20161 [Member]", "documentation": "AGA S 2016-1." } } }, "auth_ref": [] }, "gnft_AGAS2018Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "AGAS2018Member", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "A G A S2018 [Member]", "label": "A G A S2018 [Member]", "documentation": "AGA S 2018." } } }, "auth_ref": [] }, "gnft_EstimatedFairValueOfShareWarrant": { "xbrltype": "perShareItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "EstimatedFairValueOfShareWarrant", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated fair value - valued by expert opinion", "label": "Estimated Fair Value Of Share Warrant", "documentation": "Estimated fair value of share warrant." } } }, "auth_ref": [] }, "gnft_KatherineKALINMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "KatherineKALINMember", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersScheduleofDirectorsFeesandOtherCompensationDueandPaidtoNonExecutiveDirectorsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Katherine K A L I N [Member]", "label": "Katherine K A L I N [Member]", "documentation": "Katherine KALIN." } } }, "auth_ref": [] }, "gnft_FixturesAndFittingsPremisesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "FixturesAndFittingsPremisesMember", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fixtures And Fittings Premises", "label": "Fixtures And Fittings Premises [Member]", "documentation": "Fixtures And Fittings Premises" } } }, "auth_ref": [] }, "gnft_SensitivityOfCashAndCashEquivalentsAndExpensesToVariationOfTenPercentOfTheCHFAgainstTheEuroExplanatoryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "SensitivityOfCashAndCashEquivalentsAndExpensesToVariationOfTenPercentOfTheCHFAgainstTheEuroExplanatoryTextBlock", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagementTables" ], "lang": { "en-us": { "role": { "terseLabel": "Sensitivity Of Cash And Cash Equivalents And Expenses To Variation Of Ten Percent Of The CHF Against The Euro Explanatory", "label": "Sensitivity Of Cash And Cash Equivalents And Expenses To Variation Of Ten Percent Of The CHF Against The Euro Explanatory [Text Block]", "documentation": "Sensitivity Of Cash And Cash Equivalents And Expenses To Variation Of Ten Percent Of The CHF Against The Euro Explanatory" } } }, "auth_ref": [] }, "gnft_ProceedsFromSubscriptionOrExerciseOfShareWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ProceedsFromSubscriptionOrExerciseOfShareWarrants", "crdr": "debit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "+ Proceeds from subscription / exercise of share warrants", "label": "Proceeds From Subscription Or Exercise Of Share Warrants", "documentation": "Proceeds from subscription or exercise of share warrants." } } }, "auth_ref": [] }, "ifrs-full_IntangibleAssetsAndGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IntangibleAssetsAndGoodwill", "crdr": "debit", "calculation": { "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails": { "parentTag": "gnft_TotalAcquiredAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets and goodwill", "label": "Intangible assets and goodwill" } }, "en": { "role": { "documentation": "The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]" } } }, "auth_ref": [ "r332" ] }, "gnft_RelatedPartyTransactionCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "RelatedPartyTransactionCost", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/RelatedPartiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Technology transfers cost", "label": "Related Party Transaction Cost", "documentation": "Related party transaction cost." } } }, "auth_ref": [] }, "gnft_DisclosureOfCashAndCashEquivalentsAndShortTermDepositsClassifiedAsCashAndCashEquivalentsExplanatoryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DisclosureOfCashAndCashEquivalentsAndShortTermDepositsClassifiedAsCashAndCashEquivalentsExplanatoryTextBlock", "presentation": [ "http://www.genfit.com/role/CashandCashEquivalentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Cash and Cash Equivalents", "label": "Disclosure Of Cash And Cash Equivalents And Short Term Deposits Classified As Cash And Cash Equivalents Explanatory [Text Block]", "documentation": "The disclosure of cash and cash equivalents and short-term deposits classified as cash and cash equivalents." } } }, "auth_ref": [] }, "ifrs-full_IntangibleAssetsAndGoodwillMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IntangibleAssetsAndGoodwillMember", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets and goodwill [member]", "label": "Intangible assets and goodwill [member]" } }, "en": { "role": { "documentation": "This member stands for intangible assets and goodwill. It also represents the standard value for the 'Classes of intangible assets and goodwill' axis if no other member is used. [Refer: Goodwill; Intangible assets other than goodwill]" } } }, "auth_ref": [ "r350" ] }, "gnft_IncreaseDecreaseInFinancialAssetsDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "IncreaseDecreaseInFinancialAssetsDomain", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase Decrease In Financial Assets [Domain]", "label": "Increase Decrease In Financial Assets [Domain]", "documentation": "Increase Decrease In Financial Assets [Domain]" } } }, "auth_ref": [] }, "gnft_DateDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DateDomain", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Date [Domain]", "label": "Date [Domain]", "documentation": "Date" } } }, "auth_ref": [] }, "gnft_TransitionServicesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "TransitionServicesAgreementMember", "presentation": [ "http://www.genfit.com/role/DeferredIncomeandRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transition Services Agreement", "label": "Transition Services Agreement [Member]", "documentation": "Transition Services Agreement" } } }, "auth_ref": [] }, "gnft_SOUS2016Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "SOUS2016Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "SO US 2016", "label": "S O U S2016 [Member]", "documentation": "SO US 2016." } } }, "auth_ref": [] }, "gnft_SOD2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "SOD2022Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SO D 2022", "label": "SO D 2022 [Member]", "documentation": "SO D 2022" } } }, "auth_ref": [] }, "gnft_PSEMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "PSEMember", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PSE", "label": "PSE [Member]", "documentation": "PSE" } } }, "auth_ref": [] }, "gnft_BNPPGEMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "BNPPGEMember", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BNP PGE [Member]", "label": "BNP PGE [Member]", "documentation": "BNP PGE" } } }, "auth_ref": [] }, "gnft_JeanFrancoisMouneyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "JeanFrancoisMouneyMember", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersScheduleofDirectorsFeesandOtherCompensationDueandPaidtoNonExecutiveDirectorsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Jean Francois MOUNEY", "label": "Jean Francois Mouney [Member]", "documentation": "Jean Francois Mouney." } } }, "auth_ref": [] }, "ifrs-full_DateOfAcquisition2013": { "xbrltype": "dateItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DateOfAcquisition2013", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Date of acquisition", "label": "Date of acquisition" } }, "en": { "role": { "documentation": "The date on which the acquirer obtains control of the acquiree in a business combination." } } }, "auth_ref": [ "r219" ] }, "gnft_RevenueByDestination": { "xbrltype": "pureItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "RevenueByDestination", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue By Destination", "label": "Revenue By Destination", "documentation": "Revenue By Destination" } } }, "auth_ref": [] }, "gnft_SO20171Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "SO20171Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "S O20171 [Member]", "label": "S O20171 [Member]", "documentation": "SO 2017-1." } } }, "auth_ref": [] }, "gnft_DevelopmentAndCommercialMilestonesPaymentsRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DevelopmentAndCommercialMilestonesPaymentsRecognized", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Development and commercial milestones payments recognized", "label": "Development And Commercial Milestones Payments Recognized", "documentation": "Development and commercial milestones payments recognized." } } }, "auth_ref": [] }, "ifrs-full_IntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IntangibleAssetsOtherThanGoodwill", "crdr": "debit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "periodStartLabel": "Intangible assets other than goodwill Period Start", "periodEndLabel": "Intangible assets other than goodwill Period End", "label": "Intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]" } } }, "auth_ref": [ "r12", "r131" ] }, "gnft_AdditionsOtherThanThroughBusinessCombinationsAndAccumulatedDepreciationAndImpairmentPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "AdditionsOtherThanThroughBusinessCombinationsAndAccumulatedDepreciationAndImpairmentPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentSummaryofVariationsinTangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase", "label": "Additions Other Than Through Business Combinations And Accumulated Depreciation And Impairment Property Plant And Equipment", "documentation": "Additions other than through business combinations and accumulated depreciation and impairment property plant and equipment." } } }, "auth_ref": [] }, "gnft_PercentageOfExercisableInstrumentsRelatingToTheNIS4DiagnosticTechnology": { "xbrltype": "percentItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "PercentageOfExercisableInstrumentsRelatingToTheNIS4DiagnosticTechnology", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsParentheticalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of exercisable instruments relating to the NIS4 diagnostic technology", "label": "Percentage Of Exercisable Instruments Relating To The NIS4 Diagnostic Technology", "documentation": "Percentage Of Exercisable Instruments Relating To The NIS4 Diagnostic Technology" } } }, "auth_ref": [] }, "gnft_TenPercentIncreaseDecreaseInUSDollarVsEuroMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "TenPercentIncreaseDecreaseInUSDollarVsEuroMember", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofUSDollaragainstEuroDetails" ], "lang": { "en-us": { "role": { "terseLabel": "10% Increase (Decrease) in US Dollar vs Euro", "label": "Ten Percent Increase Decrease In U S Dollar Vs Euro [Member]", "documentation": "Ten percent increase decrease in US dollar vs Euro." } } }, "auth_ref": [] }, "gnft_LeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "LeaseMember", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofMaturitiesofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease", "label": "Lease [Member]", "documentation": "Lease." } } }, "auth_ref": [] }, "gnft_OtherInvestmentsNumberOfUnitsOfSubscription": { "xbrltype": "integerItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "OtherInvestmentsNumberOfUnitsOfSubscription", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Investments - Number of units of subscription", "label": "Other Investments - Number of units of subscription", "documentation": "Other Investments - Number of units of subscription" } } }, "auth_ref": [] }, "gnft_BeneficiariesInShareBasedPaymentArrangements": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "BeneficiariesInShareBasedPaymentArrangements", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Beneficiaries", "label": "Beneficiaries In Share Based Payment Arrangements", "documentation": "Beneficiaries in share based payment arrangements." } } }, "auth_ref": [] }, "gnft_AccruedExpensesClinicalTrials": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "AccruedExpensesClinicalTrials", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/TradeandOtherPayablesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses related to clinical trials", "label": "Accrued Expenses, Clinical Trials", "documentation": "Accrued Expenses, Clinical Trials" } } }, "auth_ref": [] }, "gnft_BorrowingsOptionalRepaymentTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "BorrowingsOptionalRepaymentTerm", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings, Optional Repayment Term", "label": "Borrowings, Optional Repayment Term", "documentation": "Borrowings, Optional Repayment Term" } } }, "auth_ref": [] }, "gnft_LiquidityContractVariations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "LiquidityContractVariations", "crdr": "debit", "calculation": { "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails": { "parentTag": "gnft_FinancialAssetsVariations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liquidity Contract, Variations", "label": "Liquidity Contract, Variations", "documentation": "Liquidity Contract, Variations" } } }, "auth_ref": [] }, "ifrs-full_IntangibleAssetsOtherThanGoodwillMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IntangibleAssetsOtherThanGoodwillMember", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets other than goodwill [member]", "label": "Intangible assets other than goodwill [member]" } }, "en": { "role": { "documentation": "This member stands for intangible assets other than goodwill. It also represents the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r132", "r285", "r300" ] }, "gnft_AccruedExpensesClinicalTrialsRequiringConversionToEuros": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "AccruedExpensesClinicalTrialsRequiringConversionToEuros", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/TradeandOtherPayablesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses related to clinical trials requiring conversion to euros", "label": "Accrued Expenses, Clinical Trials Requiring Conversion To Euros", "documentation": "Accrued Expenses, Clinical Trials Requiring Conversion To Euros" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOtherAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfOtherAssetsExplanatory", "presentation": [ "http://www.genfit.com/role/OtherAssets" ], "lang": { "en-us": { "role": { "terseLabel": "Other Assets", "label": "Disclosure of other assets [text block]" } }, "en": { "role": { "documentation": "The disclosure of other assets. [Refer: Other assets]" } } }, "auth_ref": [ "r323" ] }, "gnft_IssuePricePerShareWarrants": { "xbrltype": "perShareItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "IssuePricePerShareWarrants", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issue price (in EUR per share)", "label": "Issue Price Per Share Warrants", "documentation": "The issue price per share warrants." } } }, "auth_ref": [] }, "gnft_ApprenticesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ApprenticesMember", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Apprentices [Member]", "label": "Apprentices [Member]", "documentation": "Apprentices." } } }, "auth_ref": [] }, "gnft_RepaymentsOfLoansAndBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "RepaymentsOfLoansAndBorrowings", "crdr": "credit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "- Repayments of loans and borrowings", "label": "Repayments Of Loans And Borrowings", "documentation": "The net value between the amount repaid on loans and the accrued interest on loans." } } }, "auth_ref": [] }, "gnft_EmployeesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "EmployeesMember", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Employees", "label": "Employees [Member]", "documentation": "Employees." } } }, "auth_ref": [] }, "gnft_StateGuaranteedLoansNumberOfFinancialInstitutions": { "xbrltype": "integerItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "StateGuaranteedLoansNumberOfFinancialInstitutions", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of French banks", "label": "State-Guaranteed Loans, Number of Financial Institutions", "documentation": "State-Guaranteed Loans, Number of Financial Institutions" } } }, "auth_ref": [] }, "gnft_DisclosureOfRevenueBreakdownByGeographicalAreaTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DisclosureOfRevenueBreakdownByGeographicalAreaTableTextBlock", "presentation": [ "http://www.genfit.com/role/OperatingsegmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of revenue breakdown by geographical area", "label": "Disclosure of revenue breakdown by geographical area [Table Text Block]", "documentation": "Disclosure of revenue breakdown by geographical area" } } }, "auth_ref": [] }, "gnft_CAPTECHSanteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "CAPTECHSanteMember", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CAPTECH Sant\u00e9", "label": "CAPTECH Sant\u00e9 [Member]", "documentation": "CAPTECH Sant\u00e9" } } }, "auth_ref": [] }, "gnft_NatureOfReveivablesDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "NatureOfReveivablesDomain", "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nature of reveivables [Domain]", "label": "Nature of reveivables [Domain]", "documentation": "Nature of reveivables [Domain]" } } }, "auth_ref": [] }, "ifrs-full_DebtInstrumentsHeld": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DebtInstrumentsHeld", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying value debt at amortized cost", "label": "Debt instruments held" } }, "en": { "role": { "documentation": "The amount of instruments representing indebtedness held by the entity." } } }, "auth_ref": [ "r332" ] }, "gnft_TotalPurchasePrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "TotalPurchasePrice", "crdr": "debit", "calculation": { "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total purchase price", "label": "Total purchase price", "documentation": "Total purchase price" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfOtherOperatingIncomeExplanatory", "presentation": [ "http://www.genfit.com/role/OperatingIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Income", "label": "Disclosure of other operating income [text block]" } }, "en": { "role": { "documentation": "The disclosure of other operating income. [Refer: Other operating income (expense)]" } } }, "auth_ref": [ "r323" ] }, "gnft_ConditionalAdvancesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ConditionalAdvancesMember", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conditional Advances [Member]", "label": "Conditional Advances [Member]", "documentation": "Conditional advances." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory", "presentation": [ "http://www.genfit.com/role/LitigationandContingentLiabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation and Contingent Liabilities", "label": "Disclosure of other provisions, contingent liabilities and contingent assets [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for other provisions, contingent liabilities and contingent assets." } } }, "auth_ref": [ "r126" ] }, "gnft_DisclosureOfMajorEventsInThePeriodAndEventsAfterThePeriodLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DisclosureOfMajorEventsInThePeriodAndEventsAfterThePeriodLineItems", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodSignatureofaLicensingandPartnershipAgreementwithIpsenDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Major Events In The Period And Events After The Period [Line Items]", "label": "Disclosure Of Major Events In The Period And Events After The Period [Line Items]", "documentation": "Disclosure of major events in the period and events after the period." } } }, "auth_ref": [] }, "gnft_SO20172Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "SO20172Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "S O20172 [Member]", "label": "S O20172 [Member]", "documentation": "SO 2017-2." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOtherProvisionsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfOtherProvisionsLineItems", "presentation": [ "http://www.genfit.com/role/ProvisionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of other provisions [line items]", "label": "Disclosure of other provisions [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "gnft_NonRefundableUpfrontPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "NonRefundableUpfrontPayment", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-refundable upfront payment", "label": "Non Refundable Upfront Payment", "documentation": "Non-refundable upfront payment." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOtherProvisionsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfOtherProvisionsTable", "presentation": [ "http://www.genfit.com/role/ProvisionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of other provisions [table]", "label": "Disclosure of other provisions [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to other provisions." } } }, "auth_ref": [ "r123" ] }, "gnft_RestructuringAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "RestructuringAxis", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring [Axis]", "label": "Restructuring [Axis]", "documentation": "Restructuring" } } }, "auth_ref": [] }, "gnft_ClassesOfDisclosureDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ClassesOfDisclosureDomain", "presentation": [ "http://www.genfit.com/role/OperatingExpenseAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of Disclosure [Domain]", "label": "Classes of Disclosure [Domain]", "documentation": "Classes of Disclosure [Domain]" } } }, "auth_ref": [] }, "gnft_InsurancePremiumToBePaid": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "InsurancePremiumToBePaid", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Insurance premium to be paid", "label": "Insurance Premium To Be Paid", "documentation": "Insurance premium to be paid" } } }, "auth_ref": [] }, "gnft_DisclosureOfOtherIncomeExplanatoryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DisclosureOfOtherIncomeExplanatoryTextBlock", "presentation": [ "http://www.genfit.com/role/OperatingIncomeTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Income", "label": "Disclosure Of Other Income Explanatory [Text Block]", "documentation": "Disclosure of other income." } } }, "auth_ref": [] }, "ifrs-full_DebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DebtSecurities", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails", "http://www.genfit.com/role/FinancialRisksManagementAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate nominal amount", "label": "Debt instruments issued" } }, "en": { "role": { "documentation": "The amount of instruments issued by the entity that represent indebtedness." } } }, "auth_ref": [ "r332" ] }, "gnft_TaxableProfitWithinOneYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "TaxableProfitWithinOneYear", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/IncomeTaxNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Taxable profit limit", "label": "Taxable Profit Within One Year", "documentation": "Taxable profit within one year." } } }, "auth_ref": [] }, "gnft_DisclosureOfCompanyInformationExplanatoryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DisclosureOfCompanyInformationExplanatoryTextBlock", "presentation": [ "http://www.genfit.com/role/TheCompany" ], "lang": { "en-us": { "role": { "terseLabel": "The Company", "label": "Disclosure Of Company Information Explanatory [Text Block]", "documentation": "Disclosure of company information." } } }, "auth_ref": [] }, "ifrs-full_MaterialIncomeAndExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "MaterialIncomeAndExpenseAbstract", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses and other operating income (expenses)", "label": "Material income and expense [abstract]" } } }, "auth_ref": [] }, "gnft_SharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "SharesAuthorized", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares authorized (in shares)", "label": "Shares Authorized", "documentation": "Shares authorized." } } }, "auth_ref": [] }, "gnft_ResearchTaxCreditDisputeReversal": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ResearchTaxCreditDisputeReversal", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/ProvisionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research tax credit dispute reversal", "label": "Research Tax Credit Dispute Reversal", "documentation": "Research tax credit dispute reversal." } } }, "auth_ref": [] }, "ifrs-full_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.genfit.com/role/FinancialIncomeandExpensesSummaryofFinancialIncomeandExpensesDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/FinancialIncomeandExpensesSummaryofFinancialIncomeandExpensesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest expense", "negatedLabel": "Interest expense", "label": "Interest expense" } }, "en": { "role": { "documentation": "The amount of expense arising from interest." } } }, "auth_ref": [ "r174", "r252", "r259" ] }, "gnft_FemaleMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "FemaleMember", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Female [Member]", "label": "Female [Member]", "documentation": "Female." } } }, "auth_ref": [] }, "gnft_DepreciationAndAmortizationAndImpairmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DepreciationAndAmortizationAndImpairmentMember", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation, amortization & impairment charges", "label": "Depreciation And Amortization And Impairment [Member]", "documentation": "Depreciation, and amortization, and impairment." } } }, "auth_ref": [] }, "gnft_KeyManagementPersonnelCompensationFixedCompensationFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "KeyManagementPersonnelCompensationFixedCompensationFees", "crdr": "debit", "calculation": { "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Key management personnel compensation, fixed compensation fees", "label": "Key management personnel compensation, fixed compensation fees", "documentation": "Key management personnel compensation, fixed compensation fees" } } }, "auth_ref": [] }, "gnft_ImpactAttributableToDeferredTaxLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ImpactAttributableToDeferredTaxLiabilitiesMember", "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impact Attributable To Deferred Tax Liabilities [Member]", "label": "Impact Attributable To Deferred Tax Liabilities [Member]", "documentation": "Impact Attributable To Deferred Tax Liabilities" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about property, plant and equipment [abstract]", "label": "Disclosure of detailed information about property, plant and equipment [abstract]" } } }, "auth_ref": [] }, "gnft_AGADMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "AGADMember", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA D", "label": "A G A D [Member]", "documentation": "AGAD." } } }, "auth_ref": [] }, "gnft_ExistingHeadquartersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ExistingHeadquartersMember", "presentation": [ "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Existing Headquarters", "label": "Existing Headquarters [Member]", "documentation": "Existing headquarters." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://www.genfit.com/role/PropertyPlantandEquipment" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment", "label": "Disclosure of property, plant and equipment [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for property, plant and equipment." } } }, "auth_ref": [ "r77" ] }, "gnft_OtherInvestmentsSubscriptionPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "OtherInvestmentsSubscriptionPaid", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Investments - Subscription paid", "label": "Other Investments - Subscription paid", "documentation": "Other Investments - Subscription paid" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentSummaryofVariationsinTangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about property, plant and equipment [line items]", "label": "Disclosure of detailed information about property, plant and equipment [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "gnft_SO2019USMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "SO2019USMember", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "S O2019 U S [Member]", "label": "S O2019 U S [Member]", "documentation": "SO 2019 - US." } } }, "auth_ref": [] }, "gnft_NumberOfSharesVested": { "xbrltype": "sharesItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "NumberOfSharesVested", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares vested (in shares)", "label": "Number Of Shares Vested", "documentation": "Number of shares vested." } } }, "auth_ref": [] }, "gnft_DenominatedInUSDMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DenominatedInUSDMember", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofUSDollaragainstEuroDetails", "http://www.genfit.com/role/FinancialRisksManagementSummaryofCashCashEquivalentsandFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Denominated in USD", "label": "Denominated In U S D [Member]", "documentation": "denominated in USD." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentSummaryofVariationsinTangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about property, plant and equipment [table]", "label": "Disclosure of detailed information about property, plant and equipment [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of property, plant and equipment." } } }, "auth_ref": [ "r74" ] }, "ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InterestExpenseIncomeNetDefinedBenefitLiabilityAsset", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails", "http://www.genfit.com/role/EmployeeBenefitsSummaryofChangesinPresentValueofDefinedBenefitObligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)", "label": "Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)" } }, "en": { "role": { "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from the passage of time. [Refer: Interest expense; Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r81" ] }, "gnft_SO20161Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "SO20161Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "S O20161 [Member]", "label": "S O20161 [Member]", "documentation": "SO 2016-1." } } }, "auth_ref": [] }, "gnft_NatureOfReveivablesAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "NatureOfReveivablesAxis", "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nature of reveivables [Axis]", "label": "Nature of reveivables [Axis]", "documentation": "Nature of reveivables" } } }, "auth_ref": [] }, "gnft_CashAndCashEquivalentsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "CashAndCashEquivalentsTable", "presentation": [ "http://www.genfit.com/role/CashandCashEquivalentsSummaryofCashandCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash And Cash Equivalents [Table]", "label": "Cash And Cash Equivalents [Table]", "documentation": "Cash and cash equivalents." } } }, "auth_ref": [] }, "gnft_AdjustmentsForProfitSharingGrantedToEmployees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "AdjustmentsForProfitSharingGrantedToEmployees", "crdr": "debit", "calculation": { "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.genfit.com/role/OperatingExpenseAdditionalInformationDetails", "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Profit sharing granted to employees", "negatedTerseLabel": "Profit sharing granted to employees", "label": "Adjustments For Profit Sharing Granted To Employees", "documentation": "Adjustments For Profit Sharing Granted To Employees" } } }, "auth_ref": [] }, "gnft_SOUS1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "SOUS1Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SO US 1", "label": "S O U S1 [Member]", "documentation": "SO US 1." } } }, "auth_ref": [] }, "gnft_ValuationAssumptionCreditSpread": { "xbrltype": "percentItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ValuationAssumptionCreditSpread", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit spread", "label": "Valuation Assumption, Credit Spread", "documentation": "Valuation Assumption, Credit Spread" } } }, "auth_ref": [] }, "gnft_BSA2014AMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "BSA2014AMember", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSA 2014-A", "label": "B S A2014 A [Member]", "documentation": "BSA 2014-A." } } }, "auth_ref": [] }, "gnft_DateOfDecisionAndDelegationOfBoardOfDirectorsToCEO": { "xbrltype": "dateItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DateOfDecisionAndDelegationOfBoardOfDirectorsToCEO", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Date of the decision and delegation of the Board of Directors to the CEO", "label": "Date Of Decision And Delegation Of Board Of Directors To C E O", "documentation": "Date of decision and delegation of Board of Directors to CEO." } } }, "auth_ref": [] }, "gnft_BuybackOfDebtInstrumentAccruedInterestPerInstrument": { "xbrltype": "decimalItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "BuybackOfDebtInstrumentAccruedInterestPerInstrument", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest portion of buyback amount (in EUR per share)", "label": "Buyback Of Debt Instrument, Accrued Interest Per Instrument", "documentation": "Buyback of debt instrument accrued interest per instrument." } } }, "auth_ref": [] }, "gnft_AGADAndSMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "AGADAndSMember", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA D and S", "label": "A G A D And S [Member]", "documentation": "AGA D and S." } } }, "auth_ref": [] }, "gnft_DescriptionOfAccountingPolicyForConsolidationExplanatoryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DescriptionOfAccountingPolicyForConsolidationExplanatoryTextBlock", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation", "label": "Description Of Accounting Policy For Consolidation Explanatory [Text Block]", "documentation": "The description of the entity's accounting policy for consolidation." } } }, "auth_ref": [] }, "gnft_NumberOfOtherEquityInstrumentsExercisableInShareBasedPaymentArrangementRelatingToNTZProgram": { "xbrltype": "sharesItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "NumberOfOtherEquityInstrumentsExercisableInShareBasedPaymentArrangementRelatingToNTZProgram", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of other equity instruments exercisable in share-based payment arrangement relating to NTZ Program", "label": "Number of other equity instruments exercisable in share-based payment arrangement relating to NTZ Program", "documentation": "Number of other equity instruments exercisable in share-based payment arrangement relating to NTZ Program" } } }, "auth_ref": [] }, "gnft_DebtInstrumentsDebtComponentPerInstrument": { "xbrltype": "decimalItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DebtInstrumentsDebtComponentPerInstrument", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt component of a new amended OCEANE (in EUR per bond)", "label": "Debt Instruments Debt Component Per Instrument", "documentation": "Debt Instruments, debt component per instrument." } } }, "auth_ref": [] }, "gnft_OtherFinancialLoansAndBorrowingsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "OtherFinancialLoansAndBorrowingsMember", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofMaturitiesofFinancialLiabilitiesDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofOtherLoansandBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Financial Loans And Borrowings [Member]", "label": "Other Financial Loans And Borrowings [Member]", "documentation": "Other financial loans and borrowings." } } }, "auth_ref": [] }, "gnft_DisclosureOfTradeAndOtherPayablesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DisclosureOfTradeAndOtherPayablesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Trade And Other Payables [Abstract]", "label": "Disclosure Of Trade And Other Payables [Abstract]", "documentation": "Disclosure of trade and other payables abstract." } } }, "auth_ref": [] }, "gnft_DisclosureOfMajorEventsInThePeriodAndEventsAfterThePeriodAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DisclosureOfMajorEventsInThePeriodAndEventsAfterThePeriodAbstract", "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Major Events In The Period And Events After The Period [Abstract]", "label": "Disclosure Of Major Events In The Period And Events After The Period [Abstract]", "documentation": "Disclosure of major events in the period and events after the period." } } }, "auth_ref": [] }, "gnft_ValuationAssumptionVolatilitySecondLevel": { "xbrltype": "percentItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ValuationAssumptionVolatilitySecondLevel", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Volatility, second level", "label": "Valuation Assumption, Volatility, Second Level", "documentation": "Valuation Assumption, Volatility, Second Level" } } }, "auth_ref": [] }, "gnft_MaximumDilutionOfConvertibleInstrumentsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "MaximumDilutionOfConvertibleInstrumentsPercentage", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum dilution of convertible instruments, percentage", "label": "Maximum Dilution Of Convertible Instruments, Percentage", "documentation": "Maximum Dilution Of Convertible Instruments, Percentage" } } }, "auth_ref": [] }, "gnft_RenegotiationCostsRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "RenegotiationCostsRecognized", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Renegotiation costs recognized", "label": "Renegotiation Costs Recognized", "documentation": "Renegotiation costs recognized." } } }, "auth_ref": [] }, "gnft_SO2016Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "SO2016Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SO 2016", "label": "SO 2016 [Member]", "documentation": "SO 2016" } } }, "auth_ref": [] }, "gnft_ExpenseByNatureDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ExpenseByNatureDomain", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expense By Nature [Domain]", "label": "Expense By Nature [Domain]", "documentation": "Expense By Nature [Domain]" } } }, "auth_ref": [] }, "gnft_NumberOfSharesIssuedDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "NumberOfSharesIssuedDuringPeriod", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares issued during period (in shares)", "label": "Number Of Shares Issued During Period", "documentation": "Number Of Shares Issued During Period" } } }, "auth_ref": [] }, "gnft_SOUS2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "SOUS2022Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SO US 2022", "label": "SO US 2022 [Member]", "documentation": "SO US 2022" } } }, "auth_ref": [] }, "gnft_RefundableAndConditionalAdvancesGrantDate": { "xbrltype": "dateItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "RefundableAndConditionalAdvancesGrantDate", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofRefundableandConditionalAdvancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Refundable and conditional advances, Grant date", "label": "Refundable And Conditional Advances Grant Date", "documentation": "Refundable and conditional advances grant date." } } }, "auth_ref": [] }, "gnft_AverageForeignExchangeRateUSDEuro": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "AverageForeignExchangeRateUSDEuro", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofApplicableExchangeRatesUsedtoTranslateFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AverageForeignExchangeRateUSDEuro", "label": "AverageForeignExchangeRateUSDEuro", "documentation": "AverageForeignExchangeRateUSDEuro" } } }, "auth_ref": [] }, "gnft_ConversionExchangePremium": { "xbrltype": "percentItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ConversionExchangePremium", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBondsDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion Exchange Premium", "label": "Conversion Exchange Premium", "documentation": "Conversion Exchange Premium" } } }, "auth_ref": [] }, "gnft_DisclosureOfOperatingExpensesAndOtherOperatingIncomeExpensesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DisclosureOfOperatingExpensesAndOtherOperatingIncomeExpensesTable", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Operating Expenses And Other Operating Income Expenses [Table]", "label": "Disclosure Of Operating Expenses And Other Operating Income Expenses [Table]", "documentation": "Disclosure of operating expenses and other operating income (expenses)." } } }, "auth_ref": [] }, "gnft_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DebtInstrumentTerm", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, initial term (in years)", "label": "Debt Instrument, Term", "documentation": "Debt Instrument, Term" } } }, "auth_ref": [] }, "ifrs-full_NetDeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NetDeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/IncomeTaxNarrativeDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liabilities", "label": "Net deferred tax liabilities" } }, "en": { "role": { "documentation": "The amount of deferred tax liabilities net of deferred tax assets, when the absolute amount of deferred tax liabilities is greater than the absolute amount of deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]" } } }, "auth_ref": [ "r338" ] }, "ifrs-full_BorrowingsByNameMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BorrowingsByNameMember", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails", "http://www.genfit.com/role/FinancialIncomeandExpensesAdditionalInformationDetails", "http://www.genfit.com/role/FinancialRisksManagementAdditionalInformationDetails", "http://www.genfit.com/role/IncomeTaxNarrativeDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBondsDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofConvertibleBondsDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofMaturitiesofFinancialLiabilitiesDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofOtherLoansandBorrowingsDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings by name [member]", "label": "Borrowings by name [member]" } }, "en": { "role": { "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]" } } }, "auth_ref": [ "r362" ] }, "ifrs-full_ClassesOfShareCapitalMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfShareCapitalMember", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share capital [member]", "label": "Share capital [member]" } }, "en": { "role": { "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used." } } }, "auth_ref": [ "r38" ] }, "ifrs-full_DisclosureOfEarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfEarningsPerShareExplanatory", "presentation": [ "http://www.genfit.com/role/EarningsLossPerShare" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings (Loss) Per Share", "label": "Disclosure of earnings per share [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r115" ] }, "ifrs-full_VehiclesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "VehiclesMember", "presentation": [ "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentSummaryofVariationsinTangibleAssetsDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vehicles [member]", "label": "Vehicles [member]" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing vehicles used in the entity's operations, specifically to include aircraft, motor vehicles and ships. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r339" ] }, "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total number of SO voided", "label": "Number of share options forfeited in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of share options forfeited in a share-based payment arrangement." } } }, "auth_ref": [ "r211" ] }, "ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Functional Currency", "label": "Disclosure of effect of changes in foreign exchange rates [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for the effect of changes in foreign exchange rates." } } }, "auth_ref": [ "r94" ] }, "ifrs-full_ClosingForeignExchangeRate": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClosingForeignExchangeRate", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofApplicableExchangeRatesUsedtoTranslateFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Closing foreign exchange rate", "verboseLabel": "Closing foreign exchange rate", "label": "Closing foreign exchange rate" } }, "en": { "role": { "documentation": "The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery." } } }, "auth_ref": [ "r328" ] }, "ifrs-full_WagesAndSalaries": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WagesAndSalaries", "crdr": "debit", "calculation": { "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Wages and salaries", "label": "Wages and salaries" } }, "en": { "role": { "documentation": "A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]" } } }, "auth_ref": [ "r345" ] }, "ifrs-full_BorrowingsInterestRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BorrowingsInterestRate", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBondsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate (in percent)", "verboseLabel": "Annual nominal interest rate (in percent)", "label": "Borrowings, interest rate" } }, "en": { "role": { "documentation": "The interest rate on borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r362" ] }, "ifrs-full_NumberOfSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfSharesIssued", "calculation": { "http://www.genfit.com/role/EquityAdditionalInformationDetails": { "parentTag": "ifrs-full_NumberOfSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodSignatureofaLicensingandPartnershipAgreementwithIpsenDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New shares created (in shares)", "verboseLabel": "Issuance of new shares (in shares)", "label": "Number of shares issued" } }, "en": { "role": { "documentation": "The number of shares issued by the entity." } } }, "auth_ref": [ "r325" ] }, "ifrs-full_DisclosureOfEmployeeBenefitsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfEmployeeBenefitsExplanatory", "presentation": [ "http://www.genfit.com/role/EmployeeBenefits" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of employee benefits [text block]", "label": "Disclosure of employee benefits [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for employee benefits." } } }, "auth_ref": [ "r88" ] }, "ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfEntitysReportableSegmentsExplanatory", "presentation": [ "http://www.genfit.com/role/Operatingsegments" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of entity's operating segments [text block]", "label": "Disclosure of entity's operating segments [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for operating segments." } } }, "auth_ref": [ "r264" ] }, "ifrs-full_BorrowingsMaturity": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BorrowingsMaturity", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt maturity date", "label": "Borrowings, maturity" } }, "en": { "role": { "documentation": "The maturity of borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r362" ] }, "ifrs-full_NetForeignExchangeGain": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NetForeignExchangeGain", "crdr": "credit", "calculation": { "http://www.genfit.com/role/FinancialIncomeandExpensesSummaryofFinancialIncomeandExpensesDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/FinancialIncomeandExpensesSummaryofFinancialIncomeandExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net foreign exchange gain", "label": "Net foreign exchange gain" } }, "en": { "role": { "documentation": "The net gain arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]" } } }, "auth_ref": [ "r331", "r346" ] }, "ifrs-full_DisclosureOfExpensesByNatureExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfExpensesByNatureExplanatory", "presentation": [ "http://www.genfit.com/role/OperatingExpense" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Expense", "label": "Disclosure of expenses by nature [text block]" } }, "en": { "role": { "documentation": "The disclosure of expenses by nature. [Refer: Expenses, by nature]" } } }, "auth_ref": [ "r323" ] }, "ifrs-full_NumberOfSharesIssuedAndFullyPaid": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfSharesIssuedAndFullyPaid", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares issued and fully paid", "label": "Number of shares issued and fully paid" } }, "en": { "role": { "documentation": "The number of shares issued by the entity, for which full payment has been received." } } }, "auth_ref": [ "r35" ] }, "ifrs-full_NumberOfSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfSharesOutstanding", "calculation": { "http://www.genfit.com/role/EquityAdditionalInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity", "http://www.genfit.com/role/EquityAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at beginning of period (in shares)", "periodEndLabel": "Balance at end of period (in shares)", "terseLabel": "Number of shares outstanding", "totalLabel": "Total number of shares comprising the share capital (in shares)", "label": "Number of shares outstanding" } }, "en": { "role": { "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]" } } }, "auth_ref": [ "r37" ] }, "ifrs-full_NetForeignExchangeLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NetForeignExchangeLoss", "crdr": "debit", "calculation": { "http://www.genfit.com/role/FinancialIncomeandExpensesSummaryofFinancialIncomeandExpensesDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/FinancialIncomeandExpensesSummaryofFinancialIncomeandExpensesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Net foreign exchange loss", "negatedLabel": "Net foreign exchange loss", "label": "Net foreign exchange loss" } }, "en": { "role": { "documentation": "The net loss arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]" } } }, "auth_ref": [ "r331", "r346" ] }, "ifrs-full_BottomOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BottomOfRangeMember", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bottom of Range", "label": "Bottom of range [member]" } }, "en": { "role": { "documentation": "This member stands for the bottom of a range." } } }, "auth_ref": [ "r182", "r200", "r214", "r298", "r299", "r362" ] }, "ifrs-full_OfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OfficeEquipmentMember", "presentation": [ "http://www.genfit.com/role/OperatingExpenseAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Office equipment", "label": "Office equipment [member]" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing equipment used to support office functions, not specifically used in the production process. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r282" ] }, "ifrs-full_AccumulatedDepreciationAndAmortisationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AccumulatedDepreciationAndAmortisationMember", "presentation": [ "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentSummaryofVariationsinTangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Depreciation", "label": "Accumulated depreciation and amortisation [member]" } }, "en": { "role": { "documentation": "This member stands for accumulated depreciation and amortisation. [Refer: Depreciation and amortisation expense]" } } }, "auth_ref": [ "r75", "r340", "r348", "r352", "r353" ] }, "ifrs-full_ComponentsOfEquityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComponentsOfEquityAxis", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Components of equity [axis]", "label": "Components of equity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r7" ] }, "ifrs-full_NewIFRSsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NewIFRSsMember", "presentation": [ "http://www.genfit.com/role/BasisofPresentationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New IFRSs [member]", "label": "New IFRSs [member]" } }, "en": { "role": { "documentation": "This member stands for IFRSs that have been issued but are not yet effective. It also represents the standard value for the 'New IFRSs' axis if no other member is used. [Refer: IFRSs [member]]" } } }, "auth_ref": [ "r155" ] }, "ifrs-full_DisclosureOfFairValueMeasurementExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFairValueMeasurementExplanatory", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstruments" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value of Financial Instruments", "label": "Disclosure of fair value measurement [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for fair value measurement." } } }, "auth_ref": [ "r181" ] }, "ifrs-full_ComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComprehensiveIncome", "crdr": "credit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofOtherComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.genfit.com/role/ConsolidatedStatementsofOtherComprehensiveLoss_1": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity", "http://www.genfit.com/role/ConsolidatedStatementsofOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Total comprehensive income (loss)", "terseLabel": "Comprehensive income", "label": "Comprehensive income" } }, "en": { "role": { "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners." } } }, "auth_ref": [ "r1", "r42", "r158", "r160", "r169", "r297" ] }, "ifrs-full_NewIFRSsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NewIFRSsAxis", "presentation": [ "http://www.genfit.com/role/BasisofPresentationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New IFRSs [axis]", "label": "New IFRSs [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r155" ] }, "ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Opening balance before adjustment, cumulative effect at date of initial application [member]", "label": "Opening balance before adjustment, cumulative effect at date of initial application [member]" } }, "en": { "role": { "documentation": "This member indicates the opening balance before the cumulative effect adjustment in the financial statements at the date of initial application of a new or amended IFRS Standard. It also represents the standard value for the \u2018Cumulative effect at date of initial application\u2019 axis if no other member is used." } } }, "auth_ref": [ "r326" ] }, "ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComprehensiveIncomeAttributableToNoncontrollingInterests", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Comprehensive income, attributable to non-controlling interests", "label": "Comprehensive income, attributable to non-controlling interests" } }, "en": { "role": { "documentation": "The amount of comprehensive income attributable to non-controlling interests. [Refer: Comprehensive income; Non-controlling interests]" } } }, "auth_ref": [ "r1", "r45" ] }, "ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of financial assets and liabilities carrying values by category and fair values", "label": "Disclosure of fair value of financial instruments [text block]" } }, "en": { "role": { "documentation": "The disclosure of the fair value of financial instruments. [Refer: Financial instruments, class [member]; At fair value [member]]" } } }, "auth_ref": [ "r323" ] }, "ifrs-full_NonadjustingEventsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NonadjustingEventsMember", "presentation": [ "http://www.genfit.com/role/EarningsLossPerShareSummaryofEarningsLossPerShareDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-adjusting events after reporting period [member]", "label": "Non-adjusting events after reporting period [member]" } }, "en": { "role": { "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used." } } }, "auth_ref": [ "r58" ] }, "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComprehensiveIncomeAttributableToOwnersOfParent", "crdr": "credit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofOtherComprehensiveLoss_1": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Attributable to owners of the Company", "label": "Comprehensive income, attributable to owners of parent" } }, "en": { "role": { "documentation": "The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]" } } }, "auth_ref": [ "r1", "r46" ] }, "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NonadjustingEventsAfterReportingPeriodAxis", "presentation": [ "http://www.genfit.com/role/EarningsLossPerShareSummaryofEarningsLossPerShareDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-adjusting events after reporting period [axis]", "label": "Non-adjusting events after reporting period [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r58" ] }, "ifrs-full_InvestmentAccountedForUsingEquityMethod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InvestmentAccountedForUsingEquityMethod", "crdr": "debit", "calculation": { "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails_1": { "parentTag": "ifrs-full_OtherFinancialAssets", "weight": 1.0, "order": 3.0 }, "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails": { "parentTag": "gnft_FinancialAssetsVariations", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investments accounted for using equity method", "label": "Investments accounted for using equity method" } }, "en": { "role": { "documentation": "The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]" } } }, "auth_ref": [ "r14", "r176", "r255" ] }, "ifrs-full_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Profit or loss [abstract]", "label": "Profit or loss [abstract]" } } }, "auth_ref": [] }, "ifrs-full_IncomeTaxExpenseContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncomeTaxExpenseContinuingOperations", "crdr": "debit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofOperations": { "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0, "order": 2.0 }, "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofOperations", "http://www.genfit.com/role/DeferredIncomeandRevenueDetails", "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Income tax benefit (expense)", "terseLabel": "Tax expense (income)", "negatedTotalLabel": "Tax expense (income)", "label": "Tax expense (income)" } }, "en": { "role": { "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]" } } }, "auth_ref": [ "r49", "r59", "r61", "r62", "r107", "r175", "r253" ] }, "ifrs-full_DisclosureOfRelatedPartyExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfRelatedPartyExplanatory", "presentation": [ "http://www.genfit.com/role/RelatedParties", "http://www.genfit.com/role/Statementoffinancialpositioncurrentnoncurrent" ], "lang": { "en-us": { "role": { "terseLabel": "Related Parties", "label": "Disclosure of related party [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for related parties." } } }, "auth_ref": [ "r103" ] }, "ifrs-full_ActuarialAssumptionOfDiscountRates": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ActuarialAssumptionOfDiscountRates", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails", "http://www.genfit.com/role/EmployeeBenefitsSummaryofAssumptionsUsedforEmployeesfortheMeasurementofRetirementIndemnitytoEmployeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount rate (as a percent)", "label": "Actuarial assumption of discount rates" } }, "en": { "role": { "documentation": "The discount rate used as the significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [member]]" } } }, "auth_ref": [ "r343" ] }, "ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory", "presentation": [ "http://www.genfit.com/role/EmployeeBenefits", "http://www.genfit.com/role/EmployeeBenefitsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of sensitivity analysis for actuarial assumptions [text block]", "label": "Disclosure of sensitivity analysis for actuarial assumptions [text block]" } }, "en": { "role": { "documentation": "The disclosure of a sensitivity analysis for significant actuarial assumptions used to determine the present value of a defined benefit obligation. [Refer: Actuarial assumptions [member]; Defined benefit obligation, at present value]" } } }, "auth_ref": [ "r86" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Country Region", "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "srt_CurrencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CurrencyAxis", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency [Axis]", "label": "Currency [Axis]" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForOffsettingOfFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForOffsettingOfFinancialInstrumentsExplanatory", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Financial instruments", "label": "Description of accounting policy for offsetting of financial instruments [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for the offsetting of financial instruments. [Refer: Financial instruments, class [member]]" } } }, "auth_ref": [ "r329" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment", "label": "Description of accounting policy for property, plant and equipment [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r329" ] }, "ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForProvisionsExplanatory", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Provisions", "label": "Description of accounting policy for provisions [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for provisions. [Refer: Provisions]" } } }, "auth_ref": [ "r329" ] }, "ifrs-full_DisclosureOfFinancialRiskManagementExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFinancialRiskManagementExplanatory", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagement" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Risks Management", "label": "Disclosure of financial risk management [text block]" } }, "en": { "role": { "documentation": "The disclosure of the entity's financial risk management practices and policies." } } }, "auth_ref": [ "r323" ] }, "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForRecognitionOfRevenue", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues from ongoing activities under client agreements", "label": "Description of accounting policy for recognition of revenue [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]" } } }, "auth_ref": [ "r329" ] }, "ifrs-full_SharePremiumMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SharePremiumMember", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Share premium", "label": "Share premium [member]" } }, "en": { "role": { "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value." } } }, "auth_ref": [ "r7" ] }, "ifrs-full_SharePremium": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SharePremium", "crdr": "credit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Share premium", "label": "Share premium" } }, "en": { "role": { "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value." } } }, "auth_ref": [ "r275" ] }, "ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory", "presentation": [ "http://www.genfit.com/role/OperatingExpense", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development expenses", "label": "Description of accounting policy for research and development expense [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]" } } }, "auth_ref": [ "r329" ] }, "ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForSegmentReportingExplanatory", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Operating segments", "label": "Description of accounting policy for segment reporting [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for segment reporting." } } }, "auth_ref": [ "r329" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r313" ] }, "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "Description of accounting policy for share-based payment transactions [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]" } } }, "auth_ref": [ "r329" ] }, "ifrs-full_SharebasedPaymentArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SharebasedPaymentArrangementsMember", "presentation": [ "http://www.genfit.com/role/EarningsLossPerShareSummaryofEarningsLossPerShareDetails", "http://www.genfit.com/role/EquityAdditionalInformationDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails", "http://www.genfit.com/role/ShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payment arrangements [member]", "label": "Share-based payment arrangements [member]" } }, "en": { "role": { "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used." } } }, "auth_ref": [ "r215" ] }, "ifrs-full_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Basic and diluted earnings (loss) per share", "label": "Earnings per share [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesPolicies", "http://www.genfit.com/role/TradeandOtherPayables" ], "lang": { "en-us": { "role": { "terseLabel": "Trade and other payables", "label": "Description of accounting policy for trade and other payables [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for trade and other payables. [Refer: Trade and other payables]" } } }, "auth_ref": [ "r329" ] }, "ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssets", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Trade and other receivables", "label": "Description of accounting policy for trade and other receivables [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for trade and other receivables. [Refer: Trade and other receivables]" } } }, "auth_ref": [ "r329" ] }, "ifrs-full_EarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EarningsPerShareExplanatory", "presentation": [ "http://www.genfit.com/role/EarningsLossPerShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Earnings (Loss) Per Share", "label": "Earnings per share [text block]" } }, "en": { "role": { "documentation": "The disclosure of earnings per share." } } }, "auth_ref": [ "r112" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents", "presentation": [ "http://www.genfit.com/role/CashandCashEquivalents", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Description of accounting policy for determining components of cash and cash equivalents [text block]" } }, "en": { "role": { "documentation": "The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r149" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r315" ] }, "ifrs-full_EarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EarningsPerShareTable", "presentation": [ "http://www.genfit.com/role/EarningsLossPerShareSummaryofEarningsLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings per share [table]", "label": "Earnings per share [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to earnings per share." } } }, "auth_ref": [ "r112" ] }, "ifrs-full_FixedInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FixedInterestRateMember", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual Nominal Interest Rate", "label": "Fixed interest rate [member]" } }, "en": { "role": { "documentation": "This member stands for a fixed interest rate. [Refer: Interest rate risk [member]]" } } }, "auth_ref": [ "r361" ] }, "ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ShorttermDepositsClassifiedAsCashEquivalents", "crdr": "debit", "calculation": { "http://www.genfit.com/role/CashandCashEquivalentsSummaryofCashandCashEquivalentsDetails": { "parentTag": "ifrs-full_CashAndCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.genfit.com/role/CashandCashEquivalentsSummaryofCashandCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term deposits, classified as cash equivalents", "label": "Short-term deposits, classified as cash equivalents" } }, "en": { "role": { "documentation": "A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]" } } }, "auth_ref": [ "r359" ] }, "ifrs-full_DisclosureOfIncomeTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfIncomeTaxExplanatory", "presentation": [ "http://www.genfit.com/role/IncomeTax", "http://www.genfit.com/role/TradeandOtherReceivables" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax", "label": "Disclosure of income tax [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for income taxes." } } }, "auth_ref": [ "r67" ] }, "ifrs-full_CurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentLiabilities", "crdr": "credit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "Total - Current liabilities", "label": "Current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } } }, "auth_ref": [ "r30", "r167", "r297" ] }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Effects of exchange rate changes on cash", "label": "Effect of exchange rate changes on cash and cash equivalents" } }, "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r144", "r145" ] }, "ifrs-full_FixturesAndFittingsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FixturesAndFittingsMember", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentSummaryofVariationsinTangibleAssetsDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Fittings, Fittings and Improvements", "terseLabel": "Fixtures and fittings [member]", "label": "Fixtures and fittings [member]" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing fixtures and fittings that are not permanently attached to real property. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r281" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "ifrs-full_CurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentLiabilitiesAbstract", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "label": "Current liabilities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialAssetsAtFairValueThroughProfitOrLoss", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying value of Assets at fair value through profit and loss", "label": "Financial assets at fair value through profit or loss" } }, "en": { "role": { "documentation": "The amount of financial assets that are measured at fair value and for which gains (losses) are recognised in profit or loss. A financial asset shall be measured at fair value through profit or loss unless it is measured at amortised cost or at fair value through other comprehensive income. A gain (loss) on a financial asset measured at fair value shall be recognised in profit or loss unless it is part of a hedging relationship, it is an investment in an equity instrument for which the entity has elected to present gains and losses in other comprehensive income or it is a financial asset measured at fair value through other comprehensive income. [Refer: At fair value [member]; Financial assets]" } } }, "auth_ref": [ "r246" ] }, "ifrs-full_DescriptionOfPrimaryReasonsForBusinessCombination": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfPrimaryReasonsForBusinessCombination", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Description of primary reasons for business combination", "label": "Description of primary reasons for business combination" } }, "en": { "role": { "documentation": "The description of the primary reasons for a business combination. [Refer: Business combinations [member]]" } } }, "auth_ref": [ "r221" ] }, "ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentSummaryofVariationsinTangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Translation adjustments", "label": "Reclassification adjustments on exchange differences on translation of foreign operations, net of tax" } }, "en": { "role": { "documentation": "The amount of reclassification adjustments related to exchange differences when the financial statements of foreign operations are translated, net of tax. Reclassification adjustments are amounts reclassified to profit (loss) in the current period that were recognised in other comprehensive income in the current or previous periods. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r52", "r91" ] }, "ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DerivativeFinancialLiabilitiesUndiscountedCashFlows", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofMaturitiesofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "TOTAL", "label": "Derivative financial liabilities, undiscounted cash flows" } }, "en": { "role": { "documentation": "The amount of contractual undiscounted cash flows in relation to derivative financial liabilities. [Refer: Derivative financial liabilities]" } } }, "auth_ref": [ "r241" ] }, "ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial assets measured at fair value through other comprehensive income", "label": "Financial assets measured at fair value through other comprehensive income" } }, "en": { "role": { "documentation": "The amount of financial assets that are measured at fair value through other comprehensive income. A financial asset shall be measured at fair value through other comprehensive income if both of the following conditions are met: (a) the financial asset is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets and (b) the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. [Refer: At fair value [member]; Financial assets]" } } }, "auth_ref": [ "r247" ] }, "ifrs-full_FinancialAssetsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialAssetsMember", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofUSDollaragainstEuroDetails", "http://www.genfit.com/role/FinancialRisksManagementSummaryofCashCashEquivalentsandFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial assets, class [member]", "label": "Financial assets, class [member]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r207", "r243", "r244", "r265", "r266" ] }, "ifrs-full_OtherReversalsOfProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherReversalsOfProvisions", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/ProvisionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other reversals of provisions", "label": "Other reversals of provisions" } }, "en": { "role": { "documentation": "The amount of reversals of provisions that the entity does not separately disclose in the same statement or note. [Refer: Provisions]" } } }, "auth_ref": [ "r56" ] }, "ifrs-full_ExercisePriceShareOptionsGranted2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ExercisePriceShareOptionsGranted2019", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Excercise price (in EUR per share)", "label": "Exercise price, share options granted" } }, "en": { "role": { "documentation": "The exercise price of share options granted." } } }, "auth_ref": [ "r216" ] }, "ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "MaturityAnalysisForNonderivativeFinancialLiabilities", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Maturities of Financial Liabilities", "label": "Disclosure of maturity analysis for non-derivative financial liabilities [text block]" } }, "en": { "role": { "documentation": "The disclosure of a maturity analysis for non-derivative financial liabilities (including issued financial guarantee contracts) that shows the remaining contractual maturities. [Refer: Derivative financial liabilities]" } } }, "auth_ref": [ "r240" ] }, "ifrs-full_OtherRevenue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherRevenue", "crdr": "credit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofOperations": { "parentTag": "ifrs-full_Revenue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofOperations", "http://www.genfit.com/role/DeferredIncomeandRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other income", "label": "Other revenue" } }, "en": { "role": { "documentation": "The amount of revenue arising from sources that the entity does not separately disclose in the same statement or note. [Refer: Revenue]" } } }, "auth_ref": [ "r328" ] }, "ifrs-full_Level1OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Level1OfFairValueHierarchyMember", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 1", "label": "Level 1 of fair value hierarchy [member]" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date." } } }, "auth_ref": [ "r84", "r179" ] }, "ifrs-full_MaturityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "MaturityAxis", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails", "http://www.genfit.com/role/EmployeeBenefitsSummaryofAssumptionsUsedforEmployeesfortheMeasurementofRetirementIndemnitytoEmployeesDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofMaturitiesofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maturity [axis]", "label": "Maturity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r28", "r189", "r194", "r196", "r197", "r198", "r200", "r206", "r229", "r242", "r283", "r304" ] }, "ifrs-full_Level2OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Level2OfFairValueHierarchyMember", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Level 2 of fair value hierarchy [member]" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly." } } }, "auth_ref": [ "r179" ] }, "gnft_DisclosureOfCompensationOfCorporateOfficersLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DisclosureOfCompensationOfCorporateOfficersLineItems", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersAdditionalInformationDetails", "http://www.genfit.com/role/CompensationofCorporateOfficersScheduleofDirectorsFeesandOtherCompensationDueandPaidtoNonExecutiveDirectorsDetails", "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Compensation Of Corporate Officers [Line Items]", "label": "Disclosure Of Compensation Of Corporate Officers [Line Items]", "documentation": "Disclosure of compensation of corporate officers." } } }, "auth_ref": [] }, "ifrs-full_Level3OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Level3OfFairValueHierarchyMember", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 3", "label": "Level 3 of fair value hierarchy [member]" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability." } } }, "auth_ref": [ "r179" ] }, "ifrs-full_OtherShorttermEmployeeBenefits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherShorttermEmployeeBenefits", "crdr": "debit", "calculation": { "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Other short-term employee benefits", "label": "Other short-term employee benefits" } }, "en": { "role": { "documentation": "The amount of expense from employee benefits (other than termination benefits), which are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services, that the entity does not separately disclose in the same statement or note. [Refer: Employee benefits expense]" } } }, "auth_ref": [ "r345" ] }, "ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ExpectedDividendAsPercentageShareOptionsGranted", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected dividends", "label": "Expected dividend as percentage, share options granted" } }, "en": { "role": { "documentation": "The percentage of an expected dividend used to calculate the fair value of share options granted." } } }, "auth_ref": [ "r216" ] }, "ifrs-full_LevelsOfFairValueHierarchyAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LevelsOfFairValueHierarchyAxis", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Levels of fair value hierarchy [axis]", "label": "Levels of fair value hierarchy [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r84", "r179" ] }, "ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome", "crdr": "debit", "calculation": { "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other tax effects for reconciliation between accounting profit and tax expense (income)", "negatedTerseLabel": "Other tax effects for reconciliation between accounting profit and tax expense (income)", "label": "Other tax effects for reconciliation between accounting profit and tax expense (income)" } }, "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that the entity does not separately disclose in the same statement or note. [Refer: Accounting profit; Applicable tax rate]" } } }, "auth_ref": [ "r61" ] }, "ifrs-full_NoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentLiabilities", "crdr": "credit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "Total - Non-current liabilities", "label": "Non-current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } } }, "auth_ref": [ "r30", "r168", "r297" ] }, "ifrs-full_CounterpartiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CounterpartiesAxis", "presentation": [ "http://www.genfit.com/role/DeferredIncomeandRevenueDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofMaturitiesofFinancialLiabilitiesDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofRefundableandConditionalAdvancesDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodSignatureofaLicensingandPartnershipAgreementwithIpsenDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodTerminationofRESOLVEITandthedevelopmentprogramofelafibranorinNASHDetails", "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails", "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails", "http://www.genfit.com/role/OperatingIncomeScheduleofOtherIncomeDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparties [axis]", "label": "Counterparties [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r248" ] }, "gnft_KeyManagementPersonnelCompensationVariableCompensationFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "KeyManagementPersonnelCompensationVariableCompensationFees", "crdr": "debit", "calculation": { "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Key management personnel compensation, variable compensation fees", "label": "Key management personnel compensation, variable compensation fees", "documentation": "Key management personnel compensation, variable compensation fees" } } }, "auth_ref": [] }, "ifrs-full_MeasurementAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "MeasurementAxis", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement [axis]", "label": "Measurement [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r136", "r140", "r178" ] }, "ifrs-full_NoncurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentLiabilitiesAbstract", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current liabilities", "label": "Non-current liabilities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CounterpartiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CounterpartiesMember", "presentation": [ "http://www.genfit.com/role/DeferredIncomeandRevenueDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofMaturitiesofFinancialLiabilitiesDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofRefundableandConditionalAdvancesDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodSignatureofaLicensingandPartnershipAgreementwithIpsenDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodTerminationofRESOLVEITandthedevelopmentprogramofelafibranorinNASHDetails", "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails", "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails", "http://www.genfit.com/role/OperatingIncomeScheduleofOtherIncomeDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparties [member]", "label": "Counterparties [member]" } }, "en": { "role": { "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used." } } }, "auth_ref": [ "r248" ] }, "ifrs-full_AdjustedWeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustedWeightedAverageShares", "presentation": [ "http://www.genfit.com/role/EarningsLossPerShareSummaryofEarningsLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average number of ordinary shares used in calculating diluted earnings (loss) per share (in shares)", "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share" } }, "en": { "role": { "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r114" ] }, "ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProceedsFromBorrowingsClassifiedAsFinancingActivities", "crdr": "debit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "+ Proceeds from new loans and borrowings net of issue costs", "label": "Proceeds from borrowings, classified as financing activities" } }, "en": { "role": { "documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]" } } }, "auth_ref": [ "r293" ] }, "ifrs-full_NoncurrentLoansAndReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentLoansAndReceivables", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current loans and receivables", "label": "Non-current loans and receivables" } }, "en": { "role": { "documentation": "The amount of non-current loans and receivables. [Refer: Loans and receivables]" } } }, "auth_ref": [ "r268" ] }, "gnft_AcquisitionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "AcquisitionCosts", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition costs", "label": "Acquisition costs", "documentation": "Acquisition costs" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForIncomeTaxExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForIncomeTaxExpense", "crdr": "debit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows", "http://www.genfit.com/role/IncomeTaxNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "+ Income tax expense (benefit)", "label": "Adjustments for income tax expense" } }, "en": { "role": { "documentation": "Adjustments for income tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r147" ] }, "ifrs-full_GovernmentGrants": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GovernmentGrants", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Government grants", "label": "Government grants" } }, "en": { "role": { "documentation": "The amount of assistance by government in the form of transfers of resources to an entity in return for past or future compliance with certain conditions relating to the operating activities of the entity, recognised as deferred income. They exclude those forms of government assistance that cannot reasonably have a value placed upon them and transactions with government that cannot be distinguished from the normal trading transactions of the entity. [Refer: Deferred income other than contract liabilities; Government [member]]" } } }, "auth_ref": [ "r332" ] }, "ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ReversalOfImpairmentLossRecognisedInProfitOrLoss", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/OperatingExpenseAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reversal of impairment loss recognised in profit or loss", "label": "Reversal of impairment loss recognised in profit or loss" } }, "en": { "role": { "documentation": "The amount of reversal of impairment loss recognised in profit or loss. [Refer: Reversal of impairment loss; Profit (loss)]" } } }, "auth_ref": [ "r116", "r117" ] }, "ifrs-full_NoncurrentPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentPayables", "crdr": "credit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 3.0 }, "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/TradeandOtherPayablesAdditionalInformationDetails", "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current trade and other payables", "totalLabel": "Total trade and other non-current payables", "label": "Trade and other non-current payables" } }, "en": { "role": { "documentation": "The amount of non-current trade payables and non-current other payables. [Refer: Other non-current payables; Non-current trade payables]" } } }, "auth_ref": [ "r18" ] }, "ifrs-full_ExpenseOfRestructuringActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ExpenseOfRestructuringActivities", "crdr": "debit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofOperations": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofOperations", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Reorganization and restructuring income (expenses)", "terseLabel": "Expense of restructuring activities", "label": "Expense of restructuring activities" } }, "en": { "role": { "documentation": "The amount of expense relating to restructuring. Restructuring is a programme that is planned and controlled by management and materially changes either the scope of a business undertaken by an entity or the manner in which that business is conducted. Such programmes include: (a) the sale or termination of a line of business; (b) closure of business locations in a country or region or the relocation of activities from one country or region to another; (c) changes in management structure; and (d) fundamental reorganisations that have a material effect on the nature and focus of the entity's operations." } } }, "auth_ref": [ "r54" ] }, "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems", "presentation": [ "http://www.genfit.com/role/BasisofPresentationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of expected impact of initial application of new standards or interpretations [line items]", "label": "Disclosure of expected impact of initial application of new standards or interpretations [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_GrossCarryingAmountMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GrossCarryingAmountMember", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails", "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentSummaryofVariationsinTangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross", "label": "Gross carrying amount [member]" } }, "en": { "role": { "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]" } } }, "auth_ref": [ "r69", "r128", "r138", "r141", "r225", "r235", "r238", "r302" ] }, "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable", "presentation": [ "http://www.genfit.com/role/BasisofPresentationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of expected impact of initial application of new standards or interpretations [table]", "label": "Disclosure of expected impact of initial application of new standards or interpretations [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the expected impact of the initial application of new standards or interpretations." } } }, "auth_ref": [ "r155" ] }, "gnft_ReferenceSharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ReferenceSharePrice", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBondsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reference share price", "label": "Reference Share Price", "documentation": "Reference share price." } } }, "auth_ref": [] }, "ifrs-full_ParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ParValuePerShare", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nominal value (in EUR per share)", "label": "Par value per share" } }, "en": { "role": { "documentation": "The nominal value per share." } } }, "auth_ref": [ "r36" ] }, "ifrs-full_NoncurrentPayablesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentPayablesAbstract", "presentation": [ "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade and other payables - Non current", "label": "Trade and other non-current payables [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility", "label": "Expected volatility, share options granted" } }, "en": { "role": { "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time." } } }, "auth_ref": [ "r216" ] }, "ifrs-full_ReversalOfProvisionsForCostOfRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ReversalOfProvisionsForCostOfRestructuring", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/ProvisionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reversal of provisions for cost of restructuring", "label": "Reversal of provisions for cost of restructuring" } }, "en": { "role": { "documentation": "The amount of reversals of provisions for the cost of restructuring. [Refer: Restructuring provision]" } } }, "auth_ref": [ "r54" ] }, "ifrs-full_NoncurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax", "crdr": "credit", "calculation": { "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails": { "parentTag": "ifrs-full_NoncurrentPayables", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.genfit.com/role/TradeandOtherPayablesAdditionalInformationDetails", "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current payables on social security and taxes other than income tax", "label": "Non-current payables on social security and taxes other than income tax" } }, "en": { "role": { "documentation": "The amount of non-current payables on social security and taxes other than incomes tax. [Refer: Payables on social security and taxes other than income tax]" } } }, "auth_ref": [ "r335" ] }, "ifrs-full_NoncurrentPayablesToTradeSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentPayablesToTradeSuppliers", "crdr": "credit", "calculation": { "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails": { "parentTag": "ifrs-full_NoncurrentPayables", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.genfit.com/role/TradeandOtherPayablesAdditionalInformationDetails", "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current trade payables", "label": "Non-current trade payables" } }, "en": { "role": { "documentation": "The non-current amount of payment due to suppliers for goods and services used in the entity's business. [Refer: Trade payables]" } } }, "auth_ref": [ "r335" ] }, "ifrs-full_RightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RightofuseAssets", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right of use asset", "label": "Right-of-use assets" } }, "en": { "role": { "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee." } } }, "auth_ref": [ "r191", "r193" ] }, "ifrs-full_IncreaseDecreaseInIntangibleAssetsAndGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseInIntangibleAssetsAndGoodwill", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in intangible assets and goodwill", "label": "Increase (decrease) in intangible assets and goodwill" } }, "en": { "role": { "documentation": "The increase (decrease) in intangible assets and goodwill. [Refer: Intangible assets and goodwill]" } } }, "auth_ref": [ "r349" ] }, "ifrs-full_ProceedsFromIssueOfOrdinaryShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProceedsFromIssueOfOrdinaryShares", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issue of ordinary shares", "verboseLabel": "Gross amount received from issuance of shares", "label": "Proceeds from issue of ordinary shares" } }, "en": { "role": { "documentation": "The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]" } } }, "auth_ref": [ "r356" ] }, "ifrs-full_NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued", "crdr": "credit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofConvertibleBondsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current convertible loans", "label": "Non-current portion of non-current notes and debentures issued" } }, "en": { "role": { "documentation": "The non-current portion of non-current notes and debentures issued. [Refer: Notes and debentures issued]" } } }, "auth_ref": [ "r328" ] }, "ifrs-full_ProceedsFromIssuingShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProceedsFromIssuingShares", "crdr": "debit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows", "http://www.genfit.com/role/EquityAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodSignatureofaLicensingandPartnershipAgreementwithIpsenDetails" ], "lang": { "en-us": { "role": { "terseLabel": "+ Proceeds from issue of share capital (net)", "label": "Proceeds from issuing shares" } }, "en": { "role": { "documentation": "The cash inflow from issuing shares." } } }, "auth_ref": [ "r292" ] }, "ifrs-full_LiabilityAssetOfDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LiabilityAssetOfDefinedBenefitPlans", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails", "http://www.genfit.com/role/EmployeeBenefitsSummaryofChangesinPresentValueofDefinedBenefitObligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net defined benefit liability (asset)", "periodStartLabel": "Defined benefit obligation, beginning balance", "periodEndLabel": "Defined benefit obligation, ending balance", "label": "Net defined benefit liability (asset)" } }, "en": { "role": { "documentation": "The amount of deficit or surplus in a defined benefit plan, adjusted for any effect of limiting a net defined benefit asset to the asset ceiling. [Refer: Defined benefit plans [member]]" } } }, "auth_ref": [ "r79" ] }, "ifrs-full_NoncurrentPortionOfOtherNoncurrentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentPortionOfOtherNoncurrentBorrowings", "crdr": "credit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofOtherLoansandBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current loans and borrowings", "label": "Non-current portion of other non-current borrowings" } }, "en": { "role": { "documentation": "The non-current portion of non-current other borrowings. [Refer: Other borrowings]" } } }, "auth_ref": [ "r328" ] }, "ifrs-full_LicenceFeeIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LicenceFeeIncome", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Licence fee income", "label": "Licence fee income" } }, "en": { "role": { "documentation": "The amount of income arising from licence fees." } } }, "auth_ref": [ "r328" ] }, "gnft_DenominatedInCHFMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DenominatedInCHFMember", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofUSDollaragainstEuroDetails", "http://www.genfit.com/role/FinancialRisksManagementSummaryofCashCashEquivalentsandFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Denominated In C H F", "label": "Denominated In C H F [Member]", "documentation": "Denominated In C H F" } } }, "auth_ref": [] }, "gnft_InterestRateYearsDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "InterestRateYearsDomain", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Years [Domain]", "label": "Interest Rate Years [Domain]", "documentation": "Interest Rate Years [Domain]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems", "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]", "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "gnft_BSAAR2014ABEtCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "BSAAR2014ABEtCMember", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "B S A A R2014 A B Et C [Member]", "label": "B S A A R2014 A B Et C [Member]", "documentation": "BSAAR 2014-A - B et C." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable", "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]", "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to temporary differences, unused tax losses and unused tax credits." } } }, "auth_ref": [ "r66" ] }, "gnft_MarketingAndCommercialMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "MarketingAndCommercialMember", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Marketing And Commercial [Member]", "label": "Marketing And Commercial [Member]", "documentation": "Marketing and commercial." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [abstract]", "label": "Disclosure of terms and conditions of share-based payment arrangement [abstract]" } } }, "auth_ref": [] }, "gnft_FinanceIncomeFromRenegotiationOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "FinanceIncomeFromRenegotiationOfDebt", "crdr": "credit", "calculation": { "http://www.genfit.com/role/FinancialIncomeandExpensesSummaryofFinancialIncomeandExpensesDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/FinancialIncomeandExpensesAdditionalInformationDetails", "http://www.genfit.com/role/FinancialIncomeandExpensesSummaryofFinancialIncomeandExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance income from renegotiation of debt", "label": "Finance income from renegotiation of debt", "documentation": "Finance income from renegotiation of debt" } } }, "auth_ref": [] }, "gnft_KeyManagementPersonnelCompensationConsultingFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "KeyManagementPersonnelCompensationConsultingFees", "crdr": "debit", "calculation": { "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Key management personnel compensation, consulting fees", "label": "Key management personnel compensation, consulting fees", "documentation": "Key management personnel compensation, consulting fees" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensation", "http://www.genfit.com/role/ShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Key Terms and Conditions of Share-Based Compensation Based", "label": "Disclosure of terms and conditions of share-based payment arrangement [text block]" } }, "en": { "role": { "documentation": "The disclosure of the general terms and conditions of share-based payment arrangements. [Refer: Share-based payment arrangements [member]]" } } }, "auth_ref": [ "r215" ] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationAdditionalInformationDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsParentheticalDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails", "http://www.genfit.com/role/ShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [line items]", "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationAdditionalInformationDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsParentheticalDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails", "http://www.genfit.com/role/ShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [table]", "label": "Disclosure of terms and conditions of share-based payment arrangement [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements." } } }, "auth_ref": [ "r215" ] }, "gnft_GrantDate": { "xbrltype": "dateItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "GrantDate", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Grant date", "label": "Grant date", "documentation": "Grant date" } } }, "auth_ref": [] }, "gnft_BuybackOfDebtInstrumentNominalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "BuybackOfDebtInstrumentNominalAmount", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Buyback (nominal amount)", "label": "Buyback Of Debt Instrument Nominal Amount", "documentation": "Buyback of debt instrument nominal amount." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTradeAndOtherPayablesExplanatory", "presentation": [ "http://www.genfit.com/role/TradeandOtherPayables" ], "lang": { "en-us": { "role": { "terseLabel": "Trade and Other Payables", "label": "Disclosure of trade and other payables [text block]" } }, "en": { "role": { "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]" } } }, "auth_ref": [ "r323" ] }, "gnft_DisclosureOfDetailedInformationAboutRefundableAndConditionalAdvancesExplanatoryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DisclosureOfDetailedInformationAboutRefundableAndConditionalAdvancesExplanatoryTextBlock", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Refundable and Conditional Advances", "label": "Disclosure Of Detailed Information About Refundable And Conditional Advances Explanatory [Text Block]", "documentation": "Disclosure of detailed information about Refundable and conditional advances." } } }, "auth_ref": [] }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans", "crdr": "credit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofOtherComprehensiveLoss": { "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Actuarial gains and losses net of tax", "label": "Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [member]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]" } } }, "auth_ref": [ "r31", "r50", "r341" ] }, "gnft_DisclosureOfOtherFinancialAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DisclosureOfOtherFinancialAssetsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Other Financial Assets [Abstract]", "label": "Disclosure Of Other Financial Assets [Abstract]", "documentation": "Disclosure of other financial assets." } } }, "auth_ref": [] }, "gnft_DisclosureOfCompensationOfCorporateOfficersTable": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DisclosureOfCompensationOfCorporateOfficersTable", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersAdditionalInformationDetails", "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Compensation Of Corporate Officers [Table]", "label": "Disclosure Of Compensation Of Corporate Officers [Table]", "documentation": "Schedule disclosing information related to compensation of corporate officers." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTradeAndOtherReceivablesExplanatory", "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivables" ], "lang": { "en-us": { "role": { "terseLabel": "Trade and Other Receivables", "label": "Disclosure of trade and other receivables [text block]" } }, "en": { "role": { "documentation": "The disclosure of trade and other receivables. [Refer: Trade and other receivables]" } } }, "auth_ref": [ "r323" ] }, "gnft_SegmentInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "SegmentInformationAbstract", "lang": { "en-us": { "role": { "label": "Segment information [Abstract]", "documentation": "Segment information [Abstract]" } } }, "auth_ref": [] }, "gnft_XavierGUILLEDESBUTTESMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "XavierGUILLEDESBUTTESMember", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersScheduleofDirectorsFeesandOtherCompensationDueandPaidtoNonExecutiveDirectorsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Xavier G U I L L E D E S B U T T E S [Member]", "label": "Xavier G U I L L E D E S B U T T E S [Member]", "documentation": "Xavier GUILLE DES BUTTES." } } }, "auth_ref": [] }, "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GainsLossesOnExchangeDifferencesOnTranslationBeforeTax", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange gains on trade receivables", "label": "Gains (losses) on exchange differences on translation of foreign operations, before tax" } }, "en": { "role": { "documentation": "The gains (losses) recognised in other comprehensive income on exchange differences on the translation of financial statements of foreign operations, before tax, before reclassification adjustments. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r51" ] }, "gnft_EffectiveInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "EffectiveInterestRate", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBondsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective Interest Rate", "label": "Effective Interest Rate", "documentation": "Effective Interest Rate" } } }, "auth_ref": [] }, "gnft_ShareBasedCompensationAcquisitionPeriod": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ShareBasedCompensationAcquisitionPeriod", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition period", "label": "Share Based Compensation Acquisition Period", "documentation": "Share based compensation acquisition period." } } }, "auth_ref": [] }, "gnft_BuybackOfDebtInstrumentsShareholderVotingPercentageToExtendMaturityTerm": { "xbrltype": "percentItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "BuybackOfDebtInstrumentsShareholderVotingPercentageToExtendMaturityTerm", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Buyback of debt instruments, shareholder voting percentage to extend maturity term", "label": "Buyback Of Debt Instruments, Shareholder Voting Percentage To Extend Maturity Term", "documentation": "Buyback Of Debt Instruments, Shareholder Voting Percentage To Extend Maturity Term" } } }, "auth_ref": [] }, "gnft_RepaymentsOfRefundableAndConditionalAdvances": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "RepaymentsOfRefundableAndConditionalAdvances", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofRefundableandConditionalAdvancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Refundable and conditional advances, Repayments", "label": "Repayments Of Refundable And Conditional Advances", "documentation": "Repayments of refundable and conditional advances." } } }, "auth_ref": [] }, "gnft_FinanceIncomeConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "FinanceIncomeConvertibleDebt", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlowsParenthetical", "http://www.genfit.com/role/ConsolidatedStatementsofOperationsParenthetical" ], "lang": { "en-us": { "role": { "verboseLabel": "Includes the bonus generated by the partial OCEANE buyback", "terseLabel": "Of which Financial income incurred by renegotiating the convertible bond debt OCEANE", "label": "Finance Income, Convertible Debt", "documentation": "Finance Income, Convertible Debt" } } }, "auth_ref": [] }, "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/FinancialIncomeandExpensesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange gain (loss)", "label": "Foreign exchange gain (loss)" } }, "en": { "role": { "documentation": "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]" } } }, "auth_ref": [ "r10", "r92" ] }, "gnft_ContractedResearchAndDevelopmentActivitiesConductedByThirdPartiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ContractedResearchAndDevelopmentActivitiesConductedByThirdPartiesMember", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contracted research & development activities conducted by third parties", "label": "Contracted Research And Development Activities Conducted By Third Parties [Member]", "documentation": "Contracted research and development activities conducted by third parties." } } }, "auth_ref": [] }, "gnft_SO2017Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "SO2017Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SO 2017", "label": "SO 2017 [Member]", "documentation": "SO 2017" } } }, "auth_ref": [] }, "gnft_IFRS38Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "IFRS38Member", "presentation": [ "http://www.genfit.com/role/BasisofPresentationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "IFRS 38", "label": "IFRS 38 [Member]", "documentation": "IFRS 38" } } }, "auth_ref": [] }, "gnft_DisclosureOfOperatingExpensesAndOtherOperatingIncomeExpensesExplanatoryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DisclosureOfOperatingExpensesAndOtherOperatingIncomeExpensesExplanatoryTextBlock", "presentation": [ "http://www.genfit.com/role/OperatingExpenseTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Operating Expenses and Other Operating Income", "label": "Disclosure Of Operating Expenses And Other Operating Income Expenses Explanatory [Text Block]", "documentation": "Disclosure of operating expenses and other operating income (expenses)." } } }, "auth_ref": [] }, "gnft_CICPGEMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "CICPGEMember", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CIC PGE [Member]", "label": "CIC PGE [Member]", "documentation": "CIC PGE" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Disclosure of transactions between related parties [abstract]", "label": "Disclosure of transactions between related parties [abstract]" } } }, "auth_ref": [] }, "gnft_A16October2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "A16October2025Member", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "16October2025 [Member]", "label": "16October2025 [Member]", "documentation": "16October2025" } } }, "auth_ref": [] }, "gnft_AdministrativeCostDestructionOfDrugTabletsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "AdministrativeCostDestructionOfDrugTabletsMember", "presentation": [ "http://www.genfit.com/role/OperatingExpenseAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Administrative Cost, Destruction Of Drug Tablets", "label": "Administrative Cost, Destruction Of Drug Tablets [Member]", "documentation": "Administrative Cost, Destruction Of Drug Tablets" } } }, "auth_ref": [] }, "gnft_RestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "RestructuringDomain", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring [Domain]", "label": "Restructuring [Domain]", "documentation": "Restructuring [Domain]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems", "presentation": [ "http://www.genfit.com/role/RelatedPartiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of transactions between related parties [line items]", "label": "Disclosure of transactions between related parties [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "gnft_NumberOfCommercialBanks": { "xbrltype": "decimalItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "NumberOfCommercialBanks", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number Of Commercial Banks", "label": "Number Of Commercial Banks", "documentation": "Number Of Commercial Banks" } } }, "auth_ref": [] }, "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "crdr": "credit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofOtherComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "that are or may be reclassified to profit or loss", "label": "Other comprehensive income that will be reclassified to profit or loss, net of tax" } }, "en": { "role": { "documentation": "The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r276", "r277" ] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable", "presentation": [ "http://www.genfit.com/role/RelatedPartiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of transactions between related parties [table]", "label": "Disclosure of transactions between related parties [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to transactions between related parties." } } }, "auth_ref": [ "r101" ] }, "gnft_GainLossOnBuybackOfDebtInstrument": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "GainLossOnBuybackOfDebtInstrument", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recognition of financial gain before tax", "label": "Gain (Loss) On Buyback Of Debt Instrument", "documentation": "Gain (Loss) On Buyback Of Debt Instrument" } } }, "auth_ref": [] }, "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax", "crdr": "credit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofOtherComprehensiveLoss": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "that will never be reclassified to profit or loss", "label": "Other comprehensive income that will not be reclassified to profit or loss, net of tax" } }, "en": { "role": { "documentation": "The amount of other comprehensive income that will not be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r276", "r277" ] }, "gnft_ResearchTaxCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ResearchTaxCredit", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails", "http://www.genfit.com/role/TradeandOtherReceivablesAdditionalInformationDetails", "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research Tax Credit", "label": "Research Tax Credit", "documentation": "Research tax credit." } } }, "auth_ref": [] }, "ifrs-full_OtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherCurrentAssets", "crdr": "debit", "calculation": { "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails": { "parentTag": "gnft_TotalAcquiredAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Other current assets" } }, "en": { "role": { "documentation": "The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]" } } }, "auth_ref": [ "r332" ] }, "gnft_ShareWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ShareWarrantsMember", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Share Warrants", "label": "Share Warrants [Member]", "documentation": "Share warrants." } } }, "auth_ref": [] }, "gnft_PercentageOfExercisableInstrumentsRelatingToDevelopmentOfElafibranorInPBCAndElativeClinical": { "xbrltype": "percentItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "PercentageOfExercisableInstrumentsRelatingToDevelopmentOfElafibranorInPBCAndElativeClinical", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsParentheticalDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of exercisable instruments relating to the development of elafibranor in pbc and elative clinical", "label": "Percentage Of Exercisable Instruments Relating To Development Of Elafibranor In P B C And Elative Clinical", "documentation": "Percentage of exercisable instruments relating to the development of elafibranor in pbc and the elative clinical." } } }, "auth_ref": [] }, "gnft_RevenueFromSalesOfInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "RevenueFromSalesOfInventories", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from sales of inventories", "label": "Revenue from sales of inventories", "documentation": "Revenue from sales of inventories" } } }, "auth_ref": [] }, "gnft_AdditionsOtherThanThroughBusinessCombinationsAndAmortisationIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "AdditionsOtherThanThroughBusinessCombinationsAndAmortisationIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase", "label": "Additions Other Than Through Business Combinations And Amortisation Intangible Assets Other Than Goodwill", "documentation": "Additions other than through business combinations and amortisation, intangible assets other than goodwill," } } }, "auth_ref": [] }, "gnft_NumberOfSharesNonIncludedInTheComputationOfDilutedEarningsPerShare": { "xbrltype": "sharesItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "NumberOfSharesNonIncludedInTheComputationOfDilutedEarningsPerShare", "presentation": [ "http://www.genfit.com/role/EarningsLossPerShareSummaryofEarningsLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number Of Shares Non Included In The Computation Of Diluted Earnings Per Share", "label": "Number Of Shares Non Included In The Computation Of Diluted Earnings Per Share", "documentation": "Number Of Shares Non Included In The Computation Of Diluted Earnings Per Share" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTreasurySharesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTreasurySharesExplanatory", "presentation": [ "http://www.genfit.com/role/Equity" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of treasury shares [text block]", "label": "Disclosure of treasury shares [text block]" } }, "en": { "role": { "documentation": "The disclosure of treasury shares. [Refer: Treasury shares]" } } }, "auth_ref": [ "r323" ] }, "ifrs-full_OtherCurrentFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherCurrentFinancialAssets", "crdr": "debit", "calculation": { "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails": { "parentTag": "ifrs-full_OtherFinancialAssets", "weight": 1.0, "order": 1.0 }, "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current financial assets", "label": "Other current financial assets" } }, "en": { "role": { "documentation": "The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]" } } }, "auth_ref": [ "r13" ] }, "ifrs-full_OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings", "crdr": "credit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofOtherLoansandBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current loans and borrowings", "label": "Other current borrowings and current portion of other non-current borrowings" } }, "en": { "role": { "documentation": "The amount of current other borrowings and the current portion of non-current other borrowings. [Refer: Other borrowings]" } } }, "auth_ref": [ "r328" ] }, "gnft_OtherRemunerationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "OtherRemunerationMember", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersScheduleofDirectorsFeesandOtherCompensationDueandPaidtoNonExecutiveDirectorsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Remuneration", "label": "Other Remuneration [Member]", "documentation": "Other remuneration." } } }, "auth_ref": [] }, "gnft_NonCurrentAssetsByGeographical": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "NonCurrentAssetsByGeographical", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofApplicableExchangeRatesUsedtoTranslateFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non Current Assets By Geographical", "label": "Non Current Assets By Geographical", "documentation": "Non Current Assets By Geographical" } } }, "auth_ref": [] }, "gnft_FurnitureMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "FurnitureMember", "presentation": [ "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentSummaryofVariationsinTangibleAssetsDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture [Member]", "label": "Furniture [Member]", "documentation": "Furniture." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfVoluntaryChangeInAccountingPolicyAbstract", "lang": { "en-us": { "role": { "terseLabel": "Disclosure of voluntary change in accounting policy [abstract]", "label": "Disclosure of voluntary change in accounting policy [abstract]" } } }, "auth_ref": [] }, "gnft_SOUS20162Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "SOUS20162Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "S O U S20162 [Member]", "label": "S O U S20162 [Member]", "documentation": "SO US 2016-2." } } }, "auth_ref": [] }, "gnft_SO1Et22016Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "SO1Et22016Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SO US 2016", "label": "S O1 Et22016 [Member]", "documentation": "SO 1 et 2 2016." } } }, "auth_ref": [] }, "gnft_TernsPharmaceuticalsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "TernsPharmaceuticalsMember", "presentation": [ "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Terns Pharmaceuticals", "label": "Terns Pharmaceuticals [Member]", "documentation": "Terns Pharmaceuticals." } } }, "auth_ref": [] }, "gnft_TenPercentIncreaseOfUSDollarVsEuroMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "TenPercentIncreaseOfUSDollarVsEuroMember", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofUSDollaragainstEuroDetails" ], "lang": { "en-us": { "role": { "terseLabel": "10% Increase of US Dollar vs Euro", "label": "Ten Percent Increase Of U S Dollar Vs Euro [Member]", "documentation": "10% increase of US dollar vs Euro." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfVoluntaryChangeInAccountingPolicyLineItems", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of voluntary change in accounting policy [line items]", "label": "Disclosure of voluntary change in accounting policy [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "gnft_TaxEffectOfRecognitionOfDeferredTaxAssetsAgainstDeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "TaxEffectOfRecognitionOfDeferredTaxAssetsAgainstDeferredTaxLiabilities", "crdr": "debit", "calculation": { "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Effect Of Recognition Of Deferred Tax Assets Against Deferred Tax Liabilities", "negatedTerseLabel": "Tax Effect Of Recognition Of Deferred Tax Assets Against Deferred Tax Liabilities", "label": "Tax Effect Of Recognition Of Deferred Tax Assets Against Deferred Tax Liabilities", "documentation": "Tax Effect Of Recognition Of Deferred Tax Assets Against Deferred Tax Liabilities" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfVoluntaryChangeInAccountingPolicyTable", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of voluntary change in accounting policy [table]", "label": "Disclosure of voluntary change in accounting policy [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to a voluntary change in accounting policy." } } }, "auth_ref": [ "r154" ] }, "gnft_AverageForeignExchangeRateCHFEuro": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "AverageForeignExchangeRateCHFEuro", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofApplicableExchangeRatesUsedtoTranslateFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AverageForeignExchangeRateCHFEuro", "label": "AverageForeignExchangeRateCHFEuro", "documentation": "AverageForeignExchangeRateCHFEuro" } } }, "auth_ref": [] }, "gnft_PropertyPlantAndEquipmentByFinanceLeaseStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "PropertyPlantAndEquipmentByFinanceLeaseStatusAxis", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property Plant And Equipment By Finance Lease Status", "label": "Property Plant And Equipment By Finance Lease Status [Axis]", "documentation": "Property plant and equipment by finance lease status." } } }, "auth_ref": [] }, "gnft_PretGarantiParLEtatPGEBancaireMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "PretGarantiParLEtatPGEBancaireMember", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pret Garanti Par L etat (PGE) Bancaire", "label": "Pret Garanti Par L etat (PGE) Bancaire [Member]", "documentation": "Pret Garanti Par L etat (PGE) Bancaire" } } }, "auth_ref": [] }, "ifrs-full_OtherCurrentNonfinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherCurrentNonfinancialAssets", "crdr": "debit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/OtherAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Other current non-financial assets" } }, "en": { "role": { "documentation": "The amount of current non-financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]" } } }, "auth_ref": [ "r332" ] }, "gnft_ValuationAssumptionVolatilityFirstLevel": { "xbrltype": "percentItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ValuationAssumptionVolatilityFirstLevel", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Volatility, first level", "label": "Valuation Assumption, Volatility, First Level", "documentation": "Valuation Assumption, Volatility, First Level" } } }, "auth_ref": [] }, "gnft_OtherInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "OtherInvestments", "crdr": "debit", "calculation": { "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails": { "parentTag": "gnft_FinancialAssetsVariations", "weight": 1.0, "order": 5.0 }, "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails_1": { "parentTag": "ifrs-full_OtherFinancialAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Investments", "label": "Other Investments", "documentation": "Other Investments" } } }, "auth_ref": [] }, "gnft_MaleMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "MaleMember", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Male [Member]", "label": "Male [Member]", "documentation": "Male." } } }, "auth_ref": [] }, "ifrs-full_OtherCurrentPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherCurrentPayables", "crdr": "credit", "calculation": { "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentPayables", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.genfit.com/role/TradeandOtherPayablesAdditionalInformationDetails", "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current payables", "label": "Other current payables" } }, "en": { "role": { "documentation": "The amount of current payables that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r332" ] }, "gnft_BSA2015BMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "BSA2015BMember", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSA 2015-B", "label": "B S A2015 B [Member]", "documentation": "BSA 2015-B." } } }, "auth_ref": [] }, "gnft_DisclosureOfBenefitPaymentsUndereCompanysFrenchRetirementEntityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DisclosureOfBenefitPaymentsUndereCompanysFrenchRetirementEntityTextBlock", "presentation": [ "http://www.genfit.com/role/EmployeeBenefits", "http://www.genfit.com/role/EmployeeBenefitsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of benefit payments undere company's french retirement entity", "label": "Disclosure of benefit payments undere company's french retirement entity [Text Block]", "documentation": "Disclosure of benefit payments undere company's french retirement entity" } } }, "auth_ref": [] }, "gnft_DisclosureOfTradeAndOtherReceivablesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DisclosureOfTradeAndOtherReceivablesLineItems", "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of trade and other receivables [Line Items]", "label": "Disclosure of trade and other receivables [Line Items]", "documentation": "Disclosure of trade and other receivables [Line Items]" } } }, "auth_ref": [] }, "gnft_StaffMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "StaffMember", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Staff [Member]", "label": "Staff [Member]", "documentation": "Staff." } } }, "auth_ref": [] }, "gnft_GenfitCorpMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "GenfitCorpMember", "presentation": [ "http://www.genfit.com/role/DeferredIncomeandRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Genfit Corp", "label": "Genfit Corp [Member]", "documentation": "Genfit Corp" } } }, "auth_ref": [] }, "gnft_LifeExpectancyDescription": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "LifeExpectancyDescription", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails", "http://www.genfit.com/role/EmployeeBenefitsSummaryofAssumptionsUsedforEmployeesfortheMeasurementofRetirementIndemnitytoEmployeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Life expectancy", "label": "Life Expectancy Description", "documentation": "Life expectancy description." } } }, "auth_ref": [] }, "gnft_NumberOfSegment": { "xbrltype": "integerItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "NumberOfSegment", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofApplicableExchangeRatesUsedtoTranslateFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of segment", "label": "Number Of Segment", "documentation": "Number of segment." } } }, "auth_ref": [] }, "gnft_DisclosureOfCommitmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DisclosureOfCommitmentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Commitments [Abstract]", "label": "Disclosure Of Commitments [Abstract]", "documentation": "Disclosure of commitments." } } }, "auth_ref": [] }, "gnft_IncreaseInInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "IncreaseInInterestRate", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in interest rate (in percent)", "label": "Increase In Interest Rate", "documentation": "Increase In Interest Rate" } } }, "auth_ref": [] }, "ifrs-full_OtherCurrentReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherCurrentReceivables", "crdr": "debit", "calculation": { "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current receivables", "label": "Other current receivables" } }, "en": { "role": { "documentation": "The amount of current other receivables. [Refer: Other receivables]" } } }, "auth_ref": [ "r274" ] }, "gnft_RoyaltyIncomePercentOfCollaborativeSales": { "xbrltype": "percentItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "RoyaltyIncomePercentOfCollaborativeSales", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodSignatureofaLicensingandPartnershipAgreementwithIpsenDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty income, percent of collaborative sales", "label": "Royalty income, Percent Of Collaborative Sales", "documentation": "Royalty income, Percent Of Collaborative Sales" } } }, "auth_ref": [] }, "gnft_RoyaltiesOnCommercialSalesRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "RoyaltiesOnCommercialSalesRecognized", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalties on commercial sales recognized", "label": "Royalties On Commercial Sales Recognized", "documentation": "Royalties on commercial sales recognized." } } }, "auth_ref": [] }, "gnft_BuybackOfDebtInstrumentAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "BuybackOfDebtInstrumentAmount", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Buyback amount", "label": "Buyback Of Debt Instrument Amount", "documentation": "Buyback of debt instrument amount." } } }, "auth_ref": [] }, "gnft_BuybackOfDebtInstrument": { "xbrltype": "integerItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "BuybackOfDebtInstrument", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Buyback instrument", "label": "Buyback Of Debt Instrument", "documentation": "Buyback of debt instrument." } } }, "auth_ref": [] }, "gnft_AdjustmentsForImpairmentAndProvisionForLitigation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "AdjustmentsForImpairmentAndProvisionForLitigation", "crdr": "debit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "+ Impairment and provision for litigation", "label": "Adjustments For Impairment And Provision For Litigation", "documentation": "Adjustments for impairment and provision for litigation." } } }, "auth_ref": [] }, "gnft_LoansGrantedInContextOfCOVID19Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "LoansGrantedInContextOfCOVID19Member", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loans Granted in Context of COVID-19", "label": "Loans Granted in Context of COVID-19 [Member]", "documentation": "Loans Granted in Context of COVID-19" } } }, "auth_ref": [] }, "gnft_AGAD2019Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "AGAD2019Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "A G A D2019 [Member]", "label": "A G A D2019 [Member]", "documentation": "AGA D 2019." } } }, "auth_ref": [] }, "gnft_ChangesInWorkingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ChangesInWorkingCapitalAbstract", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Changes In Working Capital [Abstract]", "label": "Changes In Working Capital [Abstract]", "documentation": "Changes in working capital abstract." } } }, "auth_ref": [] }, "gnft_NumberOfYearsOfSuccessivePlan": { "xbrltype": "durationItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "NumberOfYearsOfSuccessivePlan", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of years of successive plan", "label": "Number Of Years Of Successive Plan", "documentation": "Number of years of successive plan." } } }, "auth_ref": [] }, "ifrs-full_TaxEffectOfForeignTaxRates": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TaxEffectOfForeignTaxRates", "crdr": "debit", "calculation": { "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax effect of foreign tax rates", "negatedTerseLabel": "Tax effect of foreign tax rates", "label": "Tax effect of foreign tax rates" } }, "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to foreign tax rates. [Refer: Accounting profit]" } } }, "auth_ref": [ "r61" ] }, "ifrs-full_TaxEffectOfTaxLosses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TaxEffectOfTaxLosses", "crdr": "debit", "calculation": { "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxNarrativeDetails", "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax effect of tax losses", "negatedTerseLabel": "Tax effect of tax losses", "label": "Tax effect of tax losses" } }, "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to tax losses. [Refer: Accounting profit]" } } }, "auth_ref": [ "r61" ] }, "ifrs-full_TaxExpenseIncomeAtApplicableTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TaxExpenseIncomeAtApplicableTaxRate", "crdr": "debit", "calculation": { "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax expense (income) at applicable tax rate", "negatedTerseLabel": "Tax expense (income) at applicable tax rate", "label": "Tax expense (income) at applicable tax rate" } }, "en": { "role": { "documentation": "The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]" } } }, "auth_ref": [ "r61" ] }, "ifrs-full_CapitalRequirementsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CapitalRequirementsAxis", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capital requirements [axis]", "label": "Capital requirements [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r8" ] }, "ifrs-full_CapitalRequirementsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CapitalRequirementsMember", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capital requirements [member]", "label": "Capital requirements [member]" } }, "en": { "role": { "documentation": "This member stands for capital requirements that the entity is subject to. It also represents the standard value for the 'Capital requirements' axis if no other member is used." } } }, "auth_ref": [ "r8" ] }, "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails", "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentSummaryofVariationsinTangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]", "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r69", "r73", "r128", "r131", "r137", "r138", "r139", "r140", "r141", "r225", "r234", "r235" ] }, "ifrs-full_CarryingAmountMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CarryingAmountMember", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails", "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentSummaryofVariationsinTangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying amount [member]", "label": "Carrying amount [member]" } }, "en": { "role": { "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]" } } }, "auth_ref": [ "r73", "r131", "r137", "r139", "r140", "r225", "r234", "r235" ] }, "ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised", "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Temporary differences", "label": "Deductible temporary differences for which no deferred tax asset is recognised" } }, "en": { "role": { "documentation": "The amount of deductible temporary differences for which no deferred tax asset is recognised in the statement of financial position. [Refer: Temporary differences [member]]" } } }, "auth_ref": [ "r63" ] }, "ifrs-full_Cash": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Cash", "crdr": "debit", "calculation": { "http://www.genfit.com/role/CashandCashEquivalentsSummaryofCashandCashEquivalentsDetails": { "parentTag": "ifrs-full_CashAndCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.genfit.com/role/CashandCashEquivalentsSummaryofCashandCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash", "label": "Cash" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]" } } }, "auth_ref": [ "r359" ] }, "ifrs-full_TemporaryDifferenceMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TemporaryDifferenceMember", "presentation": [ "http://www.genfit.com/role/IncomeTaxNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Temporary differences", "label": "Temporary differences [member]" } }, "en": { "role": { "documentation": "This member stands for differences between the carrying amount of an asset or liability in the statement of financial position and its tax base. Temporary differences may be either: (a) taxable temporary differences; or (b) deductible temporary differences. [Refer: Carrying amount [member]]" } } }, "auth_ref": [ "r66" ] }, "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember", "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Temporary difference, unused tax losses and unused tax credits [member]", "label": "Temporary difference, unused tax losses and unused tax credits [member]" } }, "en": { "role": { "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits. It also represents the standard value for the 'Temporary difference, unused tax losses and unused tax credits' axis if no other member is used. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } } }, "auth_ref": [ "r66" ] }, "ifrs-full_DeferredIncomeIncludingContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DeferredIncomeIncludingContractLiabilities", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/DeferredIncomeandRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income including contract liabilities", "label": "Deferred income including contract liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities representing income that has been received (or the amount is due) but is not yet earned, including contract liabilities. [Refer: Contract liabilities]" } } }, "auth_ref": [ "r332", "r335" ] }, "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis", "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Temporary difference, unused tax losses and unused tax credits [axis]", "label": "Temporary difference, unused tax losses and unused tax credits [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r66" ] }, "ifrs-full_DeferredIncomeOtherThanContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DeferredIncomeOtherThanContractLiabilities", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/DeferredIncomeandRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income other than contract liabilities", "label": "Deferred income other than contract liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities representing income that has been received (or the amount is due) but is not yet earned, other than contract liabilities. [Refer: Contract liabilities]" } } }, "auth_ref": [ "r332", "r335" ] }, "ifrs-full_TerminationBenefitsExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TerminationBenefitsExpense", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee expenses related to work force reduction", "label": "Termination benefits expense" } }, "en": { "role": { "documentation": "The amount of expense in relation to termination benefits. Termination benefits are employee benefits provided in exchange for the termination of an employee's employment as a result of either: (a) an entity's decision to terminate an employee's employment before the normal retirement date; or (b) an employee's decision to accept an offer of benefits in exchange for the termination of employment. [Refer: Employee benefits expense]" } } }, "auth_ref": [ "r344" ] }, "ifrs-full_CashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 2.0 }, "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails": { "parentTag": "gnft_TotalAcquiredAssets", "weight": 1.0, "order": 6.0 }, "http://www.genfit.com/role/CashandCashEquivalentsSummaryofCashandCashEquivalentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.genfit.com/role/CashandCashEquivalentsSummaryofCashandCashEquivalentsDetails", "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows", "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofCHFagainstEuroDetails", "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofUSDollaragainstEuroDetails", "http://www.genfit.com/role/FinancialRisksManagementSummaryofCashCashEquivalentsandFinancialAssetsDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "periodStartLabel": "Cash and cash equivalents at the beginning of the period", "periodEndLabel": "Cash and cash equivalents at the end of the period", "verboseLabel": "Cash and cash equivalents", "totalLabel": "Total cash and cash equivalents", "label": "Cash and cash equivalents" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } } }, "auth_ref": [ "r17", "r148", "r172" ] }, "country_CH": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "CH", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofApplicableExchangeRatesUsedtoTranslateFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SWITZERLAND", "label": "SWITZERLAND" } } }, "auth_ref": [] }, "ifrs-full_DeferredTaxAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DeferredTaxAssets", "crdr": "debit", "calculation": { "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails": { "parentTag": "ifrs-full_DeferredTaxLiabilityAsset", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxNarrativeDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Deferred tax assets", "periodEndLabel": "Deferred tax assets", "terseLabel": "Deferred tax assets", "label": "Deferred tax assets" } }, "en": { "role": { "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } } }, "auth_ref": [ "r21", "r25", "r64" ] }, "ifrs-full_CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashAndCashEquivalentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents [abstract]", "label": "Cash and cash equivalents [abstract]" } } }, "auth_ref": [] }, "gnft_NumberOfEmployeesHoldShareCapitalOfRelatedParty": { "xbrltype": "integerItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "NumberOfEmployeesHoldShareCapitalOfRelatedParty", "presentation": [ "http://www.genfit.com/role/RelatedPartiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of employees hold share capital of related party", "label": "Number Of Employees Hold Share Capital Of Related Party", "documentation": "Number of employees hold share capital of related party." } } }, "auth_ref": [] }, "gnft_GovernmentGrantNetOfFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "GovernmentGrantNetOfFees", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Government grant, net of fees", "label": "Government Grant, Net Of Fees", "documentation": "Government Grant, Net Of Fees" } } }, "auth_ref": [] }, "gnft_DenominatedInEURMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DenominatedInEURMember", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagementSummaryofCashCashEquivalentsandFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Denominated in EUR", "label": "Denominated In E U R [Member]", "documentation": "Denominated in EUR." } } }, "auth_ref": [] }, "gnft_NumberOfOtherEquityInstrumentsExercisableInShareBasedPaymentArrangementRelatingToTheProductPipelineOfTheCompany": { "xbrltype": "sharesItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "NumberOfOtherEquityInstrumentsExercisableInShareBasedPaymentArrangementRelatingToTheProductPipelineOfTheCompany", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of other equity instruments exercisable in share-based payment arrangement relating to the product pipeline of the Company", "label": "Number of other equity instruments exercisable in share-based payment arrangement relating to the product pipeline of the Company", "documentation": "Number of other equity instruments exercisable in share-based payment arrangement relating to the product pipeline of the Company" } } }, "auth_ref": [] }, "gnft_TradePayablesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "TradePayablesMember", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade Payables [Member]", "label": "Trade Payables [Member]", "documentation": "Trade payables." } } }, "auth_ref": [] }, "ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AccumulatedDepreciationAmortisationAndImpairmentMember", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Depreciation and Impairment", "label": "Accumulated depreciation, amortisation and impairment [member]" } }, "en": { "role": { "documentation": "This member stands for accumulated depreciation, amortisation and impairment. [Refer: Impairment loss; Depreciation and amortisation expense]" } } }, "auth_ref": [ "r69", "r75", "r128", "r138", "r141" ] }, "gnft_CelloramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "CelloramMember", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Celloram", "label": "Celloram [Member]", "documentation": "Celloram" } } }, "auth_ref": [] }, "gnft_BorrowingsAmountDerecognizedAmendedObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "BorrowingsAmountDerecognizedAmendedObligation", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount derecognized", "label": "Borrowings, Amount Derecognized, Amended Obligation", "documentation": "Borrowings, Amount Derecognized, Amended Obligation" } } }, "auth_ref": [] }, "gnft_BuybackOfDebtInstrumentPercentageOfOutstanding": { "xbrltype": "percentItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "BuybackOfDebtInstrumentPercentageOfOutstanding", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Buyback amount (percent)", "label": "Buyback Of Debt Instrument Percentage Of Outstanding", "documentation": "Buyback of debt instrument percentage of outstanding." } } }, "auth_ref": [] }, "gnft_AGAD20161Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "AGAD20161Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "A G A D20161 [Member]", "label": "A G A D20161 [Member]", "documentation": "AGA D 2016-1." } } }, "auth_ref": [] }, "gnft_TotalAcquiredLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "TotalAcquiredLiabilities", "crdr": "credit", "calculation": { "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails": { "parentTag": "gnft_TotalPurchasePrice", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total acquired liabilities", "label": "Total acquired liabilities", "documentation": "Total acquired liabilities" } } }, "auth_ref": [] }, "gnft_ReorganizationCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ReorganizationCosts", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reorganization costs", "label": "Reorganization Costs", "documentation": "Reorganization costs." } } }, "auth_ref": [] }, "ifrs-full_AggregatedMeasurementMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AggregatedMeasurementMember", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregated measurement [member]", "label": "Aggregated measurement [member]" } }, "en": { "role": { "documentation": "This member stands for all types of measurement. It also represents the standard value for the 'Measurement' axis if no other member is used." } } }, "auth_ref": [ "r136", "r140", "r178" ] }, "gnft_BonusGeneratedByThePartialBuybackFollowingTheRenegotiation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "BonusGeneratedByThePartialBuybackFollowingTheRenegotiation", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/CashflowstatementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bonus generated by the partial buyback following the renegotiation", "label": "Bonus generated by the partial buyback following the renegotiation", "documentation": "Bonus generated by the partial buyback following the renegotiation" } } }, "auth_ref": [] }, "ifrs-full_RestatedMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RestatedMember", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Currently stated [member]", "label": "Currently stated [member]" } }, "en": { "role": { "documentation": "This member stands for the information currently stated in the financial statements. It also represents the standard value for the 'Retrospective application and retrospective restatement' and 'Departure from requirement of IFRS' axes if no other member is used." } } }, "auth_ref": [ "r2", "r152", "r153", "r156", "r199", "r330" ] }, "gnft_NumberOfFreeSharesAcquried": { "xbrltype": "sharesItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "NumberOfFreeSharesAcquried", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of free shares acquried", "label": "Number of free shares acquried", "documentation": "Number of free shares acquried" } } }, "auth_ref": [] }, "gnft_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatoryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatoryTextBlock", "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Trade and Other Receivables", "label": "Disclosure Of Detailed Information About Trade And Other Receivables Explanatory [Text Block]", "documentation": "The disclosure of detailed information about trade and other receivables." } } }, "auth_ref": [] }, "ifrs-full_AggregatedTimeBandsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AggregatedTimeBandsMember", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails", "http://www.genfit.com/role/EmployeeBenefitsSummaryofAssumptionsUsedforEmployeesfortheMeasurementofRetirementIndemnitytoEmployeesDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofMaturitiesofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregated time bands [member]", "label": "Aggregated time bands [member]" } }, "en": { "role": { "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used." } } }, "auth_ref": [ "r28", "r189", "r194", "r196", "r197", "r198", "r200", "r206", "r229", "r283", "r304", "r306" ] }, "gnft_RevenueOnSupplyOfDrugProductRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "RevenueOnSupplyOfDrugProductRecognized", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue on supply of drug product recognized", "label": "Revenue On Supply Of Drug Product Recognized", "documentation": "Revenue on supply of drug product recognized." } } }, "auth_ref": [] }, "gnft_ReversalImpairmentOfRightsRelatedToLeasedEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ReversalImpairmentOfRightsRelatedToLeasedEquipmentMember", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reversal Impairment Of Rights Related To Leased Equipment", "label": "Reversal Impairment Of Rights Related To Leased Equipment [Member]", "documentation": "Reversal Impairment Of Rights Related To Leased Equipment" } } }, "auth_ref": [] }, "gnft_ResearchTaxCreditReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ResearchTaxCreditReceivable", "crdr": "debit", "calculation": { "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails": { "parentTag": "ifrs-full_TradeAndOtherReceivables", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research Tax Credit Receivable", "label": "Research Tax Credit Receivable", "documentation": "Research Tax Credit Receivable" } } }, "auth_ref": [] }, "gnft_BPIPGEMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "BPIPGEMember", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BPI PGE [Member]", "label": "BPI PGE [Member]", "documentation": "BPI PGE" } } }, "auth_ref": [] }, "gnft_DisclosureOfCompensationOfCorporateOfficersAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DisclosureOfCompensationOfCorporateOfficersAbstract", "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Compensation Of Corporate Officers [Abstract]", "label": "Disclosure Of Compensation Of Corporate Officers [Abstract]", "documentation": "Disclosure of compensation of corporate officers." } } }, "auth_ref": [] }, "gnft_BPIPretTauxBonifieMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "BPIPretTauxBonifieMember", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BPI Pret Taux Bonifie [Member]", "label": "BPI Pret Taux Bonifie [Member]", "documentation": "BPI Pret Taux Bonifie" } } }, "auth_ref": [] }, "gnft_IncreaseDecreaseInProvisionClosingCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "IncreaseDecreaseInProvisionClosingCost", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Increase (Decrease) In Provision Closing Cost", "label": "Increase (Decrease) In Provision Closing Cost", "documentation": "Increase (Decrease) In Provision Closing Cost" } } }, "auth_ref": [] }, "gnft_PercentageOfExercisableInstrumentsRelatingToTheDevelopmentOfNTZAndTheACLFFranchise": { "xbrltype": "percentItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "PercentageOfExercisableInstrumentsRelatingToTheDevelopmentOfNTZAndTheACLFFranchise", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsParentheticalDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of exercisable instruments relating to the development of NTZ and the ACLF franchise", "label": "Percentage Of Exercisable Instruments Relating To The Development Of NTZ And The ACLF Franchise", "documentation": "Percentage Of Exercisable Instruments Relating To The Development Of NTZ And The ACLF Franchise" } } }, "auth_ref": [] }, "ifrs-full_RestructuringProvision": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RestructuringProvision", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provision recognized for closing costs", "label": "Restructuring provision" } }, "en": { "role": { "documentation": "The amount of provision for restructuring, such as the sale or termination of a line of business; closure of business locations in a country or region or relocation of activities from one country or region to another; changes in management structure; and fundamental reorganisations that have a material effect on the nature and focus of the entity's operations. [Refer: Other provisions]" } } }, "auth_ref": [ "r286" ] }, "gnft_RentalPaymentObligationUnderLeaseAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "RentalPaymentObligationUnderLeaseAgreement", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/CommitmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rental payment obligation under the lease agreement", "label": "Rental Payment Obligation Under Lease Agreement", "documentation": "Rental payment obligation under lease agreement." } } }, "auth_ref": [] }, "gnft_ResearchAndLaboratoryEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ResearchAndLaboratoryEquipmentMember", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Laboratory Equipment", "label": "Research And Laboratory Equipment [Member]", "documentation": "Research and laboratory equipment." } } }, "auth_ref": [] }, "gnft_DiscountedRate": { "xbrltype": "percentItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DiscountedRate", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discounted rate", "label": "Discounted Rate", "documentation": "Discounted rate." } } }, "auth_ref": [] }, "gnft_LoansAndReceivablesVariations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "LoansAndReceivablesVariations", "crdr": "debit", "calculation": { "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails": { "parentTag": "gnft_FinancialAssetsVariations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loans And Receivables, Variations", "label": "Loans And Receivables, Variations", "documentation": "Loans And Receivables, Variations" } } }, "auth_ref": [] }, "gnft_NumberOfBankLoans": { "xbrltype": "decimalItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "NumberOfBankLoans", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number Of Bank Loans", "label": "Number Of Bank Loans", "documentation": "Number Of Bank Loans" } } }, "auth_ref": [] }, "gnft_StockOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "StockOptionsMember", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options", "label": "Stock Options [Member]", "documentation": "Stock Options." } } }, "auth_ref": [] }, "ifrs-full_RestructuringProvisionMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RestructuringProvisionMember", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/OperatingExpenseAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring provision", "label": "Restructuring provision [member]" } }, "en": { "role": { "documentation": "This member stands for a provision for restructuring, such as the sale or termination of a line of business; closure of business locations in a country or region or relocation of activities from one country or region to another; changes in management structure; and fundamental reorganisations that have a material effect on the nature and focus of the entity's operations. [Refer: Other provisions [member]]" } } }, "auth_ref": [ "r286" ] }, "gnft_LiquidityContractNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "LiquidityContractNet", "crdr": "debit", "calculation": { "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails_1": { "parentTag": "ifrs-full_OtherFinancialAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsAdditionalInformationDetails", "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liquidity Contract Net", "verboseLabel": "Liquidity account, cash balance", "label": "Liquidity Contract Net", "documentation": "Liquidity contract net." } } }, "auth_ref": [] }, "gnft_DeferredIncomeAndRevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DeferredIncomeAndRevenueAbstract", "lang": { "en-us": { "role": { "label": "Deferred Income and Revenue [Abstract]", "documentation": "Deferred Income and Revenue [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_AllLevelsOfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AllLevelsOfFairValueHierarchyMember", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "All levels of fair value hierarchy [member]", "label": "All levels of fair value hierarchy [member]" } }, "en": { "role": { "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used." } } }, "auth_ref": [ "r84", "r179" ] }, "gnft_FirstYearMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "FirstYearMember", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "First Year", "label": "First Year [Member]", "documentation": "First Year" } } }, "auth_ref": [] }, "gnft_DebtInstrumentLoanDefermentOnInterestPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DebtInstrumentLoanDefermentOnInterestPeriod", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loan deferment on interest, period (in years)", "label": "Debt Instrument, Loan Deferment on Interest, Period", "documentation": "Debt Instrument, Loan Deferment on Interest, Period" } } }, "auth_ref": [] }, "gnft_LongTermDepositsAndGuaranteesVariations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "LongTermDepositsAndGuaranteesVariations", "crdr": "debit", "calculation": { "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails": { "parentTag": "gnft_FinancialAssetsVariations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long Term Deposits And Guarantees, Variations", "label": "Long Term Deposits And Guarantees, Variations", "documentation": "Long Term Deposits And Guarantees, Variations" } } }, "auth_ref": [] }, "gnft_IncreaseDecreaseInFinancialAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "IncreaseDecreaseInFinancialAssetsAxis", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase Decrease In Financial Assets [Axis]", "label": "Increase Decrease In Financial Assets [Axis]", "documentation": "Increase Decrease In Financial Assets" } } }, "auth_ref": [] }, "gnft_LicenseAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "LicenseAgreementsMember", "presentation": [ "http://www.genfit.com/role/DeferredIncomeandRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "License Agreements", "label": "License Agreements [Member]", "documentation": "License Agreements" } } }, "auth_ref": [] }, "gnft_AccountReversalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "AccountReversalMember", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Account Reversal", "label": "Account Reversal [Member]", "documentation": "Account Reversal" } } }, "auth_ref": [] }, "ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriodMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RetainedEarningsExcludingProfitLossForReportingPeriodMember", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings, excluding profit (loss) for reporting period [member]", "label": "Retained earnings, excluding profit (loss) for reporting period [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit, excluding profit or loss for the reporting period. [Refer: Retained earnings [member]]" } } }, "auth_ref": [ "r327" ] }, "ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RetainedEarningsExcludingProfitLossForReportingPeriod", "crdr": "credit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings (accumulated deficit)", "label": "Retained earnings, excluding profit (loss) for reporting period" } }, "en": { "role": { "documentation": "A component of equity representing the entity\u2019s cumulative undistributed earnings or deficit excluding the profit or loss for the reporting period. [Refer: Retained earnings]" } } }, "auth_ref": [ "r334" ] }, "ifrs-full_TypesOfInterestRatesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TypesOfInterestRatesAxis", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of interest rates [axis]", "label": "Types of interest rates [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r361" ] }, "gnft_BSA2017BMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "BSA2017BMember", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "B S A2017 B [Member]", "label": "B S A2017 B [Member]", "documentation": "BSA 2017-B." } } }, "auth_ref": [] }, "ifrs-full_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RetainedEarningsMember", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings (accumulated deficit)", "label": "Retained earnings [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit." } } }, "auth_ref": [ "r7", "r271" ] }, "gnft_SOUS12019Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "SOUS12019Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "S O US 1 2019", "label": "S O US 1 2019 [Member]", "documentation": "S O US 1 2019" } } }, "auth_ref": [] }, "ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RetainedEarningsProfitLossForReportingPeriodMember", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Net profit (loss)", "label": "Retained earnings, profit (loss) for reporting period [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing the entity\u2019s undistributed profit or loss for the reporting period. [Refer: Retained earnings [member]; Profit (loss)]" } } }, "auth_ref": [ "r327" ] }, "gnft_FairValueOfShareOptionsShareBasedPaymentArrangement": { "xbrltype": "perShareItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "FairValueOfShareOptionsShareBasedPaymentArrangement", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value", "label": "Fair Value Of Share Options Share Based Payment Arrangement", "documentation": "Fair value of share options share based payment arrangement." } } }, "auth_ref": [] }, "ifrs-full_RetainedEarningsProfitLossForReportingPeriod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RetainedEarningsProfitLossForReportingPeriod", "crdr": "credit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Net profit (loss)", "label": "Retained earnings, profit (loss) for reporting period" } }, "en": { "role": { "documentation": "A component of equity representing the entity\u2019s undistributed profit or loss for the reporting period. [Refer: Retained earnings; Profit (loss)]" } } }, "auth_ref": [ "r334" ] }, "gnft_NoncurrentGrantsReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "NoncurrentGrantsReceivables", "crdr": "debit", "calculation": { "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails": { "parentTag": "ifrs-full_NoncurrentReceivables", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Noncurrent Grants Receivables", "label": "Noncurrent Grants Receivables", "documentation": "Noncurrent grants receivables." } } }, "auth_ref": [] }, "gnft_CICFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "CICFiveMember", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "C I C Five [Member]", "label": "C I C Five [Member]", "documentation": "CIC 5." } } }, "auth_ref": [] }, "gnft_TaxEffectOfNonRecognitionOfDeferredTaxAssetsRelatedToTemporaryDifferences": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "TaxEffectOfNonRecognitionOfDeferredTaxAssetsRelatedToTemporaryDifferences", "crdr": "debit", "calculation": { "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax expense (income) relating to origination and reversal of temporary differences", "negatedTerseLabel": "Tax Effect Of Non-Recognition Of Deferred Tax Assets Related To Temporary Differences", "label": "Tax Effect Of Non-Recognition Of Deferred Tax Assets Related To Temporary Differences", "documentation": "Tax Effect Of Non-Recognition Of Deferred Tax Assets Related To Temporary Differences" } } }, "auth_ref": [] }, "gnft_GenosciencePharmaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "GenosciencePharmaMember", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/OtherFinancialAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Genoscience Pharma", "label": "Genoscience Pharma [Member]", "documentation": "Genoscience Pharma" } } }, "auth_ref": [] }, "gnft_ReturnToWorkBonusesTrainingsBusinessStartUpAssistanceAndOtherBenefitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ReturnToWorkBonusesTrainingsBusinessStartUpAssistanceAndOtherBenefitsMember", "presentation": [ "http://www.genfit.com/role/ProvisionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Return-to-Work Bonuses, Trainings, Business Start-Up Assistance and Other Benefits", "label": "Return-To-Work Bonuses, Trainings, Business Start-Up Assistance And Other Benefits [Member]", "documentation": "Return-To-Work Bonuses, Trainings, Business Start-Up Assistance And Other Benefits" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfVestingRequirementsForSharebasedPaymentArrangement", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting period", "label": "Description of vesting requirements for share-based payment arrangement" } }, "en": { "role": { "documentation": "The description of the vesting requirements for a type of share-based payment arrangement that existed at any time during the period. An entity with substantially similar types of share-based payment arrangements may aggregate this information. [Refer: Share-based payment arrangements [member]]" } } }, "auth_ref": [ "r209" ] }, "gnft_FredericDESDOUITSMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "FredericDESDOUITSMember", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersScheduleofDirectorsFeesandOtherCompensationDueandPaidtoNonExecutiveDirectorsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Frederic D E S D O U I T S [Member]", "label": "Frederic D E S D O U I T S [Member]", "documentation": "Frederic DESDOUITS." } } }, "auth_ref": [] }, "ifrs-full_TypesOfRisksAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TypesOfRisksAxis", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagementAdditionalInformationDetails", "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofCHFagainstEuroDetails", "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofUSDollaragainstEuroDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of risks [axis]", "label": "Types of risks [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r201", "r202", "r203", "r205", "r228", "r231", "r232" ] }, "ifrs-full_PropertyPlantAndEquipmentSubjectToOperatingLeasesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PropertyPlantAndEquipmentSubjectToOperatingLeasesMember", "presentation": [ "http://www.genfit.com/role/OperatingExpenseAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment subject to operating leases [member]", "label": "Property, plant and equipment subject to operating leases [member]" } }, "en": { "role": { "documentation": "This member stands for property, plant and equipment that is subject to operating leases. Operating lease is a lease that does not transfer substantially all the risks and rewards incidental to ownership of an underlying asset. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r195" ] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipAxis", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodSignatureofaLicensingandPartnershipAgreementwithIpsenDetails", "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails", "http://www.genfit.com/role/RelatedPartiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Axis]", "label": "Ownership [Axis]" } } }, "auth_ref": [] }, "ifrs-full_ProvisionsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProvisionsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Provisions [abstract]", "label": "Provisions [abstract]" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipDomain", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodSignatureofaLicensingandPartnershipAgreementwithIpsenDetails", "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails", "http://www.genfit.com/role/RelatedPartiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Domain]", "label": "Ownership [Domain]" } } }, "auth_ref": [] }, "ifrs-full_ProportionOfOwnershipInterestInAssociate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProportionOfOwnershipInterestInAssociate", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodSignatureofaLicensingandPartnershipAgreementwithIpsenDetails", "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails", "http://www.genfit.com/role/RelatedPartiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proportion of ownership interest in associate (as a percent)", "label": "Proportion of ownership interest in associate" } }, "en": { "role": { "documentation": "The proportion of ownership interest in an associate attributable to the entity. [Refer: Associates [member]]" } } }, "auth_ref": [ "r108", "r110", "r164" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails", "http://www.genfit.com/role/ShareBasedCompensationAdditionalInformationDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/ShareBasedCompensationAdditionalInformationDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [] }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CumulativeEffectPeriodOfAdoptionDomain", "presentation": [ "http://www.genfit.com/role/BasisofPresentationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative Effect, Period of Adoption [Domain]", "label": "Cumulative Effect, Period of Adoption [Domain]" } } }, "auth_ref": [] }, "ifrs-full_ProvisionUsedOtherProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProvisionUsedOtherProvisions", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provision used, other provisions", "label": "Provision used, other provisions" } }, "en": { "role": { "documentation": "The amount used (ie incurred and charged against the provision) for other provisions. [Refer: Other provisions]" } } }, "auth_ref": [ "r121" ] }, "ifrs-full_ChangesInOtherProvisionsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ChangesInOtherProvisionsAbstract", "lang": { "en-us": { "role": { "label": "Changes in other provisions [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ActuarialAssumptionOfExpectedRatesOfSalaryIncreases", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails", "http://www.genfit.com/role/EmployeeBenefitsSummaryofAssumptionsUsedforEmployeesfortheMeasurementofRetirementIndemnitytoEmployeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Salary growth rate (as a percent)", "label": "Actuarial assumption of expected rates of salary increases" } }, "en": { "role": { "documentation": "The expected rate of salary increases used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit plans [member]; Defined benefit obligation, at present value; Actuarial assumptions [member]]" } } }, "auth_ref": [ "r343" ] }, "ifrs-full_ProvisionsForEmployeeBenefits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProvisionsForEmployeeBenefits", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/BasisofPresentationDetails", "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provisions for employee benefits", "label": "Provisions for employee benefits" } }, "en": { "role": { "documentation": "The amount of provisions for employee benefits. [Refer: Employee benefits expense; Provisions]" } } }, "auth_ref": [ "r33" ] }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CumulativeEffectPeriodOfAdoptionAxis", "presentation": [ "http://www.genfit.com/role/BasisofPresentationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative Effect, Period of Adoption [Axis]", "label": "Cumulative Effect, Period of Adoption [Axis]" } } }, "auth_ref": [] }, "gnft_IncreaseDecreaseThroughCapitalIncrease": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "IncreaseDecreaseThroughCapitalIncrease", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity", "http://www.genfit.com/role/EquityAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase Decrease Through Capital Increase", "label": "Increase Decrease Through Capital Increase", "documentation": "Increase (decrease) through capital increase." } } }, "auth_ref": [] }, "gnft_ReorganizationAndRestructuringExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ReorganizationAndRestructuringExpenses", "crdr": "debit", "calculation": { "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails": { "parentTag": "gnft_ResearchAndDevelopmentExpenseGeneralAndAdministrativeExpenseMarketingAndMarketAccessExpenseAndOtherOperatingIncomeAndExpense", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Reorganization And Restructuring Expenses", "label": "Reorganization And Restructuring Expenses", "documentation": "This amount represents a transfer of expenses relating to employee training expenses." } } }, "auth_ref": [] }, "ifrs-full_IssuedCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IssuedCapital", "crdr": "credit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Share capital", "label": "Issued capital" } }, "en": { "role": { "documentation": "The nominal value of capital issued." } } }, "auth_ref": [ "r275" ] }, "gnft_ImpactOnSubcontractingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ImpactOnSubcontractingCosts", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriod", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodTerminationofRESOLVEITandthedevelopmentprogramofelafibranorinNASHDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impact On Subcontracting Costs", "label": "Impact On Subcontracting Costs", "documentation": "Impact On Subcontracting Costs" } } }, "auth_ref": [] }, "gnft_IFRS19Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "IFRS19Member", "presentation": [ "http://www.genfit.com/role/BasisofPresentationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "IFRS 19", "label": "IFRS 19 [Member]", "documentation": "IFRS 19" } } }, "auth_ref": [] }, "gnft_BorrowingsInterestRatePayableSemiAnnually": { "xbrltype": "percentItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "BorrowingsInterestRatePayableSemiAnnually", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBondsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual nominal interest rate, payable semi-annually (in percent)", "label": "Borrowings, Interest rate, Payable Semi-annually", "documentation": "Borrowings, Interest rate, Payable Semi-annually" } } }, "auth_ref": [] }, "gnft_GainLossOnDisposalOfPropertyPlantAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "GainLossOnDisposalOfPropertyPlantAndEquipmentMember", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain / (loss) on disposal of property, plant & equipment", "label": "Gain Loss On Disposal Of Property Plant And Equipment [Member]", "documentation": "Gain loss on disposal of property, plant, and equipment." } } }, "auth_ref": [] }, "gnft_DisclosureOfDetailedInformationAboutFinancialIncomeAndExpensesExplanatoryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DisclosureOfDetailedInformationAboutFinancialIncomeAndExpensesExplanatoryTextBlock", "presentation": [ "http://www.genfit.com/role/FinancialIncomeandExpensesTables", "http://www.genfit.com/role/Statementoffinancialpositioncurrentnoncurrent" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Financial Income and Expenses", "label": "Disclosure Of Detailed Information About Financial Income And Expenses Explanatory [Text Block]", "documentation": "Disclosure of detailed information about financial income and expenses." } } }, "auth_ref": [] }, "gnft_TenPercentDecreaseOfUSDollarVsEuroMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "TenPercentDecreaseOfUSDollarVsEuroMember", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofUSDollaragainstEuroDetails" ], "lang": { "en-us": { "role": { "terseLabel": "10% Decrease of US Dollar vs Euro", "label": "Ten Percent Decrease Of U S Dollar Vs Euro [Member]", "documentation": "10% decrease of US dollar vs Euro." } } }, "auth_ref": [] }, "gnft_NumberOfSharesWithDoubleVotingRights": { "xbrltype": "sharesItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "NumberOfSharesWithDoubleVotingRights", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares in entity held to entitle double voting rights (in shares)", "label": "Number Of Shares With Double Voting Rights", "documentation": "Number of shares with double voting rights." } } }, "auth_ref": [] }, "gnft_DisclosureOfShareBasedCompensationExpenseExplanatoryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DisclosureOfShareBasedCompensationExpenseExplanatoryTextBlock", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Share-based Compensation Under Each Plan According to Change in Estimate", "label": "Disclosure Of Share Based Compensation Expense Explanatory [Text Block]", "documentation": "Disclosure of share based compensation expense." } } }, "auth_ref": [] }, "gnft_BondsConvertibleOrExchangeableIntoExistingOrNewSharesOCEANEMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "BondsConvertibleOrExchangeableIntoExistingOrNewSharesOCEANEMember", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bonds Convertible Or Exchangeable Into Existing Or New Shares O C E A N E", "label": "Bonds Convertible Or Exchangeable Into Existing Or New Shares O C E A N E [Member]", "documentation": "Bonds Convertible Or Exchangeable Into Existing Or New Shares O C E A N E" } } }, "auth_ref": [] }, "ifrs-full_IssuedCapitalMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IssuedCapitalMember", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Share capital", "label": "Issued capital [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } } }, "auth_ref": [ "r7" ] }, "gnft_DisclosureOfFinancialIncomeAndExpensesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DisclosureOfFinancialIncomeAndExpensesTable", "presentation": [ "http://www.genfit.com/role/FinancialIncomeandExpensesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Financial Income And Expenses [Table]", "label": "Disclosure Of Financial Income And Expenses [Table]", "documentation": "Disclosure of financial income and expenses." } } }, "auth_ref": [] }, "gnft_TermAccountsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "TermAccountsMember", "presentation": [ "http://www.genfit.com/role/CashandCashEquivalentsSummaryofCashandCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Accounts [Member]", "label": "Term Accounts [Member]", "documentation": "Term accounts." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "verboseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "ICFR Auditor Attestation Flag", "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r316", "r317", "r318" ] }, "gnft_LongTermDepositsAndGuarantees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "LongTermDepositsAndGuarantees", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long Term Deposits And Guarantees", "label": "Long Term Deposits And Guarantees", "documentation": "Long-term deposits and guarantees." } } }, "auth_ref": [] }, "ifrs-full_IssuedCapitalOrdinaryShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IssuedCapitalOrdinaryShares", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issued capital, ordinary shares", "label": "Issued capital, ordinary shares" } }, "en": { "role": { "documentation": "The nominal value of capital arising from issuing ordinary shares. [Refer: Issued capital]" } } }, "auth_ref": [ "r334" ] }, "gnft_AGAD20171Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "AGAD20171Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "A G A D20171 [Member]", "label": "A G A D20171 [Member]", "documentation": "AGA D 2017-1." } } }, "auth_ref": [] }, "gnft_Years2028AndThereafterMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "Years2028AndThereafterMember", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Years 2028 and thereafter", "label": "Years 2028 and thereafter [Member]", "documentation": "Years 2028 and thereafter" } } }, "auth_ref": [] }, "gnft_CEOCorporateContractNonCompeteIndemnityCompensationUponTerminationDescription1": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "CEOCorporateContractNonCompeteIndemnityCompensationUponTerminationDescription1", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CEO corporate contract non-compete indemnity compensation upon termination description", "label": "C E O Corporate Contract Non Compete Indemnity Compensation Upon Termination Description1", "documentation": "CEO corporate contract non-compete indemnity compensation upon termination description1." } } }, "auth_ref": [] }, "gnft_BNPThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "BNPThreeMember", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "B N P Three [Member]", "label": "B N P Three [Member]", "documentation": "BNP 3." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "gnft_ExpenseByNatureAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ExpenseByNatureAxis", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expense By Nature", "label": "Expense By Nature [Axis]", "documentation": "Expenses, by nature." } } }, "auth_ref": [] }, "gnft_DisclosureOfDetailedInformationAboutOtherFinancialAssetsExplanatoryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DisclosureOfDetailedInformationAboutOtherFinancialAssetsExplanatoryTextBlock", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssets", "http://www.genfit.com/role/OtherFinancialAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Other Financial Assets", "label": "Disclosure Of Detailed Information About Other Financial Assets Explanatory [Text Block]", "documentation": "Disclosure of detailed information about other financial assets." } } }, "auth_ref": [] }, "gnft_ResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ResearchAndDevelopmentMember", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research And Development [Member]", "label": "Research And Development [Member]", "documentation": "Research and development." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIntangibleAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfIntangibleAssetsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about intangible assets [abstract]", "label": "Disclosure of detailed information about intangible assets [abstract]" } } }, "auth_ref": [] }, "gnft_CatherineLARUEMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "CatherineLARUEMember", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersScheduleofDirectorsFeesandOtherCompensationDueandPaidtoNonExecutiveDirectorsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Catherine L A R U E [Member]", "label": "Catherine L A R U E [Member]", "documentation": "Catherine LARUE." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIntangibleAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfIntangibleAssetsExplanatory", "presentation": [ "http://www.genfit.com/role/IntangibleAssets" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets", "label": "Disclosure of intangible assets [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for intangible assets." } } }, "auth_ref": [ "r135" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfIntangibleAssetsLineItems", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about intangible assets [line items]", "label": "Disclosure of detailed information about intangible assets [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "gnft_IncreaseInProvisionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "IncreaseInProvisionsMember", "presentation": [ "http://www.genfit.com/role/ProvisionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in Provisions [Member]", "label": "Increase in Provisions [Member]", "documentation": "Increase in Provisions" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfIntangibleAssetsTable", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about intangible assets [table]", "label": "Disclosure of detailed information about intangible assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of intangible assets." } } }, "auth_ref": [ "r132" ] }, "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Translation adjustments", "label": "Increase (decrease) through net exchange differences, intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The increase (decrease) in intangible assets other than goodwill resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r130" ] }, "gnft_PercentageOfDoubleVotingRights": { "xbrltype": "percentItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "PercentageOfDoubleVotingRights", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of double voting rights", "label": "Percentage Of Double Voting Rights", "documentation": "Percentage of double voting rights." } } }, "auth_ref": [] }, "gnft_ServicesRelatedToResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ServicesRelatedToResearchAndDevelopmentMember", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Services Related To Research And Development [Member]", "label": "Services Related To Research And Development [Member]", "documentation": "Services related to research and development." } } }, "auth_ref": [] }, "ifrs-full_KeyManagementPersonnelCompensation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "KeyManagementPersonnelCompensation", "crdr": "debit", "calculation": { "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Key management personnel compensation", "label": "Key management personnel compensation" } }, "en": { "role": { "documentation": "The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]" } } }, "auth_ref": [ "r98" ] }, "ifrs-full_DisclosureOfIntangibleAssetsWithIndefiniteUsefulLifeLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfIntangibleAssetsWithIndefiniteUsefulLifeLineItems", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of intangible assets with indefinite useful life [line items]", "label": "Disclosure of intangible assets with indefinite useful life [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIntangibleAssetsWithIndefiniteUsefulLifeTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfIntangibleAssetsWithIndefiniteUsefulLifeTable", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofApplicableExchangeRatesUsedtoTranslateFinancialStatementsDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of intangible assets with indefinite useful life [table]", "label": "Disclosure of intangible assets with indefinite useful life [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to intangible assets with an indefinite useful life." } } }, "auth_ref": [ "r133" ] }, "ifrs-full_OperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OperatingExpense", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofCHFagainstEuroDetails", "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofUSDollaragainstEuroDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Expenses", "terseLabel": "Operating expense", "label": "Operating expense" } }, "en": { "role": { "documentation": "The amount of all operating expenses." } } }, "auth_ref": [ "r337" ] }, "ifrs-full_AssociatesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AssociatesMember", "presentation": [ "http://www.genfit.com/role/RelatedPartiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Associates [member]", "label": "Associates [member]" } }, "en": { "role": { "documentation": "This member stands for the entities over which the investor has significant influence." } } }, "auth_ref": [ "r100", "r109", "r111", "r177" ] }, "gnft_NumberOfOtherEquityInstrumentsAwardedInShareBasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "NumberOfOtherEquityInstrumentsAwardedInShareBasedPaymentArrangement", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number Of Other Equity Instruments Awarded In Share Based Payment Arrangement", "label": "Number Of Other Equity Instruments Awarded In Share Based Payment Arrangement", "documentation": "Number Of Other Equity Instruments Awarded In Share Based Payment Arrangement" } } }, "auth_ref": [] }, "gnft_RevisedTermsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "RevisedTermsMember", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revised terms", "label": "Revised terms [Member]", "documentation": "Revised terms" } } }, "auth_ref": [] }, "gnft_CurrentLiquidityContractNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "CurrentLiquidityContractNet", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current Liquidity Contract Net", "label": "Current Liquidity Contract Net", "documentation": "Current Liquidity Contract Net" } } }, "auth_ref": [] }, "gnft_OwnedEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "OwnedEquipmentMember", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodTerminationofRESOLVEITandthedevelopmentprogramofelafibranorinNASHDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Owned equipment", "label": "Owned Equipment [Member]", "documentation": "Owned equipment." } } }, "auth_ref": [] }, "ifrs-full_AtFairValueMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AtFairValueMember", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value", "label": "At fair value [member]" } }, "en": { "role": { "documentation": "This member stands for measurement based on fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date." } } }, "auth_ref": [ "r136", "r140", "r178" ] }, "ifrs-full_WeightedAverageSharePrice2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageSharePrice2019", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average share price", "label": "Weighted average share price" } }, "en": { "role": { "documentation": "The weighted average share price. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r213" ] }, "gnft_AccruedPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "AccruedPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/CashflowstatementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued property, plant and equipment", "label": "Accrued property, plant and equipment", "documentation": "Accrued property, plant and equipment" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageShares", "presentation": [ "http://www.genfit.com/role/EarningsLossPerShareSummaryofEarningsLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average number of ordinary shares for the period (shares)", "label": "Weighted average number of ordinary shares used in calculating basic earnings per share" } }, "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } } }, "auth_ref": [ "r114" ] }, "gnft_ScientificEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ScientificEquipmentMember", "presentation": [ "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentSummaryofVariationsinTangibleAssetsDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scientific Equipment [Member]", "label": "Scientific Equipment [Member]", "documentation": "Scientific equipment." } } }, "auth_ref": [] }, "gnft_SO2020Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "SO2020Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "S O 2020", "label": "S O 2020 [Member]", "documentation": "S O 2020" } } }, "auth_ref": [] }, "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AttributionOfExpensesByNatureToTheirFunctionAxis", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Attribution of expenses by nature to their function [axis]", "label": "Attribution of expenses by nature to their function [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r324", "r328" ] }, "gnft_CEOGrossNegligenceSeverancePayEligibilityPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "CEOGrossNegligenceSeverancePayEligibilityPeriod", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CEO gross negligence severance pay eligibility period", "label": "C E O Gross Negligence Severance Pay Eligibility Period", "documentation": "CEO gross negligence severance pay eligibility period." } } }, "auth_ref": [] }, "gnft_CEOCorporateContractNonCompeteIndemnityCompensationUponTerminationDescription": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "CEOCorporateContractNonCompeteIndemnityCompensationUponTerminationDescription", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CEO corporate contract non-compete indemnity compensation upon termination description", "label": "C E O Corporate Contract Non Compete Indemnity Compensation Upon Termination Description", "documentation": "CEO corporate contract non-compete indemnity compensation upon termination description." } } }, "auth_ref": [] }, "gnft_AcquisitionOfVersantisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "AcquisitionOfVersantisMember", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition of Versantis", "label": "Acquisition of Versantis [Member]", "documentation": "Acquisition of Versantis" } } }, "auth_ref": [] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/OtherFinancialAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Domain]", "label": "Investment, Name [Domain]" } } }, "auth_ref": [] }, "gnft_RevenueRemainingPerformanceObligationVariableContingentConsiderationAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "RevenueRemainingPerformanceObligationVariableContingentConsiderationAmount", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/CommitmentsAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent milestone payments", "label": "Revenue, Remaining Performance Obligation, Variable Contingent Consideration Amount", "documentation": "Revenue, Remaining Performance Obligation, Variable Contingent Consideration Amount" } } }, "auth_ref": [] }, "ifrs-full_OrdinarySharesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OrdinarySharesMember", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary shares [member]", "label": "Ordinary shares [member]" } }, "en": { "role": { "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments. It also represents the standard value for the 'Classes of ordinary shares' axis if no other member is used." } } }, "auth_ref": [ "r112", "r336" ] }, "gnft_ImpairmentReorganizationOfVacantPremises": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ImpairmentReorganizationOfVacantPremises", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/OperatingExpenseAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reorganization of vacant premises", "label": "Impairment, Reorganization Of Vacant Premises", "documentation": "Impairment, Reorganization Of Vacant Premises" } } }, "auth_ref": [] }, "gnft_BNPTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "BNPTwoMember", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "B N P Two [Member]", "label": "B N P Two [Member]", "documentation": "BNP 2." } } }, "auth_ref": [] }, "gnft_OfficersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "OfficersMember", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Officers", "verboseLabel": "Officers [Member]", "label": "Officers [Member]", "documentation": "Officers." } } }, "auth_ref": [] }, "ifrs-full_AverageEffectiveTaxRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AverageEffectiveTaxRate", "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Average effective tax rate", "label": "Average effective tax rate" } }, "en": { "role": { "documentation": "The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]" } } }, "auth_ref": [ "r62" ] }, "ifrs-full_OtherAdjustmentsForNoncashItems": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherAdjustmentsForNoncashItems", "crdr": "debit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "+ Other non-cash items", "label": "Other adjustments for non-cash items" } }, "en": { "role": { "documentation": "Adjustments for non-cash items to reconcile profit (loss) to net cash flow from (used in) operating activities that the entity does not separately disclose in the same statement or note. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r357" ] }, "gnft_PercentageOfExercisableInstrumentsRelatingToDevelopmentOfTheDevelopmentOfTheGNS561Program": { "xbrltype": "percentItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "PercentageOfExercisableInstrumentsRelatingToDevelopmentOfTheDevelopmentOfTheGNS561Program", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of exercisable instruments relating to development of the product pipeline of the company", "label": "Percentage Of Exercisable Instruments Relating To Development Of The development of the GNS561 program", "documentation": "Percentage Of Exercisable Instruments Relating To Development Of The development of the GNS561 program" } } }, "auth_ref": [] }, "gnft_RevenueFromContractsWithCustomersPotentialMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "RevenueFromContractsWithCustomersPotentialMilestonePayments", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodSignatureofaLicensingandPartnershipAgreementwithIpsenDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from collaboration, potential milestone payments", "label": "Revenue From Contracts With Customers, Potential Milestone Payments", "documentation": "Revenue From Contracts With Customers, Potential Milestone Payments" } } }, "auth_ref": [] }, "ifrs-full_AverageForeignExchangeRate": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AverageForeignExchangeRate", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofCHFagainstEuroDetails", "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofUSDollaragainstEuroDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofApplicableExchangeRatesUsedtoTranslateFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Average foreign exchange rate", "verboseLabel": "Euros equivalent to USD or CHF", "label": "Average foreign exchange rate" } }, "en": { "role": { "documentation": "The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies." } } }, "auth_ref": [ "r328" ] }, "gnft_DebtInstrumentRepaymentOptionsMaximumPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DebtInstrumentRepaymentOptionsMaximumPeriod", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repayment options, up to (in years)", "label": "Debt Instrument, Repayment Options, Maximum Period", "documentation": "Debt Instrument, Repayment Options, Maximum Period" } } }, "auth_ref": [] }, "gnft_AdditionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "AdditionsMember", "presentation": [ "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions", "label": "Additions [Member]", "documentation": "Additions" } } }, "auth_ref": [] }, "ifrs-full_AverageNumberOfEmployees": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AverageNumberOfEmployees", "presentation": [ "http://www.genfit.com/role/OperatingExpenseAdditionalInformationDetails", "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Average number of employees", "label": "Average number of employees" } }, "en": { "role": { "documentation": "The average number of personnel employed by the entity during a period." } } }, "auth_ref": [ "r328" ] }, "gnft_ReversalOfProvisionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ReversalOfProvisionMember", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reversal Of Provision", "label": "Reversal Of Provision [Member]", "documentation": "Reversal Of Provision" } } }, "auth_ref": [] }, "gnft_AnneHeleneMONSELLATOMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "AnneHeleneMONSELLATOMember", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersScheduleofDirectorsFeesandOtherCompensationDueandPaidtoNonExecutiveDirectorsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Anne Helene M O N S E L L A T O [Member]", "label": "Anne Helene M O N S E L L A T O [Member]", "documentation": "Anne-Helene MONSELLATO." } } }, "auth_ref": [] }, "gnft_TradingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "TradingPeriod", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBondsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trading period", "label": "Trading Period", "documentation": "Trading period." } } }, "auth_ref": [] }, "gnft_ResearchAndDevelopmentExpenseGeneralAndAdministrativeExpenseMarketingAndMarketAccessExpenseAndOtherOperatingIncomeAndExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ResearchAndDevelopmentExpenseGeneralAndAdministrativeExpenseMarketingAndMarketAccessExpenseAndOtherOperatingIncomeAndExpense", "crdr": "credit", "calculation": { "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Research And Development Expense General And Administrative Expense Marketing And Market Access Expense And Other Operating Income And Expense", "label": "Research And Development Expense General And Administrative Expense Marketing And Market Access Expense And Other Operating Income And Expense", "documentation": "Research and development expense, general and administrative expense, marketing and market access expense and other operating income and expense." } } }, "auth_ref": [] }, "ifrs-full_OtherBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherBorrowings", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofOtherLoansandBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other borrowings", "label": "Other borrowings" } }, "en": { "role": { "documentation": "The amount of borrowings that the entity does not separately disclose in the same statement or note. [Refer: Borrowings]" } } }, "auth_ref": [ "r328" ] }, "gnft_DebtInstrumentExtensionOfMaturityTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DebtInstrumentExtensionOfMaturityTerm", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Extension of maturity", "label": "Debt Instrument Extension Of Maturity Term", "documentation": "Debt Instrument extension of maturity." } } }, "auth_ref": [] }, "gnft_RevenueFromFranceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "RevenueFromFranceMember", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue From France", "label": "Revenue From France [Member]", "documentation": "Revenue From France" } } }, "auth_ref": [] }, "gnft_CashCashEquivalentsAndFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "CashCashEquivalentsAndFinancialAssets", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagementAdditionalInformationDetails", "http://www.genfit.com/role/FinancialRisksManagementSummaryofCashCashEquivalentsandFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total", "verboseLabel": "Cash and cash equivalents and other financial assets", "label": "Cash Cash Equivalents And Financial Assets", "documentation": "Cash, cash equivalents and financial assets." } } }, "auth_ref": [] }, "gnft_GrantsReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "GrantsReceivables", "crdr": "debit", "calculation": { "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails": { "parentTag": "ifrs-full_TradeAndOtherReceivables", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Grants Receivables", "label": "Grants Receivables", "documentation": "Grants receivables." } } }, "auth_ref": [] }, "gnft_ReorganizationAndReductionInForce": { "xbrltype": "textBlockItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ReorganizationAndReductionInForce", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriod", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodTerminationofRESOLVEITandthedevelopmentprogramofelafibranorinNASHDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ReorganizationAndReductionInForce", "label": "ReorganizationAndReductionInForce", "documentation": "ReorganizationAndReductionInForce" } } }, "auth_ref": [] }, "gnft_DateOfExecutiveBoardMeeting": { "xbrltype": "dateItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DateOfExecutiveBoardMeeting", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Date of the Executive Board Meeting", "label": "Date Of Executive Board Meeting", "documentation": "The date of the executive board meeting." } } }, "auth_ref": [] }, "ifrs-full_CurrentLoansAndReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentLoansAndReceivables", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current loans and receivables", "label": "Current loans and receivables" } }, "en": { "role": { "documentation": "The amount of current loans and receivables. [Refer: Loans and receivables]" } } }, "auth_ref": [ "r268" ] }, "currency_AllCurrenciesDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "AllCurrenciesDomain", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "All Currencies [Domain]", "label": "All Currencies [Domain]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsSummaryofMaturitiesofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of maturity analysis for derivative financial liabilities [line items]", "label": "Disclosure of maturity analysis for derivative financial liabilities [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsSummaryofMaturitiesofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of maturity analysis for derivative financial liabilities [table]", "label": "Disclosure of maturity analysis for derivative financial liabilities [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the maturity analysis for derivative financial liabilities." } } }, "auth_ref": [ "r241" ] }, "gnft_CreditNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "CreditNotesMember", "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit notes", "label": "Credit notes [Member]", "documentation": "Credit notes" } } }, "auth_ref": [] }, "ifrs-full_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComputerEquipmentMember", "presentation": [ "http://www.genfit.com/role/OperatingExpenseAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentSummaryofVariationsinTangibleAssetsDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Computer equipment [member]", "label": "Computer equipment [member]" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing computer equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r339" ] }, "gnft_BSA2017AMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "BSA2017AMember", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "B S A2017 A [Member]", "label": "B S A2017 A [Member]", "documentation": "BSA 2017-A." } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForDepreciationAndAmortisationExpense", "crdr": "debit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "+ Depreciation and amortization on tangible and intangible assets", "label": "Adjustments for depreciation and amortisation expense" } }, "en": { "role": { "documentation": "Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]" } } }, "auth_ref": [ "r357" ] }, "gnft_PerformanceConditionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "PerformanceConditionsMember", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Performance Conditions", "label": "Performance Conditions [Member]", "documentation": "Performance conditions." } } }, "auth_ref": [] }, "gnft_BuybackBonus": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "BuybackBonus", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Buyback bonus", "label": "Buyback Bonus", "documentation": "Buyback bonus." } } }, "auth_ref": [] }, "ifrs-full_ComputerSoftwareMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComputerSoftwareMember", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Computer software [member]", "verboseLabel": "Software", "label": "Computer software [member]" } }, "en": { "role": { "documentation": "This member stands for a class of intangible assets representing computer software. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r287" ] }, "gnft_TaxEffectOfRenegotiationOfConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "TaxEffectOfRenegotiationOfConvertibleDebt", "crdr": "debit", "calculation": { "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Effect Of Renegotiation Of Convertible Debt", "negatedTerseLabel": "Tax Effect Of Renegotiation Of Convertible Debt", "label": "Tax Effect Of Renegotiation Of Convertible Debt", "documentation": "Tax Effect Of Renegotiation Of Convertible Debt" } } }, "auth_ref": [] }, "ifrs-full_CurrentNotesAndDebenturesIssuedAndCurrentPortionOfNoncurrentNotesAndDebenturesIssued": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentNotesAndDebenturesIssuedAndCurrentPortionOfNoncurrentNotesAndDebenturesIssued", "crdr": "credit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofConvertibleBondsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current convertible loans", "label": "Current notes and debentures issued and current portion of non-current notes and debentures issued" } }, "en": { "role": { "documentation": "The amount of current notes and debentures issued and the current portion of non-current notes and debentures issued. [Refer: Notes and debentures issued]" } } }, "auth_ref": [ "r328" ] }, "gnft_PercentageOfFairValueInAssetValue": { "xbrltype": "percentItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "PercentageOfFairValueInAssetValue", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of fair value in asset value", "label": "Percentage of fair value in asset value", "documentation": "Percentage of fair value in asset value" } } }, "auth_ref": [] }, "gnft_DebtInstrumentsConversionOptionPerInstrument": { "xbrltype": "perShareItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DebtInstrumentsConversionOptionPerInstrument", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion option of a new amended OCEANE", "label": "Debt Instruments Conversion Option Per Instrument", "documentation": "Debt Instruments, conversion option per instrument." } } }, "auth_ref": [] }, "gnft_PropertyPlantAndEquipmentSubjectToFinanceLeasesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "PropertyPlantAndEquipmentSubjectToFinanceLeasesMember", "presentation": [ "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets under finance lease contracts", "label": "Property Plant And Equipment Subject To Finance Leases [Member]", "documentation": "Property plant and equipment subject to finance leases." } } }, "auth_ref": [] }, "gnft_ImpactAttributableToDeferredTaxAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ImpactAttributableToDeferredTaxAssetsMember", "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impact Attributable To Deferred Tax Assets [Member]", "label": "Impact Attributable To Deferred Tax Assets [Member]", "documentation": "Impact Attributable To Deferred Tax Assets" } } }, "auth_ref": [] }, "gnft_EquityComponentOfBondsConvertibleOrExchangeableIntoNewOrExistingSharesNetOfDeferredTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "EquityComponentOfBondsConvertibleOrExchangeableIntoNewOrExistingSharesNetOfDeferredTaxes", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component Of Bonds Convertible Or Exchangeable Into New Or Existing Shares Net Of Deferred Taxes", "label": "Equity Component Of Bonds Convertible Or Exchangeable Into New Or Existing Shares Net Of Deferred Taxes", "documentation": "Equity component of bonds convertible or exchangeable into new or existing shares net of deferred taxes." } } }, "auth_ref": [] }, "gnft_RefundableAndConditionalAdvancesAmountAllocated": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "RefundableAndConditionalAdvancesAmountAllocated", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofRefundableandConditionalAdvancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Refundable and conditional advances, Total amount allocated", "label": "Refundable And Conditional Advances Amount Allocated", "documentation": "Refundable and conditional advances amount allocated." } } }, "auth_ref": [] }, "ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax", "crdr": "credit", "calculation": { "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentPayables", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.genfit.com/role/TradeandOtherPayablesAdditionalInformationDetails", "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current payables on social security and taxes other than income tax", "label": "Current payables on social security and taxes other than income tax" } }, "en": { "role": { "documentation": "The amount of current payables on social security and taxes other than incomes tax. [Refer: Payables on social security and taxes other than income tax]" } } }, "auth_ref": [ "r335" ] }, "gnft_AGAS2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "AGAS2022Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA S 2022", "label": "AGA S 2022 [Member]", "documentation": "AGA S 2022" } } }, "auth_ref": [] }, "gnft_BSA2019Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "BSA2019Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "B S A2019 [Member]", "label": "B S A2019 [Member]", "documentation": "BSA 2019." } } }, "auth_ref": [] }, "gnft_AmortizedCostOfFinancialDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "AmortizedCostOfFinancialDebt", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Amortized cost of financial debt", "label": "Amortized Cost Of Financial Debt", "documentation": "Amortized cost of financial debt." } } }, "auth_ref": [] }, "gnft_JeanFranoisTINEMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "JeanFranoisTINEMember", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersScheduleofDirectorsFeesandOtherCompensationDueandPaidtoNonExecutiveDirectorsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Jean-Fran\u00e7ois TINE [Member]", "label": "Jean-Fran\u00e7ois TINE [Member]", "documentation": "Jean-Fran\u00e7ois TINE" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables", "crdr": "debit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease (increase) in trade receivables and other assets", "label": "Adjustments for decrease (increase) in trade and other receivables" } }, "en": { "role": { "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]" } } }, "auth_ref": [ "r358" ] }, "gnft_PopulationDescription": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "PopulationDescription", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails", "http://www.genfit.com/role/EmployeeBenefitsSummaryofAssumptionsUsedforEmployeesfortheMeasurementofRetirementIndemnitytoEmployeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Population Description", "label": "Population Description", "documentation": "Population description." } } }, "auth_ref": [] }, "ifrs-full_FeeAndCommissionExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FeeAndCommissionExpense", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fee and commission expense", "label": "Fee and commission expense" } }, "en": { "role": { "documentation": "The amount of expense relating to fees and commissions." } } }, "auth_ref": [ "r337" ] }, "gnft_EffectsOfDiscounting": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "EffectsOfDiscounting", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofRefundableandConditionalAdvancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Refundable and conditional advances, Effects of discounting", "label": "Effects Of Discounting", "documentation": "Effects of discounting." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory", "presentation": [ "http://www.genfit.com/role/EmployeeBenefits", "http://www.genfit.com/role/EmployeeBenefitsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of net defined benefit liability (asset) [text block]", "label": "Disclosure of net defined benefit liability (asset) [text block]" } }, "en": { "role": { "documentation": "The disclosure of a net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r79" ] }, "ifrs-full_InterestPaidClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InterestPaidClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "- Financial interests paid (including finance lease)", "label": "Interest paid, classified as financing activities" } }, "en": { "role": { "documentation": "The cash outflow for interest paid, classified as financing activities." } } }, "auth_ref": [ "r146" ] }, "gnft_NewBuildingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "NewBuildingMember", "presentation": [ "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New Building", "label": "New Building [Member]", "documentation": "New building." } } }, "auth_ref": [] }, "ifrs-full_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ConstructionInProgressMember", "presentation": [ "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentSummaryofVariationsinTangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Construction in progress [member]", "label": "Construction in progress [member]" } }, "en": { "role": { "documentation": "This member stands for expenditure capitalised during the construction of items of property, plant and equipment that are not yet available for use (ie not yet in the location and condition necessary for it to be capable of operating in the manner intended by the management). [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r339" ] }, "ifrs-full_CurrentProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentProvisions", "crdr": "credit", "calculation": { "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails": { "parentTag": "gnft_TotalAcquiredLiabilities", "weight": 1.0, "order": 3.0 }, "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 5.0 }, "http://www.genfit.com/role/ProvisionsAdditionalInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails", "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails", "http://www.genfit.com/role/ProvisionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current provisions", "totalLabel": "Current provisions", "label": "Current provisions" } }, "en": { "role": { "documentation": "The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]" } } }, "auth_ref": [ "r19" ] }, "ifrs-full_InterestPayable": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InterestPayable", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible bond, yearly interest", "label": "Interest payable" } }, "en": { "role": { "documentation": "The amount of interest recognised as a liability." } } }, "auth_ref": [ "r328" ] }, "gnft_DiscloseInNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DiscloseInNotesMember", "presentation": [ "http://www.genfit.com/role/OperatingExpenseAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclose in notes", "label": "Disclose in notes [Member]", "documentation": "Disclose in notes" } } }, "auth_ref": [] }, "ifrs-full_ConsumerLoansMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ConsumerLoansMember", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loans to consumers [member]", "label": "Loans to consumers [member]" } }, "en": { "role": { "documentation": "This member stands for loans that are made to individuals for personal use." } } }, "auth_ref": [ "r303", "r307", "r309" ] }, "gnft_ShareholderPaidInAndRegisteredPeriodForDoubleVotingRights": { "xbrltype": "durationItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ShareholderPaidInAndRegisteredPeriodForDoubleVotingRights", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shareholder paid-in and registered period for double voting rights (in years)", "label": "Shareholder Paid-in and Registered Period for Double Voting Rights", "documentation": "Shareholder Paid-in and Registered Period for Double Voting Rights" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensation" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of number and weighted average exercise prices of other equity instruments [text block]", "label": "Disclosure of number and weighted average exercise prices of other equity instruments [text block]" } }, "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options)." } } }, "auth_ref": [ "r360" ] }, "ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PastServiceCostNetDefinedBenefitLiabilityAsset", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails", "http://www.genfit.com/role/EmployeeBenefitsSummaryofChangesinPresentValueofDefinedBenefitObligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in net defined benefit liability (asset) resulting from past service cost", "label": "Increase (decrease) in net defined benefit liability (asset) resulting from past service cost" } }, "en": { "role": { "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from past service cost. Past service cost is the change in the present value of the defined benefit obligation for employee service in prior periods, resulting from a plan amendment (the introduction or withdrawal of, or changes to, a defined benefit plan) or a curtailment (a significant reduction by the entity in the number of employees covered by a plan). [Refer: Net defined benefit liability (asset); Defined benefit plans [member]]" } } }, "auth_ref": [ "r83" ] }, "ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax", "crdr": "credit", "calculation": { "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails": { "parentTag": "ifrs-full_TradeAndOtherPayables", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.genfit.com/role/TradeandOtherPayablesAdditionalInformationDetails", "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payables on social security and taxes other than income tax", "label": "Payables on social security and taxes other than income tax" } }, "en": { "role": { "documentation": "The amount of payment due on social security and taxes other than income tax. Income taxes include all domestic and foreign taxes that are based on taxable profits. Income taxes also include taxes, such as withholding taxes, that are payable by a subsidiary, associate or joint arrangement on distributions to the reporting entity." } } }, "auth_ref": [ "r335" ] }, "ifrs-full_NoncurrentProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentProvisions", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/ProvisionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Support costs related to reduction in force plan implemented", "label": "Non-current provisions" } }, "en": { "role": { "documentation": "The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]" } } }, "auth_ref": [ "r19" ] }, "ifrs-full_NoncurrentReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentReceivables", "crdr": "debit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 1.0 }, "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current trade and other receivables", "totalLabel": "Total trade and other non-current receivables", "label": "Trade and other non-current receivables" } }, "en": { "role": { "documentation": "The amount of non-current trade receivables and non-current other receivables. [Refer: Non-current trade receivables; Other non-current receivables]" } } }, "auth_ref": [ "r16", "r32" ] }, "ifrs-full_ForeignExchangeRatesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ForeignExchangeRatesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange rates [abstract]", "label": "Foreign exchange rates [abstract]" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentProvisionsForEmployeeBenefits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentProvisionsForEmployeeBenefits", "crdr": "credit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current employee benefits", "label": "Non-current provisions for employee benefits" } }, "en": { "role": { "documentation": "The amount of non-current provisions for employee benefits. [Refer: Provisions for employee benefits]" } } }, "auth_ref": [ "r33" ] }, "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "- Payments on lease debts", "label": "Payments of lease liabilities, classified as financing activities" } }, "en": { "role": { "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r294" ] }, "ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PercentageOfReasonablyPossibleDecreaseInActuarialAssumption", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails", "http://www.genfit.com/role/EmployeeBenefitsSummaryofSensitivityoftheRetirementandPostEmploymentBenefitstoaVariationoftheDiscountRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of reasonably possible decrease in actuarial assumption", "verboseLabel": "Changes in assumptions/discount rate (as a percent)", "label": "Percentage of reasonably possible decrease in actuarial assumption" } }, "en": { "role": { "documentation": "The reasonably possible percentage of the decrease in the actuarial assumption used to determine the present value of defined benefit obligation. [Refer: Actuarial assumptions [member]]" } } }, "auth_ref": [ "r85" ] }, "ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PercentageOfReasonablyPossibleIncreaseInActuarialAssumption", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails", "http://www.genfit.com/role/EmployeeBenefitsSummaryofSensitivityoftheRetirementandPostEmploymentBenefitstoaVariationoftheDiscountRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in assumptions/discount rate (as a percent)", "label": "Percentage of reasonably possible increase in actuarial assumption" } }, "en": { "role": { "documentation": "The reasonably possible percentage of the increase in the actuarial assumption used to determine the present value of defined benefit obligation. [Refer: Actuarial assumptions [member]]" } } }, "auth_ref": [ "r85" ] }, "ifrs-full_NoncurrentTradeReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentTradeReceivables", "crdr": "debit", "calculation": { "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails": { "parentTag": "ifrs-full_NoncurrentReceivables", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current trade receivables", "label": "Non-current trade receivables" } }, "en": { "role": { "documentation": "The amount of non-current trade receivables. [Refer: Trade receivables]" } } }, "auth_ref": [ "r274" ] }, "ifrs-full_PercentageOfVotingEquityInterestsAcquired": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PercentageOfVotingEquityInterestsAcquired", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of voting equity interests acquired", "label": "Percentage of voting equity interests acquired" } }, "en": { "role": { "documentation": "The percentage of voting equity interests acquired in a business combination. [Refer: Business combinations [member]]" } } }, "auth_ref": [ "r220" ] }, "ifrs-full_NoncurrentValueAddedTaxPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentValueAddedTaxPayables", "crdr": "credit", "calculation": { "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails": { "parentTag": "ifrs-full_NoncurrentPayables", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.genfit.com/role/TradeandOtherPayablesAdditionalInformationDetails", "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current value added tax payables", "label": "Non-current value added tax payables" } }, "en": { "role": { "documentation": "The amount of non-current value added tax payables. [Refer: Value added tax payables]" } } }, "auth_ref": [ "r335" ] }, "ifrs-full_PerformanceObligationsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PerformanceObligationsAxis", "presentation": [ "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsParentheticalDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance obligations [axis]", "label": "Performance obligations [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r188" ] }, "ifrs-full_NoncurrentValueAddedTaxReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentValueAddedTaxReceivables", "crdr": "debit", "calculation": { "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails": { "parentTag": "ifrs-full_NoncurrentReceivables", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current value added tax receivables", "label": "Non-current value added tax receivables" } }, "en": { "role": { "documentation": "The amount of non-current value added tax receivables. [Refer: Value added tax receivables]" } } }, "auth_ref": [ "r333" ] }, "ifrs-full_PerformanceObligationsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PerformanceObligationsMember", "presentation": [ "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsParentheticalDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance obligations [member]", "label": "Performance obligations [member]" } }, "en": { "role": { "documentation": "This member stands for all performance obligations. A performance obligation is a promise in a contract with a customer to transfer to the customer either: (a) a good or service (or a bundle of goods or services) that is distinct; or (b) a series of distinct goods or services that are substantially the same and that have the same pattern of transfer to the customer. This member also represents the standard value for the 'Performance obligations' axis if no other member is used." } } }, "auth_ref": [ "r188" ] }, "gnft_IncreaseDecreaseOfResearchTaxCreditReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "IncreaseDecreaseOfResearchTaxCreditReceivable", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/DeferredIncomeandRevenueDetails", "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) of Research Tax Credit Receivable", "label": "Increase (Decrease) of Research Tax Credit Receivable", "documentation": "Increase (Decrease) of Research Tax Credit Receivable" } } }, "auth_ref": [] }, "gnft_EstimatedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "EstimatedMember", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated", "label": "Estimated [Member]", "documentation": "Estimated" } } }, "auth_ref": [] }, "gnft_TenPercentDecreaseOfCHFVsEuroMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "TenPercentDecreaseOfCHFVsEuroMember", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofCHFagainstEuroDetails", "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofUSDollaragainstEuroDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ten Percent Decrease Of C H F Vs Euro", "label": "Ten Percent Decrease Of C H F Vs Euro [Member]", "documentation": "Ten Percent Decrease Of C H F Vs Euro" } } }, "auth_ref": [] }, "gnft_ProportionOfTradingPeriodOverNominalValueOfOCEANEs": { "xbrltype": "percentItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ProportionOfTradingPeriodOverNominalValueOfOCEANEs", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBondsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proportion of trading period over nominal value of OCEANEs (in percent)", "label": "Proportion Of Trading Period Over Nominal Value Of OCEANEs", "documentation": "Proportion Of Trading Period Over Nominal Value Of OCEANEs" } } }, "auth_ref": [] }, "gnft_DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAndAverageEffectiveTaxRateTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAndAverageEffectiveTaxRateTableTextBlock", "presentation": [ "http://www.genfit.com/role/IncomeTaxTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of effective tax rate", "label": "Disclosure Of Reconciliation Of Accounting Profit Multiplied By Applicable Tax Rates And Average Effective Tax Rate [Table Text Block]", "documentation": "Disclosure Of Reconciliation Of Accounting Profit Multiplied By Applicable Tax Rates And Average Effective Tax Rate" } } }, "auth_ref": [] }, "gnft_NumberOfOtherEquityInstrumentsExercisableInShareBasedPaymentArrangementRelatingToDevelopmentOfTheGNS561Program": { "xbrltype": "sharesItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "NumberOfOtherEquityInstrumentsExercisableInShareBasedPaymentArrangementRelatingToDevelopmentOfTheGNS561Program", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of other equity instruments exercisable in share-based payment arrangement relating to development of the GNS561 program", "label": "Number of other equity instruments exercisable in share-based payment arrangement relating to development of the GNS561 program", "documentation": "Number of other equity instruments exercisable in share-based payment arrangement relating to development of the GNS561 program" } } }, "auth_ref": [] }, "gnft_CEOGrossNegligenceSeverancePayDescription1": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "CEOGrossNegligenceSeverancePayDescription1", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CEO gross negligence severance pay description", "label": "C E O Gross Negligence Severance Pay Description1", "documentation": "CEO gross negligence severance pay description1." } } }, "auth_ref": [] }, "ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CumulativeEffectAtDateOfInitialApplicationAxis", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative effect at date of initial application [axis]", "label": "Cumulative effect at date of initial application [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r326" ] }, "gnft_EstimatedFairValueOfShareAccordingToIFRS2": { "xbrltype": "perShareItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "EstimatedFairValueOfShareAccordingToIFRS2", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated fair value - according to IFRS 2 (in EUR per share)", "label": "Estimated Fair Value Of Share According To I F R S2", "documentation": "Estimated fair value of share according to IFRS 2." } } }, "auth_ref": [] }, "gnft_SO20162Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "SO20162Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "S O20162 [Member]", "label": "S O20162 [Member]", "documentation": "SO 2016-2." } } }, "auth_ref": [] }, "gnft_SOUS2021Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "SOUS2021Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SO US 2021 [Member]", "label": "SO US 2021 [Member]", "documentation": "SO US 2021" } } }, "auth_ref": [] }, "gnft_InterestRateYearsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "InterestRateYearsMember", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Years [Member]", "label": "Interest Rate Years [Member]", "documentation": "Interest Rate Years" } } }, "auth_ref": [] }, "ifrs-full_NoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncontrollingInterests", "crdr": "credit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Non-controlling interests", "label": "Non-controlling interests" } }, "en": { "role": { "documentation": "The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Subsidiaries [member]]" } } }, "auth_ref": [ "r22", "r161", "r163" ] }, "gnft_PropertyPlantAndEquipmentByFinanceLeaseStatusMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "PropertyPlantAndEquipmentByFinanceLeaseStatusMember", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property Plant And Equipment By Finance Lease Status Member", "label": "Property Plant And Equipment By Finance Lease Status [Member]", "documentation": "Property plant and equipment by finance lease status." } } }, "auth_ref": [] }, "gnft_IncreaseDecreaseRelatedToTaxEffectAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "IncreaseDecreaseRelatedToTaxEffectAbstract", "presentation": [ "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) Related To Tax Effect [Abstract]", "label": "Increase (Decrease) Related To Tax Effect [Abstract]", "documentation": "Increase (Decrease) Related To Tax Effect" } } }, "auth_ref": [] }, "ifrs-full_ActuarialAssumptionOfRetirementAge2019": { "xbrltype": "durationItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ActuarialAssumptionOfRetirementAge2019", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsSummaryofAssumptionsUsedforEmployeesfortheMeasurementofRetirementIndemnitytoEmployeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement age", "label": "Actuarial assumption of retirement age" } }, "en": { "role": { "documentation": "The retirement age used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [member]]" } } }, "auth_ref": [ "r343" ] }, "gnft_PercentageOfPaymentOfCouponsRate": { "xbrltype": "percentItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "PercentageOfPaymentOfCouponsRate", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/FinancialIncomeandExpensesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proportion of payment of coupons rate (as a percent)", "label": "Percentage Of Payment Of Coupons Rate", "documentation": "Percentage of payment of coupons rate." } } }, "auth_ref": [] }, "gnft_NumberOfOtherEquityInstrumentsSubscribedInShareBasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "NumberOfOtherEquityInstrumentsSubscribedInShareBasedPaymentArrangement", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Total number of AGA subscribed (in shares)", "terseLabel": "Total number of BSAAR subscribed", "label": "Number Of Other Equity Instruments Subscribed In Share Based Payment Arrangement", "documentation": "Number of other equity instruments subscribed in share based payment arrangement." } } }, "auth_ref": [] }, "gnft_DisclosureOfNetAssetsAndLiabilitiesOfBusinessCombinationTable": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DisclosureOfNetAssetsAndLiabilitiesOfBusinessCombinationTable", "lang": { "en-us": { "role": { "terseLabel": "Disclosure of net assets and liabilities of Business Combination [Table]", "label": "Disclosure of net assets and liabilities of Business Combination [Table]", "documentation": "Disclosure of net assets and liabilities of Business Combination [Table]" } } }, "auth_ref": [] }, "ifrs-full_NoncontrollingInterestsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncontrollingInterestsMember", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Non-controlling interests", "label": "Non-controlling interests [member]" } }, "en": { "role": { "documentation": "This member stands for equity in a subsidiary not attributable, directly or indirectly, to the parent." } } }, "auth_ref": [ "r7" ] }, "gnft_DecreaseUsedInProvisionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DecreaseUsedInProvisionsMember", "presentation": [ "http://www.genfit.com/role/ProvisionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease (used) in Provisions [Member]", "label": "Decrease (used) in Provisions [Member]", "documentation": "Decrease (used) in Provisions" } } }, "auth_ref": [] }, "gnft_PartialRecognitionOfDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "PartialRecognitionOfDeferredRevenue", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/DeferredIncomeandRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Partial recognition of deferred revenue", "label": "Partial recognition of deferred revenue", "documentation": "Partial recognition of deferred revenue" } } }, "auth_ref": [] }, "gnft_TaxEffectOfPermanentDifferences": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "TaxEffectOfPermanentDifferences", "crdr": "debit", "calculation": { "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Effect Of Permanent Differences", "negatedTerseLabel": "Tax Effect Of Permanent Differences", "label": "Tax Effect Of Permanent Differences", "documentation": "Tax Effect Of Permanent Differences" } } }, "auth_ref": [] }, "gnft_RedeemableWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "RedeemableWarrantsMember", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Redeemable Warrants", "label": "Redeemable Warrants [Member]", "documentation": "Redeemable warrants." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r314" ] }, "gnft_ConversionOfConvertibleInstrumentsAsAPercentageOfShareCapital": { "xbrltype": "percentItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ConversionOfConvertibleInstrumentsAsAPercentageOfShareCapital", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of new shares issued (in percent)", "label": "Conversion Of Convertible Instruments As A Percentage Of Share Capital", "documentation": "Conversion Of Convertible Instruments As A Percentage Of Share Capital" } } }, "auth_ref": [] }, "gnft_ShareholderMeetingDate": { "xbrltype": "dateItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ShareholderMeetingDate", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Date of the Shareholders meeting", "label": "Shareholder Meeting Date", "documentation": "Shareholder meeting date." } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodSignatureofaLicensingandPartnershipAgreementwithIpsenDetails", "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails", "http://www.genfit.com/role/RelatedPartiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity [Axis]", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "gnft_ForeignExchangeRatesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ForeignExchangeRatesTable", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagementAdditionalInformationDetails", "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofCHFagainstEuroDetails", "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofUSDollaragainstEuroDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Exchange Rates [Table]", "label": "Foreign Exchange Rates [Table]", "documentation": "Foreign exchange rates table." } } }, "auth_ref": [] }, "gnft_NoncurrentResearchTaxCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "NoncurrentResearchTaxCredit", "crdr": "debit", "calculation": { "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails": { "parentTag": "ifrs-full_NoncurrentReceivables", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncurrent Research Tax Credit", "label": "Noncurrent Research Tax Credit", "documentation": "Noncurrent research tax credit." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodSignatureofaLicensingandPartnershipAgreementwithIpsenDetails", "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails", "http://www.genfit.com/role/RelatedPartiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity [Domain]", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "gnft_AdditionalShareBasedInstrumentsIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "AdditionalShareBasedInstrumentsIssued", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional share based instruments issued (in shares)", "label": "Additional Share Based Instruments Issued", "documentation": "Additional share based instruments issued." } } }, "auth_ref": [] }, "ifrs-full_NoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentAssets", "crdr": "debit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "Total - Non-current assets", "label": "Non-current assets" } }, "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } } }, "auth_ref": [ "r29", "r166", "r297" ] }, "gnft_VersantisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "VersantisMember", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Versantis", "label": "Versantis [Member]", "documentation": "Versantis" } } }, "auth_ref": [] }, "gnft_RefundableAndConditionalAdvancesNetBookValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "RefundableAndConditionalAdvancesNetBookValue", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofRefundableandConditionalAdvancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Refundable and conditional advances, Net book value", "label": "Refundable And Conditional Advances Net Book Value", "documentation": "Refundable and conditional advances net book value." } } }, "auth_ref": [] }, "gnft_RevenueFromOtherCountriesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "RevenueFromOtherCountriesMember", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue From Other Countries", "label": "Revenue From Other Countries [Member]", "documentation": "Revenue From Other Countries" } } }, "auth_ref": [] }, "gnft_CashAndCashEquivalentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "CashAndCashEquivalentLineItems", "presentation": [ "http://www.genfit.com/role/CashandCashEquivalentsSummaryofCashandCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalent [line items]", "label": "Cash And Cash Equivalent [Line Items]", "documentation": "Cash and cash equivalent." } } }, "auth_ref": [] }, "gnft_BSA2014BMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "BSA2014BMember", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSA 2014-B", "label": "B S A2014 B [Member]", "documentation": "BSA 2014-B." } } }, "auth_ref": [] }, "gnft_CurrentGrantsReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "CurrentGrantsReceivables", "crdr": "debit", "calculation": { "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current Grants Receivables", "label": "Current Grants Receivables", "documentation": "Current grants receivables." } } }, "auth_ref": [] }, "ifrs-full_NoncurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentAssetsAbstract", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current assets", "label": "Non-current assets [abstract]" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r314" ] }, "gnft_BondsAfterOCEANEsBuybackMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "BondsAfterOCEANEsBuybackMember", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBondsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bonds after OCEANEs buyback", "label": "Bonds After OCEANEs Buyback [Member]", "documentation": "Bonds After OCEANEs Buyback" } } }, "auth_ref": [] }, "gnft_BuildingOnNonFreeholdLandMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "BuildingOnNonFreeholdLandMember", "presentation": [ "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Building on Non-Freehold Land", "label": "Building On Non Freehold Land [Member]", "documentation": "Building on non-freehold land." } } }, "auth_ref": [] }, "gnft_CurrentResearchTaxCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "CurrentResearchTaxCredit", "crdr": "debit", "calculation": { "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current Research Tax Credit", "label": "Current Research Tax Credit", "documentation": "Current research tax credit." } } }, "auth_ref": [] }, "gnft_ReceiptsOfRefundableAndConditionalAdvances": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ReceiptsOfRefundableAndConditionalAdvances", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofRefundableandConditionalAdvancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Refundable and conditional advances, Receipts", "label": "Receipts Of Refundable And Conditional Advances", "documentation": "Receipts of refundable and conditional advances." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "ifrs-full_CurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentAssetsAbstract", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Current assets [abstract]" } } }, "auth_ref": [] }, "gnft_ExchangeRateCHFEuroUsedForVersantisAcquisitionConversion": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ExchangeRateCHFEuroUsedForVersantisAcquisitionConversion", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange Rate CHF Euro used for Versantis acquisition conversion", "label": "Exchange Rate CHF Euro used for Versantis acquisition conversion", "documentation": "Exchange Rate CHF Euro used for Versantis acquisition conversion" } } }, "auth_ref": [] }, "gnft_LeasedEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "LeasedEquipmentMember", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodTerminationofRESOLVEITandthedevelopmentprogramofelafibranorinNASHDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leased equipment", "label": "Leased Equipment [Member]", "documentation": "Leased equipment." } } }, "auth_ref": [] }, "gnft_SharePricePeriodToDetermineVolatilityAssumptions": { "xbrltype": "durationItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "SharePricePeriodToDetermineVolatilityAssumptions", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share price period to determine volatility assumptions prior to grant date", "label": "Share Price Period To Determine Volatility Assumptions", "documentation": "Share price period to determine volatility assumptions." } } }, "auth_ref": [] }, "ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/IncomeTaxNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Post-employment benefit expense, defined benefit plans impact on deferred tax assets", "label": "Non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets, and rights arising under insurance contracts" } }, "en": { "role": { "documentation": "The amount of non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets and rights arising under insurance contracts. [Refer: Deferred tax assets; Financial instruments, class [member]; Non-current assets]" } } }, "auth_ref": [ "r262" ] }, "ifrs-full_CurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentAssets", "crdr": "debit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "Total - Current assets", "label": "Current assets" } }, "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } } }, "auth_ref": [ "r29", "r165", "r297" ] }, "gnft_FreeSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "FreeSharesMember", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Free Shares", "label": "Free Shares [Member]", "documentation": "Free shares." } } }, "auth_ref": [] }, "gnft_SOD2021Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "SOD2021Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SO D 2021 [Member]", "label": "SO D 2021 [Member]", "documentation": "SO D 2021" } } }, "auth_ref": [] }, "gnft_DisclosureOfOtherIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DisclosureOfOtherIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Other Income [Abstract]", "label": "Disclosure Of Other Income [Abstract]", "documentation": "Disclosure of other income." } } }, "auth_ref": [] }, "gnft_NonRepayableMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "NonRepayableMember", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non Repayable", "label": "Non Repayable [Member]", "documentation": "Non Repayable" } } }, "auth_ref": [] }, "gnft_NumberOfShareOptionsVestedShareBasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "NumberOfShareOptionsVestedShareBasedPaymentArrangement", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total number of SO definitively vested", "label": "Number Of Share Options Vested Share Based Payment Arrangement", "documentation": "Number of share options vested share based payment arrangement." } } }, "auth_ref": [] }, "gnft_InterestReceivedClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "InterestReceivedClassifiedAsFinancingActivities", "crdr": "debit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "+ Financial interests received", "label": "Interest Received Classified As Financing Activities", "documentation": "Interest received classified as financing activities." } } }, "auth_ref": [] }, "gnft_BPIFRANCEITDIABMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "BPIFRANCEITDIABMember", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofMaturitiesofFinancialLiabilitiesDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofRefundableandConditionalAdvancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BPI FRANCE - IT-DIAB", "label": "B P I F R A N C E I T D I A B [Member]", "documentation": "BPI FRANCE - IT-DIAB." } } }, "auth_ref": [] }, "gnft_OtherLoansAndBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "OtherLoansAndBorrowings", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofMaturitiesofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Loans And Borrowings", "verboseLabel": "TOTAL - Other loans and borrowings", "label": "Other Loans And Borrowings", "documentation": "Other loans and borrowings." } } }, "auth_ref": [] }, "gnft_BorrowingsRecognizedForAmendedObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "BorrowingsRecognizedForAmendedObligation", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings, recognized for amended obligation", "label": "Borrowings, Recognized For Amended Obligation", "documentation": "Borrowings, Recognized For Amended Obligation" } } }, "auth_ref": [] }, "gnft_BorrowingsRecognizedUsingEffectiveInterestRate": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "BorrowingsRecognizedUsingEffectiveInterestRate", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings, recognized using effective interest rate", "label": "Borrowings, Recognized Using Effective Interest Rate", "documentation": "Borrowings, Recognized Using Effective Interest Rate" } } }, "auth_ref": [] }, "gnft_RenegotiationFeesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "RenegotiationFeesMember", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Renegotiation Fees", "label": "Renegotiation Fees [Member]", "documentation": "Renegotiation Fees" } } }, "auth_ref": [] }, "gnft_NumberOfOtherEquityInstrumentsExercisableInShareBasedPaymentArrangementRelatingToDevelopmentOfElafibranorInPBCAndElativeClinical": { "xbrltype": "sharesItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "NumberOfOtherEquityInstrumentsExercisableInShareBasedPaymentArrangementRelatingToDevelopmentOfElafibranorInPBCAndElativeClinical", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of other equity instruments exercisable in share-based payment arrangement relating to Development Of Elafibranor In P B C And Elative Clinical", "label": "Number of other equity instruments exercisable in share-based payment arrangement relating to Development Of Elafibranor In P B C And Elative Clinical", "documentation": "Number of other equity instruments exercisable in share-based payment arrangement relating to Development Of Elafibranor In P B C And Elative Clinical" } } }, "auth_ref": [] }, "gnft_KeyManagementPersonnelCompensationDirectorFeesOfSubsidiary": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "KeyManagementPersonnelCompensationDirectorFeesOfSubsidiary", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Key Management Personnel Compensation Director Fees Of Subsidiary", "label": "Key Management Personnel Compensation Director Fees Of Subsidiary", "documentation": "Key management personnel compensation, director fees of subsidiary." } } }, "auth_ref": [] }, "gnft_NumberOfConvertibleAndExchangeableBondsForNewOrExistingShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "NumberOfConvertibleAndExchangeableBondsForNewOrExistingShares", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of convertible and exchangeable bonds for new or existing shares", "label": "Number Of Convertible And Exchangeable Bonds For New Or Existing Shares", "documentation": "Number Of Convertible And Exchangeable Bonds For New Or Existing Shares" } } }, "auth_ref": [] }, "gnft_CompensationOfCorporateOfficersTable": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "CompensationOfCorporateOfficersTable", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersScheduleofDirectorsFeesandOtherCompensationDueandPaidtoNonExecutiveDirectorsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Of Corporate Officers [Table]", "label": "Compensation Of Corporate Officers [Table]", "documentation": "Schedule disclosing information related to compensation of corporate officers." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDeferredIncomeExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDeferredIncomeExplanatory", "presentation": [ "http://www.genfit.com/role/DeferredIncomeandRevenue" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Income and Revenue", "label": "Disclosure of deferred income [text block]" } }, "en": { "role": { "documentation": "The disclosure of deferred income. [Refer: Deferred income including contract liabilities]" } } }, "auth_ref": [ "r323" ] }, "gnft_RESOLVEITTrialMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "RESOLVEITTrialMember", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "RESOLVE-IT trial", "label": "RESOLVE-IT trial [Member]", "documentation": "RESOLVE-IT trial" } } }, "auth_ref": [] }, "gnft_BankLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "BankLoansMember", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofMaturitiesofFinancialLiabilitiesDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofOtherLoansandBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bank Loans [Member]", "label": "Bank Loans [Member]", "documentation": "Bank loans." } } }, "auth_ref": [] }, "ifrs-full_RevaluationIncreaseDecreasePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RevaluationIncreaseDecreasePropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentSummaryofVariationsinTangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification", "label": "Revaluation increase (decrease), property, plant and equipment" } }, "en": { "role": { "documentation": "The increase (decrease) in property, plant and equipment resulting from revaluations to fair value. [Refer: Property, plant and equipment; Revaluation surplus]" } } }, "auth_ref": [ "r71", "r76" ] }, "gnft_MaximumAmountToBePaidIfAnyFurtherAmountsToBePaidAsConditionalAdvance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "MaximumAmountToBePaidIfAnyFurtherAmountsToBePaidAsConditionalAdvance", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum amount to be paid if any further amounts to be paid as conditional advance", "label": "Maximum Amount To Be Paid If Any Further Amounts To Be Paid As Conditional Advance", "documentation": "Maximum amount to be paid if any further amounts to be paid as conditional advance." } } }, "auth_ref": [] }, "gnft_ChairmanAndChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ChairmanAndChiefExecutiveOfficerMember", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersAdditionalInformationDetails", "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Chairman and Chief Executive Officer", "label": "Chairman And Chief Executive Officer [Member]", "documentation": "Chairman and Chief Executive Officer." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDefinedBenefitPlansExplanatory", "presentation": [ "http://www.genfit.com/role/EmployeeBenefits", "http://www.genfit.com/role/EmployeeBenefitsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of defined benefit plans [text block]", "label": "Disclosure of defined benefit plans [text block]" } }, "en": { "role": { "documentation": "The disclosure of defined benefit plans. [Refer: Defined benefit plans [member]]" } } }, "auth_ref": [ "r78" ] }, "ifrs-full_EmployeeBenefitsExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EmployeeBenefitsExpense", "crdr": "debit", "calculation": { "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Employee benefits expense", "label": "Employee benefits expense" } }, "en": { "role": { "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment." } } }, "auth_ref": [ "r0", "r57", "r269" ] }, "ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "crdr": "debit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "+ Proceeds from disposal of / reimbursement of property, plant and equipment", "label": "Proceeds from sales of property, plant and equipment, classified as investing activities" } }, "en": { "role": { "documentation": "The cash inflow from sales of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r291" ] }, "ifrs-full_DisclosureOfDefinedBenefitPlansLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDefinedBenefitPlansLineItems", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails", "http://www.genfit.com/role/EmployeeBenefitsSummaryofAssumptionsUsedforEmployeesfortheMeasurementofRetirementIndemnitytoEmployeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of defined benefit plans [line items]", "label": "Disclosure of defined benefit plans [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "gnft_OtherInvestmentsRemainingSubscription": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "OtherInvestmentsRemainingSubscription", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Investments - Remaining subscription", "label": "Other Investments - Remaining subscription", "documentation": "Other Investments - Remaining subscription" } } }, "auth_ref": [] }, "gnft_ClinicalTrialRecruitmentPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ClinicalTrialRecruitmentPeriod", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Clinical Trial Recruitment Period", "label": "Clinical Trial Recruitment Period", "documentation": "Clinical Trial Recruitment Period" } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sales or maturity of financial instruments, classified as investing activities", "label": "Proceeds from sales or maturity of financial instruments, classified as investing activities" } }, "en": { "role": { "documentation": "The cash inflow from sales or maturity of financial instruments, classified as investing activities. [Refer: Financial instruments, class [member]]" } } }, "auth_ref": [ "r355" ] }, "gnft_DisclosureOfNetAssetsAndLiabilitiesOfBusinessCombinationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DisclosureOfNetAssetsAndLiabilitiesOfBusinessCombinationLineItems", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of net assets and liabilities of Business Combination [Line Items]", "label": "Disclosure of net assets and liabilities of Business Combination [Line Items]", "documentation": "Disclosure of net assets and liabilities of Business Combination [Line Items]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDefinedBenefitPlansTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDefinedBenefitPlansTable", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails", "http://www.genfit.com/role/EmployeeBenefitsSummaryofAssumptionsUsedforEmployeesfortheMeasurementofRetirementIndemnitytoEmployeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of defined benefit plans [table]", "label": "Disclosure of defined benefit plans [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to defined benefit plans." } } }, "auth_ref": [ "r78" ] }, "gnft_DisclosureOfUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DisclosureOfUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTextBlock", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Estimated Useful Lives", "label": "Disclosure Of Useful Lives Of Property Plant And Equipment Explanatory [Text Block]", "documentation": "Disclosure of useful lives of property, plant and equipment." } } }, "auth_ref": [] }, "gnft_BiotechAvenirSASMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "BiotechAvenirSASMember", "presentation": [ "http://www.genfit.com/role/RelatedPartiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Biotech Avenir SAS", "label": "Biotech Avenir S A S [Member]", "documentation": "Biotech Avenir SAS." } } }, "auth_ref": [] }, "gnft_InitialPublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "InitialPublicOfferingMember", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial Public Offering", "label": "Initial Public Offering [Member]", "documentation": "Initial public offering." } } }, "auth_ref": [] }, "gnft_PerformanceConditionsPlanThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "PerformanceConditionsPlanThreeMember", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance Conditions Plan Three", "label": "Performance Conditions Plan Three [Member]", "documentation": "Performance conditions plan three." } } }, "auth_ref": [] }, "gnft_SOUS22019Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "SOUS22019Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "S O US 2 2019", "label": "S O US 2 2019 [Member]", "documentation": "S O US 2 2019" } } }, "auth_ref": [] }, "ifrs-full_LineItemsByFunctionMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LineItemsByFunctionMember", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line items by function [member]", "label": "Line items by function [member]" } }, "en": { "role": { "documentation": "This member stands for the standard value of the \u2018Attribution of expenses by nature to their function' axis if no other member is used." } } }, "auth_ref": [ "r324", "r328" ] }, "gnft_LabcorpMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "LabcorpMember", "presentation": [ "http://www.genfit.com/role/DeferredIncomeandRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Labcorp", "label": "Labcorp [Member]", "documentation": "Labcorp" } } }, "auth_ref": [] }, "ifrs-full_ReclassificationIntoLoansAndReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ReclassificationIntoLoansAndReceivables", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying value loans and receivables", "label": "Reclassification into loans and receivables" } }, "en": { "role": { "documentation": "The amount of financial assets reclassified into the loans and receivables category. [Refer: Loans and receivables; Financial assets]" } } }, "auth_ref": [ "r267" ] }, "gnft_OtherPayablesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "OtherPayablesMember", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Payables [Member]", "label": "Other Payables [Member]", "documentation": "Other payables." } } }, "auth_ref": [] }, "ifrs-full_RevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RevenueAbstract", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues and other income", "label": "Revenue [abstract]" } } }, "auth_ref": [] }, "gnft_SOUSMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "SOUSMember", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SO US", "label": "S O U S [Member]", "documentation": "SOUS." } } }, "auth_ref": [] }, "ifrs-full_AmountsPayableRelatedPartyTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AmountsPayableRelatedPartyTransactions", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amounts payable, related party transactions", "label": "Amounts payable, related party transactions" } }, "en": { "role": { "documentation": "The amounts payable resulting from related party transactions. [Refer: Related parties [member]]" } } }, "auth_ref": [ "r99", "r102" ] }, "ifrs-full_Revenue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Revenue", "crdr": "credit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofOperations": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofOperations", "http://www.genfit.com/role/DeferredIncomeandRevenueDetails", "http://www.genfit.com/role/FinancialIncomeandExpensesSummaryofFinancialIncomeandExpensesDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Revenues and other income", "terseLabel": "Revenue", "verboseLabel": "Total operating income", "label": "Revenue" } }, "en": { "role": { "documentation": "The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims." } } }, "auth_ref": [ "r47", "r170", "r227", "r250", "r256", "r260", "r261", "r263", "r269", "r270", "r297" ] }, "gnft_AGAD2021Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "AGAD2021Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA D 2021 [Member]", "label": "AGA D 2021 [Member]", "documentation": "AGA D 2021" } } }, "auth_ref": [] }, "gnft_TheNASHEpidemiologyInstituteTMMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "TheNASHEpidemiologyInstituteTMMember", "presentation": [ "http://www.genfit.com/role/RelatedPartiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "The NASH Epidemiology Institute TM", "label": "The N A S H Epidemiology Institute T M [Member]", "documentation": "The NASH Epidemiology Institute TM." } } }, "auth_ref": [] }, "ifrs-full_SalesAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SalesAndMarketingExpense", "crdr": "debit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofOperations": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 2.0 }, "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails": { "parentTag": "gnft_ResearchAndDevelopmentExpenseGeneralAndAdministrativeExpenseMarketingAndMarketAccessExpenseAndOtherOperatingIncomeAndExpense", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofOperations", "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Marketing and market access expenses", "label": "Sales and marketing expense" } }, "en": { "role": { "documentation": "The amount of expense relating to the marketing and selling of goods or services." } } }, "auth_ref": [ "r337" ] }, "gnft_AttendanceAndOtherRemunerationPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "AttendanceAndOtherRemunerationPayable", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersScheduleofDirectorsFeesandOtherCompensationDueandPaidtoNonExecutiveDirectorsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amounts due", "label": "Attendance And Other Remuneration Payable", "documentation": "Attendance and other remuneration payable." } } }, "auth_ref": [] }, "gnft_NumberOfTreasuryShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "NumberOfTreasuryShares", "calculation": { "http://www.genfit.com/role/EquityAdditionalInformationDetails": { "parentTag": "ifrs-full_NumberOfSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury shares", "label": "Number of Treasury shares", "documentation": "Number of Treasury shares" } } }, "auth_ref": [] }, "gnft_PercentageOfExercisableInstrumentsRelatingToDevelopmentOfCompanyPipeline": { "xbrltype": "percentItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "PercentageOfExercisableInstrumentsRelatingToDevelopmentOfCompanyPipeline", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsParentheticalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of exercisable instruments relating to the development of company pipeline", "label": "Percentage Of Exercisable Instruments Relating To Development Of Company Pipeline", "documentation": "Percentage of exercisable instruments relating to the development of the company's pipeline." } } }, "auth_ref": [] }, "gnft_CompanyInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "CompanyInformationAbstract", "lang": { "en-us": { "role": { "terseLabel": "Company Information [Abstract]", "label": "Company Information [Abstract]", "documentation": "Company information." } } }, "auth_ref": [] }, "gnft_SOC2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "SOC2022Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SO C2022", "label": "SO C2022 [Member]", "documentation": "SO C2022" } } }, "auth_ref": [] }, "ifrs-full_RevenueFromContractsWithCustomers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RevenueFromContractsWithCustomers", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from contracts with customers", "label": "Revenue from contracts with customers" } }, "en": { "role": { "documentation": "The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity\u2019s ordinary activities in exchange for consideration." } } }, "auth_ref": [ "r185", "r186" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Other Loans and Borrowings", "label": "Disclosure of detailed information about borrowings [text block]" } }, "en": { "role": { "documentation": "The disclosure of detailed information about borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r362" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsLineItems", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBondsDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofConvertibleBondsDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofOtherLoansandBorrowingsDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofRefundableandConditionalAdvancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about borrowings [line items]", "label": "Disclosure of detailed information about borrowings [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsTable", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBondsDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofConvertibleBondsDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofOtherLoansandBorrowingsDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofRefundableandConditionalAdvancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about borrowings [table]", "label": "Disclosure of detailed information about borrowings [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of borrowings." } } }, "auth_ref": [ "r362" ] }, "gnft_LicensingAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "LicensingAgreementMember", "presentation": [ "http://www.genfit.com/role/DeferredIncomeandRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Licensing Agreement", "label": "Licensing Agreement [Member]", "documentation": "Licensing Agreement" } } }, "auth_ref": [] }, "ifrs-full_EnteringIntoSignificantCommitmentsOrContingentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EnteringIntoSignificantCommitmentsOrContingentLiabilitiesMember", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Renegotiation", "label": "Entering into significant commitments or contingent liabilities [member]" } }, "en": { "role": { "documentation": "This member stands for entering into significant commitments or contingent liabilities. [Refer: Contingent liabilities [member]]" } } }, "auth_ref": [ "r279" ] }, "gnft_A2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "A2024Member", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "2024 [Member]", "documentation": "2024" } } }, "auth_ref": [] }, "ifrs-full_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofOtherComprehensiveLoss": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 1.0 }, "http://www.genfit.com/role/ConsolidatedStatementsofOtherComprehensiveLoss_1": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 1.0 }, "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 1.0 }, "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 2.0 }, "http://www.genfit.com/role/ConsolidatedStatementsofOperations": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.genfit.com/role/ConsolidatedStatementsofOperations_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows", "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity", "http://www.genfit.com/role/ConsolidatedStatementsofOperations", "http://www.genfit.com/role/ConsolidatedStatementsofOtherComprehensiveLoss", "http://www.genfit.com/role/EarningsLossPerShareSummaryofEarningsLossPerShareDetails", "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net profit (loss)", "terseLabel": "+ Net profit (loss)", "verboseLabel": "Profit (loss)", "label": "Profit (loss)" } }, "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r3", "r40", "r143", "r158", "r160", "r254", "r257", "r297", "r301" ] }, "gnft_DisclosureOfFinancialIncomeAndExpensesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DisclosureOfFinancialIncomeAndExpensesLineItems", "presentation": [ "http://www.genfit.com/role/FinancialIncomeandExpensesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Financial Income And Expenses [Line Items]", "label": "Disclosure Of Financial Income And Expenses [Line Items]", "documentation": "Disclosure of financial income and expenses." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriod" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about business combination [text block]", "label": "Disclosure of detailed information about business combination [text block]" } }, "en": { "role": { "documentation": "The disclosure of detailed information about business combinations. [Refer: Business combinations [member]]" } } }, "auth_ref": [ "r226" ] }, "gnft_SOMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "SOMember", "presentation": [ "http://www.genfit.com/role/EarningsLossPerShareSummaryofEarningsLossPerShareDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "S O", "label": "S O [Member]", "documentation": "SO." } } }, "auth_ref": [] }, "ifrs-full_EntitysTotalForAssociatesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EntitysTotalForAssociatesMember", "presentation": [ "http://www.genfit.com/role/CashandCashEquivalentsSummaryofCashandCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity's total for associates [member]", "label": "Entity's total for associates [member]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Associates' axis if no other member is used." } } }, "auth_ref": [ "r109", "r111", "r177" ] }, "gnft_EquityInstrumentsEquityComponentPerInstrument": { "xbrltype": "decimalItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "EquityInstrumentsEquityComponentPerInstrument", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity instrument of new amended OCEANE (in EUR per bond)", "label": "Equity Instruments Equity Component Per Instrument", "documentation": "Equity Instruments Equity Component Per Instrument" } } }, "auth_ref": [] }, "gnft_InterestBearingCurrentAccountMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "InterestBearingCurrentAccountMember", "presentation": [ "http://www.genfit.com/role/CashandCashEquivalentsSummaryofCashandCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Bearing Current Account [Member]", "label": "Interest Bearing Current Account [Member]", "documentation": "Interest bearing current account." } } }, "auth_ref": [] }, "gnft_SO2018Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "SO2018Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "S O2018 [Member]", "label": "S O2018 [Member]", "documentation": "SO 2018." } } }, "auth_ref": [] }, "gnft_PaymentFromCollaborationUpFrontCashPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "PaymentFromCollaborationUpFrontCashPayment", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodSignatureofaLicensingandPartnershipAgreementwithIpsenDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payment from collaboration, up-front cash payment", "label": "Payment from collaboration, up-front cash payment", "documentation": "Payment from collaboration, up-front cash payment" } } }, "auth_ref": [] }, "ifrs-full_ProfitLossAttributableToNoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProfitLossAttributableToNoncontrollingInterests", "crdr": "credit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofOperations_1": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 2.0 }, "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows", "http://www.genfit.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Profit (loss), attributable to non-controlling interests", "label": "Profit (loss), attributable to non-controlling interests" } }, "en": { "role": { "documentation": "The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]" } } }, "auth_ref": [ "r43", "r162" ] }, "ifrs-full_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EquityAbstract", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Shareholders' equity", "label": "Equity [abstract]" } } }, "auth_ref": [] }, "gnft_PhilippeMOONSMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "PhilippeMOONSMember", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersScheduleofDirectorsFeesandOtherCompensationDueandPaidtoNonExecutiveDirectorsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Philippe M O O N S [Member]", "label": "Philippe M O O N S [Member]", "documentation": "Philippe MOONS." } } }, "auth_ref": [] }, "gnft_EffectiveInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "EffectiveInterestRateMember", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective Interest Rate", "label": "Effective Interest Rate [Member]", "documentation": "Effective Interest Rate" } } }, "auth_ref": [] }, "gnft_FinancialInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "FinancialInvestments", "crdr": "debit", "calculation": { "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails": { "parentTag": "gnft_FinancialAssetsVariations", "weight": 1.0, "order": 4.0 }, "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails_1": { "parentTag": "ifrs-full_OtherFinancialAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Investments", "label": "Financial Investments", "documentation": "Financial Investments" } } }, "auth_ref": [] }, "ifrs-full_RevenueFromInterest": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RevenueFromInterest", "crdr": "credit", "calculation": { "http://www.genfit.com/role/FinancialIncomeandExpensesSummaryofFinancialIncomeandExpensesDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/FinancialIncomeandExpensesSummaryofFinancialIncomeandExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Interest income" } }, "en": { "role": { "documentation": "The amount of income arising from interest." } } }, "auth_ref": [ "r173", "r251", "r259", "r328" ] }, "ifrs-full_LoansAndReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LoansAndReceivables", "crdr": "debit", "calculation": { "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails_1": { "parentTag": "ifrs-full_OtherFinancialAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loans and receivables", "label": "Loans and receivables" } }, "en": { "role": { "documentation": "The amount of non-derivative financial assets with fixed or determinable payments that are not quoted in an active market, other than: (a) those that the entity intends to sell immediately or in the near term, which shall be classified as held for trading, and those that the entity, upon initial recognition, designates as at fair value through profit or loss; (b) those that the entity, upon initial recognition, designates as available for sale; or (c) those for which the holder may not recover substantially all of its initial investment, other than because of credit deterioration, which shall be classified as available for sale. An interest acquired in a pool of assets that are not loans or receivables (for example, an interest in a mutual fund or a similar fund) is not a loan or receivable. [Refer: Derivative financial assets]" } } }, "auth_ref": [ "r268" ] }, "gnft_NumberOfBiannualInstallments": { "xbrltype": "integerItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "NumberOfBiannualInstallments", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of biannual installments", "label": "Number Of Biannual Installments", "documentation": "Number Of Biannual Installments" } } }, "auth_ref": [] }, "ifrs-full_ProfitLossAttributableToOwnersOfParent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProfitLossAttributableToOwnersOfParent", "crdr": "credit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofOperations_1": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Attributable to owners of the Company", "label": "Profit (loss), attributable to owners of parent" } }, "en": { "role": { "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r44" ] }, "gnft_RightsOfUseLeasedPremisedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "RightsOfUseLeasedPremisedMember", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rights of Use of Leased Premised", "label": "Rights Of Use Leased Premised [Member]", "documentation": "Rights of use leased premised." } } }, "auth_ref": [] }, "gnft_NumberOfOtherEquityInstrumentsExercisableInShareBasedPaymentArrangementRelatingToCompanyRDProgramm": { "xbrltype": "sharesItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "NumberOfOtherEquityInstrumentsExercisableInShareBasedPaymentArrangementRelatingToCompanyRDProgramm", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of other equity instruments exercisable in share-based payment arrangement relating to NSIA diagnostic", "label": "Number of other equity instruments exercisable in share-based payment arrangement relating to Company R&D programm", "documentation": "Number of other equity instruments exercisable in share-based payment arrangement relating to Company R&D programm" } } }, "auth_ref": [] }, "ifrs-full_EntitysTotalForRelatedPartiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EntitysTotalForRelatedPartiesMember", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersAdditionalInformationDetails", "http://www.genfit.com/role/CompensationofCorporateOfficersScheduleofDirectorsFeesandOtherCompensationDueandPaidtoNonExecutiveDirectorsDetails", "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails", "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails", "http://www.genfit.com/role/RelatedPartiesAdditionalInformationDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity's total for related parties [member]", "label": "Entity's total for related parties [member]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used." } } }, "auth_ref": [ "r101" ] }, "ifrs-full_ReconciliationOfChangesInDeferredTaxLiabilityAssetAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ReconciliationOfChangesInDeferredTaxLiabilityAssetAbstract", "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of changes in deferred tax liability (asset) [abstract]", "label": "Reconciliation of changes in deferred tax liability (asset) [abstract]" } } }, "auth_ref": [] }, "gnft_FurnitureAndITEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "FurnitureAndITEquipmentMember", "presentation": [ "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture and IT Equipment", "label": "Furniture And I T Equipment [Member]", "documentation": "Furniture and IT equipment." } } }, "auth_ref": [] }, "ifrs-full_ProfitLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProfitLossBeforeTax", "crdr": "credit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofOperations": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofOperations", "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net profit (loss) before tax", "terseLabel": "Profit (loss) before tax", "label": "Profit (loss) before tax" } }, "en": { "role": { "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r227", "r269", "r270", "r310", "r311" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Variations in Intangible Assets", "label": "Disclosure of detailed information about intangible assets [text block]" } }, "en": { "role": { "documentation": "The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r132" ] }, "gnft_AGAS20162Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "AGAS20162Member", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "A G A S20162 [Member]", "label": "A G A S20162 [Member]", "documentation": "AGA S 2016-2." } } }, "auth_ref": [] }, "ifrs-full_ApplicableTaxRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ApplicableTaxRate", "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Applicable tax rate", "label": "Applicable tax rate" } }, "en": { "role": { "documentation": "The applicable income tax rate." } } }, "auth_ref": [ "r62" ] }, "gnft_ChiefExecutiveOfficersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ChiefExecutiveOfficersMember", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Chief Executive Officer", "label": "Chief Executive Officers [Member]", "documentation": "Chief Executive Officer." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://www.genfit.com/role/PropertyPlantandEquipmentTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Variations in Tangible Assets", "label": "Disclosure of detailed information about property, plant and equipment [text block]" } }, "en": { "role": { "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r74" ] }, "gnft_OtherInvestmentsPercentageOfSubscriptionPaid": { "xbrltype": "percentItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "OtherInvestmentsPercentageOfSubscriptionPaid", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Investments - Percentage of Subscription paid", "label": "Other Investments - Percentage of Subscription paid", "documentation": "Other Investments - Percentage of Subscription paid" } } }, "auth_ref": [] }, "gnft_MaximumCommitmentAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "MaximumCommitmentAmount", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum commitment amount", "label": "Maximum Commitment Amount", "documentation": "Maximum commitment amount." } } }, "auth_ref": [] }, "ifrs-full_Equity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Equity", "crdr": "credit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.genfit.com/role/BasisofPresentationDetails", "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity", "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "Total - Shareholders' equity", "periodStartLabel": "Balance at beginning of period", "periodEndLabel": "Balance at end of period", "terseLabel": "Equity", "label": "Equity" } }, "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } } }, "auth_ref": [ "r24", "r34", "r157", "r159", "r178", "r179", "r180" ] }, "gnft_A2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "A2027Member", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "2027 [Member]", "documentation": "2027" } } }, "auth_ref": [] }, "ifrs-full_AssetRecognisedForExpectedReimbursementContingentLiabilitiesInBusinessCombination": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AssetRecognisedForExpectedReimbursementContingentLiabilitiesInBusinessCombination", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/CommitmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset recognised for expected reimbursement, contingent liabilities in business combination", "label": "Asset recognised for expected reimbursement, contingent liabilities in business combination" } }, "en": { "role": { "documentation": "The amount of assets that have been recognised for the expected reimbursement of contingent liabilities recognised in a business combination. [Refer: Contingent liabilities [member]; Expected reimbursement, contingent liabilities in business combination; Business combinations [member]]" } } }, "auth_ref": [ "r223", "r224" ] }, "ifrs-full_TypesOfRisksMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TypesOfRisksMember", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagementAdditionalInformationDetails", "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofUSDollaragainstEuroDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risks [member]", "label": "Risks [member]" } }, "en": { "role": { "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used." } } }, "auth_ref": [ "r201", "r202", "r203", "r205", "r228", "r231", "r232" ] }, "ifrs-full_DisclosureOfProvisionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfProvisionsExplanatory", "presentation": [ "http://www.genfit.com/role/Provisions" ], "lang": { "en-us": { "role": { "terseLabel": "Provisions", "label": "Disclosure of provisions [text block]" } }, "en": { "role": { "documentation": "The disclosure of provisions. [Refer: Provisions]" } } }, "auth_ref": [ "r323" ] }, "ifrs-full_SignificantInvestmentsInAssociatesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SignificantInvestmentsInAssociatesAxis", "presentation": [ "http://www.genfit.com/role/CashandCashEquivalentsSummaryofCashandCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Associates [axis]", "label": "Associates [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r109", "r111", "r177" ] }, "ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFinanceIncomeExpenseExplanatory", "presentation": [ "http://www.genfit.com/role/FinancialIncomeandExpenses", "http://www.genfit.com/role/Statementoffinancialpositioncurrentnoncurrent" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Income and Expenses", "label": "Disclosure of finance income (cost) [text block]" } }, "en": { "role": { "documentation": "The disclosure of finance income (cost). [Refer: Finance income (cost)]" } } }, "auth_ref": [ "r323" ] }, "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TypesOfSharebasedPaymentArrangementsAxis", "presentation": [ "http://www.genfit.com/role/EarningsLossPerShareSummaryofEarningsLossPerShareDetails", "http://www.genfit.com/role/EquityAdditionalInformationDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails", "http://www.genfit.com/role/ShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Types of share-based payment arrangements [axis]", "label": "Types of share-based payment arrangements [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r215" ] }, "ifrs-full_SocialSecurityContributions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SocialSecurityContributions", "crdr": "debit", "calculation": { "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Social security contributions", "label": "Social security contributions" } }, "en": { "role": { "documentation": "A class of employee benefits expense that represents social security contributions. [Refer: Employee benefits expense]" } } }, "auth_ref": [ "r345" ] }, "ifrs-full_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of cash flows [abstract]", "label": "Statement of cash flows [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfChangesInEquityLineItems", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of changes in equity [line items]", "label": "Statement of changes in equity [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfChangesInEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of changes in equity [abstract]", "label": "Statement of changes in equity [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFinancialAssetsLineItems", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsAdditionalInformationDetails", "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of financial assets [line items]", "label": "Disclosure of financial assets [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFinancialAssetsTable", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsAdditionalInformationDetails", "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of financial assets [table]", "label": "Disclosure of financial assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to financial assets." } } }, "auth_ref": [ "r245" ] }, "ifrs-full_StatementOfChangesInEquityTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfChangesInEquityTable", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of changes in equity [table]", "label": "Statement of changes in equity [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } } }, "auth_ref": [ "r7" ] }, "ifrs-full_StatementOfComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of comprehensive income [abstract]", "label": "Statement of comprehensive income [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of financial position [abstract]", "label": "Statement of financial position [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash flows provided by (used in ) financing activities", "label": "Cash flows from (used in) financing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity." } } }, "auth_ref": [ "r142", "r150" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities", "label": "Cash flows from (used in) financing activities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about financial instruments [abstract]", "label": "Disclosure of detailed information about financial instruments [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash flows provided by (used in ) investment activities", "label": "Cash flows from (used in) investing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents." } } }, "auth_ref": [ "r142", "r150" ] }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investment activities", "label": "Cash flows from (used in) investing activities [abstract]" } } }, "auth_ref": [] }, "gnft_CDNPGEMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "CDNPGEMember", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CDN PGE [Member]", "label": "CDN PGE [Member]", "documentation": "CDN PGE" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivities", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash flows provided by (used in) in operating activities", "label": "Cash flows from (used in) operating activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]" } } }, "auth_ref": [ "r142", "r150" ] }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities", "label": "Cash flows from (used in) operating activities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Operating cash flows before change in working capital", "label": "Cash flows from (used in) operations before changes in working capital" } }, "en": { "role": { "documentation": "The cash inflow (outflow) from the entity's operations before changes in working capital." } } }, "auth_ref": [ "r295", "r358" ] }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "presentation": [ "http://www.genfit.com/role/BasisofPresentationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative effect, period of adoption, adjustment", "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]" } } }, "auth_ref": [] }, "ifrs-full_TopOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TopOfRangeMember", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Top of Range", "label": "Top of range [member]" } }, "en": { "role": { "documentation": "This member stands for top of a range." } } }, "auth_ref": [ "r182", "r200", "r214", "r298", "r299", "r362" ] }, "srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodTerminationofRESOLVEITandthedevelopmentprogramofelafibranorinNASHDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Distribution of Assets, Liabilities and Stockholders' Equity [Line Items]", "label": "Distribution of Assets, Liabilities and Stockholders' Equity [Line Items]" } } }, "auth_ref": [] }, "ifrs-full_TradeAndOtherCurrentPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TradeAndOtherCurrentPayables", "crdr": "credit", "calculation": { "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails": { "parentTag": "gnft_TotalAcquiredLiabilities", "weight": 1.0, "order": 1.0 }, "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 6.0 }, "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails", "http://www.genfit.com/role/TradeandOtherPayablesAdditionalInformationDetails", "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current trade and other payables", "totalLabel": "Total trade and other current payables", "label": "Trade and other current payables" } }, "en": { "role": { "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]" } } }, "auth_ref": [ "r18" ] }, "ifrs-full_TradeAndOtherCurrentPayablesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TradeAndOtherCurrentPayablesAbstract", "presentation": [ "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade and other payables - Current", "label": "Trade and other current payables [abstract]" } } }, "auth_ref": [] }, "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers", "crdr": "credit", "calculation": { "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentPayables", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.genfit.com/role/TradeandOtherPayablesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade payables", "label": "Current trade payables" } }, "en": { "role": { "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]" } } }, "auth_ref": [ "r273", "r335" ] }, "ifrs-full_TradeAndOtherCurrentReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TradeAndOtherCurrentReceivables", "crdr": "debit", "calculation": { "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails": { "parentTag": "gnft_TotalAcquiredAssets", "weight": 1.0, "order": 3.0 }, "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 4.0 }, "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails", "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current trade and others receivables", "totalLabel": "Total trade and other current receivables", "label": "Trade and other current receivables" } }, "en": { "role": { "documentation": "The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]" } } }, "auth_ref": [ "r16", "r32" ] }, "ifrs-full_TradeAndOtherPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TradeAndOtherPayables", "crdr": "credit", "calculation": { "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.genfit.com/role/TradeandOtherPayablesAdditionalInformationDetails", "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total trade and other payables", "terseLabel": "Trade and other payables", "label": "Trade and other payables" } }, "en": { "role": { "documentation": "The amount of trade payables and other payables. [Refer: Trade payables; Other payables]" } } }, "auth_ref": [ "r18" ] }, "ifrs-full_TradeAndOtherPayablesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TradeAndOtherPayablesAbstract", "presentation": [ "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade and other payables - Total", "label": "Trade and other payables [abstract]" } } }, "auth_ref": [] }, "ifrs-full_TradeAndOtherPayablesToTradeSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TradeAndOtherPayablesToTradeSuppliers", "crdr": "credit", "calculation": { "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails": { "parentTag": "ifrs-full_TradeAndOtherPayables", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.genfit.com/role/TradeandOtherPayablesAdditionalInformationDetails", "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade payables", "label": "Trade payables" } }, "en": { "role": { "documentation": "The amount of payment due to suppliers for goods and services used in the entity's business." } } }, "auth_ref": [ "r335" ] }, "ifrs-full_TradeAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TradeAndOtherReceivables", "crdr": "debit", "calculation": { "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total trade and other receivables", "label": "Trade and other receivables" } }, "en": { "role": { "documentation": "The amount of trade receivables and other receivables. [Refer: Trade receivables; Other receivables]" } } }, "auth_ref": [ "r16", "r32" ] }, "ifrs-full_TradeAndOtherReceivablesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TradeAndOtherReceivablesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Trade and other receivables [abstract]", "label": "Trade and other receivables [abstract]" } } }, "auth_ref": [] }, "srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "DistributionOfAssetsLiabilitiesAndStockholdersEquityTable", "lang": { "en-us": { "role": { "terseLabel": "Distribution of Assets, Liabilities and Stockholders' Equity [Table]", "label": "Distribution of Assets, Liabilities and Stockholders' Equity [Table]" } } }, "auth_ref": [] }, "ifrs-full_TradeReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TradeReceivables", "crdr": "debit", "calculation": { "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails": { "parentTag": "ifrs-full_TradeAndOtherReceivables", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade receivables", "label": "Trade receivables" } }, "en": { "role": { "documentation": "The amount due from customers for goods and services sold." } } }, "auth_ref": [ "r274" ] }, "ifrs-full_TradeReceivablesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TradeReceivablesMember", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade receivables [member]", "label": "Trade receivables [member]" } }, "en": { "role": { "documentation": "This member stands for trade receivables. [Refer: Trade receivables]" } } }, "auth_ref": [ "r233", "r237", "r302", "r328" ] }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation", "crdr": "credit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofOtherComprehensiveLoss": { "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange differences on translation of foreign operations", "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r31", "r50" ] }, "gnft_NumberOfOtherEquityInstrumentsExercisableInShareBasedPaymentArrangementRelatingToPBCAndELATIVE": { "xbrltype": "sharesItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "NumberOfOtherEquityInstrumentsExercisableInShareBasedPaymentArrangementRelatingToPBCAndELATIVE", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of other equity instruments exercisable in share-based payment arrangement relating to PBC and ELATIVE", "label": "Number of other equity instruments exercisable in share-based payment arrangement relating to PBC and ELATIVE", "documentation": "Number of other equity instruments exercisable in share-based payment arrangement relating to PBC and ELATIVE" } } }, "auth_ref": [] }, "ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "KeyManagementPersonnelCompensationPostemploymentBenefits", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Key management personnel compensation, post-employment benefits", "label": "Key management personnel compensation, post-employment benefits" } }, "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of post-employment benefits. [Refer: Key management personnel of entity or parent [member]]" } } }, "auth_ref": [ "r96" ] }, "ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForMeasuringInventories", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Description of accounting policy for measuring inventories [text block]" } }, "en": { "role": { "documentation": "The description of the entity's accounting policy for measuring inventories. [Refer: Inventories]" } } }, "auth_ref": [ "r89" ] }, "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "KeyManagementPersonnelCompensationSharebasedPayment", "crdr": "debit", "calculation": { "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Key management personnel compensation, share-based payment", "label": "Key management personnel compensation, share-based payment" } }, "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]" } } }, "auth_ref": [ "r97" ] }, "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Key management personnel compensation, short-term employee benefits", "label": "Key management personnel compensation, short-term employee benefits" } }, "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]" } } }, "auth_ref": [ "r95" ] }, "gnft_ShareCapitalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ShareCapitalAmount", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share capital amount", "label": "Share Capital Amount", "documentation": "Share capital amount." } } }, "auth_ref": [] }, "gnft_DisclosureOfOtherFinancialAssetsExplanatoryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DisclosureOfOtherFinancialAssetsExplanatoryTextBlock", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssets" ], "lang": { "en-us": { "role": { "terseLabel": "Other Financial Assets", "label": "Disclosure Of Other Financial Assets Explanatory [Text Block]", "documentation": "Disclosure of other financial assets." } } }, "auth_ref": [] }, "gnft_SealRockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "SealRockMember", "presentation": [ "http://www.genfit.com/role/DeferredIncomeandRevenueDetails", "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Seal Rock [Member]", "label": "Seal Rock [Member]", "documentation": "Seal Rock" } } }, "auth_ref": [] }, "ifrs-full_OtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherComprehensiveIncome", "crdr": "credit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income", "label": "Other comprehensive income" } }, "en": { "role": { "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]" } } }, "auth_ref": [ "r4", "r41", "r50", "r171" ] }, "ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForEarningsPerShareExplanatory", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings (loss) per share", "label": "Description of accounting policy for earnings per share [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for earnings per share." } } }, "auth_ref": [ "r329" ] }, "gnft_SOUS2018Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "SOUS2018Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "S O U S2018 [Member]", "label": "S O U S2018 [Member]", "documentation": "SO US 2018." } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory", "presentation": [ "http://www.genfit.com/role/EmployeeBenefits", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Description of accounting policy for employee benefits [text block]", "label": "Description of accounting policy for employee benefits [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment." } } }, "auth_ref": [ "r329" ] }, "gnft_TaxLossCarriedForwardUsedToOffsetTaxableProfits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "TaxLossCarriedForwardUsedToOffsetTaxableProfits", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/IncomeTaxNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax loss carried forward used to offset taxable profits", "label": "Tax Loss Carried Forward Used To Offset Taxable Profits", "documentation": "Tax Loss Carried Forward Used To Offset Taxable Profits" } } }, "auth_ref": [] }, "gnft_ProvisionForLitigation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ProvisionForLitigation", "crdr": "credit", "calculation": { "http://www.genfit.com/role/ProvisionsAdditionalInformationDetails": { "parentTag": "ifrs-full_CurrentProvisions", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.genfit.com/role/ProvisionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for litigation [Line Items]", "label": "Provision for litigation", "documentation": "Provision for litigation" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForExpensesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForExpensesExplanatory", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Classification of operating expenses", "label": "Description of accounting policy for expenses [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for expenses." } } }, "auth_ref": [ "r329" ] }, "ifrs-full_ContingentLiabilityForGuaranteesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ContingentLiabilityForGuaranteesMember", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent liability for guarantees [member]", "label": "Contingent liability for guarantees [member]" } }, "en": { "role": { "documentation": "This member stands for a contingent liability for guarantees. [Refer: Contingent liabilities [member]; Guarantees [member]]" } } }, "auth_ref": [ "r347" ] }, "gnft_DisclosureOfDetailedInformationAboutShareCapitalTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DisclosureOfDetailedInformationAboutShareCapitalTextBlock", "presentation": [ "http://www.genfit.com/role/Equity" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Detailed Information About Share Capital", "label": "Disclosure of Detailed Information About Share Capital [Text Block]", "documentation": "Disclosure of Detailed Information About Share Capital" } } }, "auth_ref": [] }, "gnft_ClosingForeignExchangeRateUSDEuro": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ClosingForeignExchangeRateUSDEuro", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofApplicableExchangeRatesUsedtoTranslateFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ClosingForeignExchangeRateUSDEuro", "label": "ClosingForeignExchangeRateUSDEuro", "documentation": "ClosingForeignExchangeRateUSDEuro" } } }, "auth_ref": [] }, "gnft_ConversionRatio": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ConversionRatio", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion ratio", "label": "Conversion ratio", "documentation": "Conversion ratio" } } }, "auth_ref": [] }, "gnft_EquityComponentOfBondsConvertibleOrExchangeableIntoNewOrExistingSharesBeforeDeferredTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "EquityComponentOfBondsConvertibleOrExchangeableIntoNewOrExistingSharesBeforeDeferredTaxes", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in equity before deferred taxes", "label": "Equity Component Of Bonds Convertible Or Exchangeable Into New Or Existing Shares Before Deferred Taxes", "documentation": "Equity Component Of Bonds Convertible Or Exchangeable Into New Or Existing Shares Before Deferred Taxes" } } }, "auth_ref": [] }, "gnft_BSAAR2016AEtBMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "BSAAR2016AEtBMember", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSAAR 2016-A and B", "label": "B S A A R2016 A Et B [Member]", "documentation": "BSAAR 2016 A et B." } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Loans and borrowings", "label": "Description of accounting policy for financial liabilities [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for financial liabilities. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r329" ] }, "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency", "label": "Description of accounting policy for foreign currency translation [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for foreign currency translation." } } }, "auth_ref": [ "r329" ] }, "gnft_DescriptionOfNatureOfConditions": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DescriptionOfNatureOfConditions", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nature of conditions", "label": "Description Of Nature Of Conditions", "documentation": "Description of nature of conditions." } } }, "auth_ref": [] }, "ifrs-full_LaterThanFiveYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LaterThanFiveYearsMember", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofMaturitiesofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Later than five years", "label": "Later than five years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than five years." } } }, "auth_ref": [ "r194", "r196", "r206", "r304", "r305", "r308" ] }, "gnft_CreditNotesFromSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "CreditNotesFromSuppliers", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit notes from suppliers", "label": "Credit Notes From Suppliers", "documentation": "Credit notes from suppliers." } } }, "auth_ref": [] }, "ifrs-full_OtherFinanceCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherFinanceCost", "crdr": "debit", "calculation": { "http://www.genfit.com/role/FinancialIncomeandExpensesSummaryofFinancialIncomeandExpensesDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/FinancialIncomeandExpensesSummaryofFinancialIncomeandExpensesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other finance cost", "negatedLabel": "Other finance cost", "label": "Other finance cost" } }, "en": { "role": { "documentation": "The amount of finance costs that the entity does not separately disclose in the same statement or note. [Refer: Finance costs]" } } }, "auth_ref": [ "r328" ] }, "ifrs-full_FinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialLiabilities", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails", "http://www.genfit.com/role/FinancialRisksManagementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial liabilities", "label": "Financial liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]" } } }, "auth_ref": [ "r230" ] }, "ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LaterThanFourYearsAndNotLaterThanFiveYearsMember", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofMaturitiesofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Later than four years and not later than five years", "label": "Later than four years and not later than five years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than four years and not later than five years." } } }, "auth_ref": [ "r194", "r196", "r206", "r304", "r308", "r328" ] }, "gnft_TotalAcquiredAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "TotalAcquiredAssets", "crdr": "debit", "calculation": { "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails": { "parentTag": "ifrs-full_NetAssetsLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total acquired assets", "label": "Total acquired assets", "documentation": "Total acquired assets" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of tangible assets, intangible assets and goodwill", "label": "Description of accounting policy for impairment of assets [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for the impairment of assets." } } }, "auth_ref": [ "r329" ] }, "ifrs-full_OtherFinanceIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherFinanceIncome", "crdr": "credit", "calculation": { "http://www.genfit.com/role/FinancialIncomeandExpensesSummaryofFinancialIncomeandExpensesDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/FinancialIncomeandExpensesSummaryofFinancialIncomeandExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other finance income", "label": "Other finance income" } }, "en": { "role": { "documentation": "The amount of finance income that the entity does not separately disclose in the same statement or note. [Refer: Finance income]" } } }, "auth_ref": [ "r328" ] }, "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax", "label": "Description of accounting policy for income tax [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for income tax." } } }, "auth_ref": [ "r329" ] }, "gnft_CashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "CashFlowInformationAbstract", "lang": { "en-us": { "role": { "label": "Cash Flow Information [Abstract]", "documentation": "Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "gnft_FinancialAssetsVariations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "FinancialAssetsVariations", "crdr": "debit", "calculation": { "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Financial Assets, Variations", "label": "Financial Assets, Variations", "documentation": "Financial Assets, Variations" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "label": "Description of accounting policy for intangible assets other than goodwill [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r329" ] }, "ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LaterThanOneYearAndNotLaterThanTwoYearsMember", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofMaturitiesofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Later than one year and not later than two years", "label": "Later than one year and not later than two years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than one year and not later than two years." } } }, "auth_ref": [ "r194", "r196", "r206", "r304", "r308", "r328" ] }, "gnft_ManagementBoardMeetingDate": { "xbrltype": "dateItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ManagementBoardMeetingDate", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Date of the Management Board meeting", "label": "Management Board Meeting Date", "documentation": "Management board meeting date." } } }, "auth_ref": [] }, "ifrs-full_LaterThanOneYearMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LaterThanOneYearMember", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails", "http://www.genfit.com/role/EmployeeBenefitsSummaryofAssumptionsUsedforEmployeesfortheMeasurementofRetirementIndemnitytoEmployeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Beyond", "label": "Later than one year [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than one year." } } }, "auth_ref": [ "r27" ] }, "ifrs-full_ContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ContractLiabilities", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract liabilities", "label": "Contract liabilities" } }, "en": { "role": { "documentation": "The amount of an entity\u2019s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer." } } }, "auth_ref": [ "r184", "r187" ] }, "ifrs-full_OtherFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherFinancialAssets", "crdr": "debit", "calculation": { "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsAdditionalInformationDetails", "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Other financial assets", "terseLabel": "Total amount of financial assets", "label": "Other financial assets" } }, "en": { "role": { "documentation": "The amount of financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]" } } }, "auth_ref": [ "r13" ] }, "gnft_NumberOfShareWarrantsRemainingInShareBasedPaymentArrangement": { "xbrltype": "sharesItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "NumberOfShareWarrantsRemainingInShareBasedPaymentArrangement", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total number of BSAAR remaining (in shares)", "label": "Number Of Share Warrants Remaining In Share Based Payment Arrangement", "documentation": "Number of share warrants remaining in share based payment arrangement." } } }, "auth_ref": [] }, "gnft_TenPercentIncreaseDecreaseInCHFVsEuroMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "TenPercentIncreaseDecreaseInCHFVsEuroMember", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofCHFagainstEuroDetails", "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofUSDollaragainstEuroDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ten Percent Increase Decrease In C H F Vs Euro", "label": "Ten Percent Increase Decrease In C H F Vs Euro [Member]", "documentation": "Ten Percent Increase Decrease In C H F Vs Euro" } } }, "auth_ref": [] }, "gnft_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromServicePaidToEmployees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromServicePaidToEmployees", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails", "http://www.genfit.com/role/EmployeeBenefitsSummaryofChangesinPresentValueofDefinedBenefitObligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in net defined benefit liability (asset) resulting from service paid to employees", "label": "Increase (decrease) in net defined benefit liability (asset) resulting from service paid to employees", "documentation": "Increase (decrease) in net defined benefit liability (asset) resulting from service paid to employees" } } }, "auth_ref": [] }, "gnft_AGADAndS20171And20172Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "AGADAndS20171And20172Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA D and S 2017-1 and 2017-2", "label": "A G A D And S20171 And20172 [Member]", "documentation": "AGA D and S 2017-1 and 2017-2." } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForIssuedCapitalExplanatory", "presentation": [ "http://www.genfit.com/role/Equity", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Equity", "label": "Description of accounting policy for issued capital [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for issued capital. [Refer: Issued capital]" } } }, "auth_ref": [ "r329" ] }, "gnft_DeferredUpfrontPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DeferredUpfrontPayment", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodSignatureofaLicensingandPartnershipAgreementwithIpsenDetails", "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred upfront payment", "label": "Deferred Upfront Payment", "documentation": "Deferred upfront payment." } } }, "auth_ref": [] }, "gnft_CDNThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "CDNThreeMember", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "C D N Three [Member]", "label": "C D N Three [Member]", "documentation": "CDN 3." } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Description of accounting policy for leases [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time." } } }, "auth_ref": [ "r329" ] }, "ifrs-full_FinancialLiabilitiesAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialLiabilitiesAtFairValue", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of financial liabilities", "label": "Financial liabilities, at fair value" } }, "en": { "role": { "documentation": "The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]" } } }, "auth_ref": [ "r230" ] }, "gnft_PerformanceConditionsPlanFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "PerformanceConditionsPlanFourMember", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance Conditions Plan Four", "label": "Performance Conditions Plan Four [Member]", "documentation": "Performance conditions plan four." } } }, "auth_ref": [] }, "srt_LitigationCaseTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "LitigationCaseTypeDomain", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Domain]", "label": "Litigation Case [Domain]" } } }, "auth_ref": [] }, "gnft_A2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "A2025Member", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "2025 [Member]", "documentation": "2025" } } }, "auth_ref": [] }, "gnft_AdditionalMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "AdditionalMilestonePayments", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional milestone payments", "label": "Additional milestone payments", "documentation": "Additional milestone payments" } } }, "auth_ref": [] }, "gnft_RefundableAndConditionalAdvances": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "RefundableAndConditionalAdvances", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofMaturitiesofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "TOTAL - Refundable and conditional advances", "label": "Refundable And Conditional Advances", "documentation": "Refundable and conditional advances." } } }, "auth_ref": [] }, "gnft_OCEANESMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "OCEANESMember", "presentation": [ "http://www.genfit.com/role/EarningsLossPerShareSummaryofEarningsLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OCEANES", "label": "OCEANES [Member]", "documentation": "OCEANES" } } }, "auth_ref": [] }, "gnft_CDNFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "CDNFourMember", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "C D N Four [Member]", "label": "C D N Four [Member]", "documentation": "CDN 4." } } }, "auth_ref": [] }, "gnft_DisclosureOfCompensationOfCorporateOfficersExplanatoryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DisclosureOfCompensationOfCorporateOfficersExplanatoryTextBlock", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficers" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation of Corporate Officers", "label": "Disclosure Of Compensation Of Corporate Officers Explanatory [Text Block]", "documentation": "Disclosure of compensation of corporate officers." } } }, "auth_ref": [] }, "gnft_ValuationMethodUsedInShareBasedPaymentArrangements": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ValuationMethodUsedInShareBasedPaymentArrangements", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation method used", "label": "Valuation Method Used In Share Based Payment Arrangements", "documentation": "Valuation method used in share based payment arrangements." } } }, "auth_ref": [] }, "gnft_SalePriceClinicalTrialPhase": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "SalePriceClinicalTrialPhase", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale price, clinical trial phase", "label": "Sale Price, Clinical Trial Phase", "documentation": "Sale Price, Clinical Trial Phase" } } }, "auth_ref": [] }, "gnft_ReversalOfAmortizationAndImpairmentLossRelatedToFixedAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ReversalOfAmortizationAndImpairmentLossRelatedToFixedAssetsMember", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reversal Of Amortization And Impairment Loss Related To Fixed Assets", "label": "Reversal Of Amortization And Impairment Loss Related To Fixed Assets [Member]", "documentation": "Reversal Of Amortization And Impairment Loss Related To Fixed Assets" } } }, "auth_ref": [] }, "gnft_PerformanceConditionsPlanOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "PerformanceConditionsPlanOneMember", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsParentheticalDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SOD 2020 SOC2020 SOUS2020", "label": "Performance Conditions Plan One [Member]", "documentation": "Performance conditions plan one." } } }, "auth_ref": [] }, "ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncomeTaxesPaidRefundClassifiedAsOperatingActivities", "crdr": "credit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Income tax paid", "label": "Income taxes paid (refund), classified as operating activities" } }, "en": { "role": { "documentation": "The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]" } } }, "auth_ref": [ "r147", "r289" ] }, "gnft_FinancialIncomeAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "FinancialIncomeAndExpensesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Financial Income And Expenses [Abstract]", "label": "Financial Income And Expenses [Abstract]", "documentation": "Financial income and expenses [abstract]" } } }, "auth_ref": [] }, "gnft_NoncurrentSocialSecurityCostsReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "NoncurrentSocialSecurityCostsReceivables", "crdr": "debit", "calculation": { "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails": { "parentTag": "ifrs-full_NoncurrentReceivables", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncurrent Social Security Costs Receivables", "label": "Noncurrent Social Security Costs Receivables", "documentation": "Noncurrent social security costs receivables." } } }, "auth_ref": [] }, "gnft_SOUS20161Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "SOUS20161Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "S O U S20161 [Member]", "label": "S O U S20161 [Member]", "documentation": "SO US 2016-1." } } }, "auth_ref": [] }, "ifrs-full_MiscellaneousAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "MiscellaneousAssetsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Miscellaneous assets [abstract]", "label": "Miscellaneous assets [abstract]" } } }, "auth_ref": [] }, "gnft_DisclosureOfOperatingExpenseTable": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DisclosureOfOperatingExpenseTable", "presentation": [ "http://www.genfit.com/role/OperatingExpenseAdditionalInformationDetails", "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Operating Expense [Table]", "label": "Disclosure Of Operating Expense [Table]", "documentation": "Schedule disclosing information related to operating expenses." } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease due to changes in accounting policy required by IFRSs, cumulative effect at date of initial application", "label": "Increase (decrease) due to changes in accounting policy required by IFRSs, cumulative effect at date of initial application [member]" } }, "en": { "role": { "documentation": "This member stands for the financial effect of changes in accounting policy for cumulative effect adjustment in the financial statements at the date of initial application of a new or amended IFRS Standard. [Refer: IFRSs [member]]" } } }, "auth_ref": [ "r326" ] }, "ifrs-full_BasicEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BasicEarningsLossPerShare", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofOperations", "http://www.genfit.com/role/EarningsLossPerShareSummaryofEarningsLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic earnings (loss) per share (\u20ac/share)", "verboseLabel": "Basic earnings (loss) per share", "label": "Basic earnings (loss) per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } } }, "auth_ref": [ "r112", "r113" ] }, "ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentServiceCostNetDefinedBenefitLiabilityAsset", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails", "http://www.genfit.com/role/EmployeeBenefitsSummaryofChangesinPresentValueofDefinedBenefitObligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in net defined benefit liability (asset) resulting from current service cost", "label": "Increase in net defined benefit liability (asset) resulting from current service cost" } }, "en": { "role": { "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from employee service in the current period. [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r80" ] }, "gnft_IncreaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "IncreaseMember", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase", "label": "Increase [Member]", "documentation": "Increase" } } }, "auth_ref": [] }, "gnft_NumberOfShareOptionsSubscribedInShareBasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "NumberOfShareOptionsSubscribedInShareBasedPaymentArrangement", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total number of SO subscribed", "label": "Number Of Share Options Subscribed In Share Based Payment Arrangement", "documentation": "Number of share options subscribed in share based payment arrangement." } } }, "auth_ref": [] }, "ifrs-full_AccumulatedImpairmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AccumulatedImpairmentMember", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentSummaryofVariationsinTangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment", "label": "Accumulated impairment [member]" } }, "en": { "role": { "documentation": "This member stands for accumulated impairment. [Refer: Impairment loss]" } } }, "auth_ref": [ "r225", "r234", "r302", "r340", "r348", "r352", "r353" ] }, "gnft_BorrowingsDeadlineAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "BorrowingsDeadlineAxis", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings Deadline [Axis]", "label": "Borrowings Deadline [Axis]", "documentation": "Borrowings Deadline" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "crdr": "debit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Increase (decrease) in cash and cash equivalents", "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes" } }, "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } } }, "auth_ref": [ "r148" ] }, "gnft_A2023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "A2023Member", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023", "label": "2023 [Member]", "documentation": "2023" } } }, "auth_ref": [] }, "gnft_AGAD2018Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "AGAD2018Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "A G A D2018 [Member]", "label": "A G A D2018 [Member]", "documentation": "AGA D 2018." } } }, "auth_ref": [] }, "gnft_InventoryPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "InventoryPurchaseAgreementMember", "presentation": [ "http://www.genfit.com/role/DeferredIncomeandRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory Purchase Agreement", "label": "Inventory Purchase Agreement [Member]", "documentation": "Inventory Purchase Agreement" } } }, "auth_ref": [] }, "gnft_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "presentation": [ "http://www.genfit.com/role/EmployeeBenefits", "http://www.genfit.com/role/Equity", "http://www.genfit.com/role/OtherFinancialAssets", "http://www.genfit.com/role/SummaryofSignificantAccountingPolicies", "http://www.genfit.com/role/TradeandOtherPayables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of significant accounting policies [text block]", "label": "Disclosure of significant accounting policies [text block]", "documentation": "The entire disclosure for significant accounting policies applied by the entity." } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.genfit.com/role/DeferredIncomeandRevenueDetails", "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodSignatureofaLicensingandPartnershipAgreementwithIpsenDetails", "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails", "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails", "http://www.genfit.com/role/RelatedPartiesAdditionalInformationDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofApplicableExchangeRatesUsedtoTranslateFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [] }, "gnft_SO1Et22017Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "SO1Et22017Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SO 1 et 2 2017", "label": "S O1 Et22017 [Member]", "documentation": "SO 1 et 2 2017." } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails", "http://www.genfit.com/role/EmployeeBenefitsSummaryofSensitivityoftheRetirementandPostEmploymentBenefitstoaVariationoftheDiscountRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impact/present value of the undertaking", "label": "Increase (decrease) in defined benefit obligation due to reasonably possible decrease in actuarial assumption" } }, "en": { "role": { "documentation": "The increase (decrease) in a defined benefit obligation that would have been caused by a decrease in a significant actuarial assumption that was reasonably possible at the end of the reporting period. [Refer: Actuarial assumptions [member]]" } } }, "auth_ref": [ "r85" ] }, "ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails", "http://www.genfit.com/role/EmployeeBenefitsSummaryofSensitivityoftheRetirementandPostEmploymentBenefitstoaVariationoftheDiscountRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impact/present value of the undertaking", "label": "Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption" } }, "en": { "role": { "documentation": "The increase (decrease) in a defined benefit obligation that would have been caused by an increase in a significant actuarial assumption that was reasonably possible at the end of the reporting period. [Refer: Actuarial assumptions [member]]" } } }, "auth_ref": [ "r85" ] }, "gnft_NumberOfQuarterlyPaymentsAmortizationAndInterest": { "xbrltype": "integerItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "NumberOfQuarterlyPaymentsAmortizationAndInterest", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of quarterly payments, amortization and interest", "label": "Number Of Quarterly Payments, Amortization And Interest", "documentation": "Number Of Quarterly Payments, Amortization And Interest" } } }, "auth_ref": [] }, "gnft_RevenueFromContractsWithCustomersValueAddedTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "RevenueFromContractsWithCustomersValueAddedTaxes", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodSignatureofaLicensingandPartnershipAgreementwithIpsenDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payment from collaboration, up-front cash payment, VAT", "label": "Revenue From Contracts With Customers, Value Added Taxes", "documentation": "Revenue From Contracts With Customers, Value Added Taxes" } } }, "auth_ref": [] }, "ifrs-full_CurrentTaxLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentTaxLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 3.0 }, "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails": { "parentTag": "gnft_TotalAcquiredLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/IncomeTaxNarrativeDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current tax liabilities", "label": "Current tax liabilities, current" } }, "en": { "role": { "documentation": "The current amount of current tax liabilities. [Refer: Current tax liabilities]" } } }, "auth_ref": [ "r20" ] }, "gnft_InitialDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "InitialDebt", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial debt", "label": "Initial Debt", "documentation": "Initial debt." } } }, "auth_ref": [] }, "ifrs-full_BenefitsPaidOrPayable": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BenefitsPaidOrPayable", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Benefits paid or payable", "label": "Benefits paid or payable" } }, "en": { "role": { "documentation": "The amount of benefits paid or payable for retirement benefit plans." } } }, "auth_ref": [ "r106" ] }, "gnft_AGAD20162Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "AGAD20162Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "A G A D20162 [Member]", "label": "A G A D20162 [Member]", "documentation": "AGA D 2016-2." } } }, "auth_ref": [] }, "gnft_ShareWarrantsSubscriptionPeriod": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ShareWarrantsSubscriptionPeriod", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subscription period", "label": "Share Warrants Subscription Period", "documentation": "Share warrants subscription period." } } }, "auth_ref": [] }, "gnft_IpsenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "IpsenMember", "presentation": [ "http://www.genfit.com/role/DeferredIncomeandRevenueDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodSignatureofaLicensingandPartnershipAgreementwithIpsenDetails", "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ipsen", "label": "Ipsen [Member]", "documentation": "Ipsen" } } }, "auth_ref": [] }, "ifrs-full_CurrentTradeReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentTradeReceivables", "crdr": "debit", "calculation": { "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current trade receivables", "label": "Current trade receivables" } }, "en": { "role": { "documentation": "The amount of current trade receivables. [Refer: Trade receivables]" } } }, "auth_ref": [ "r272", "r274" ] }, "gnft_CompensationPaidToBoardOfDirectorsExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "CompensationPaidToBoardOfDirectorsExplanatoryTableTextBlock", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Compensation Paid to Officers", "label": "Compensation Paid To Board of Directors Explanatory [Table Text Block]", "documentation": "The disclosure of notes and other explanatory information related to compensation paid to members of Company's Board of Directors." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory", "presentation": [ "http://www.genfit.com/role/IncomeTaxTables" ], "lang": { "en-us": { "role": { "terseLabel": "Breakdown of deferred taxes by nature", "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [text block]" } }, "en": { "role": { "documentation": "The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]" } } }, "auth_ref": [ "r66" ] }, "dei_EntityNumberOfEmployees": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityNumberOfEmployees", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity number of employees", "label": "Entity Number of Employees", "documentation": "Number of persons employed by the Entity" } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Well-known Seasoned Issuer", "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r321" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Voluntary Filers", "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "ifrs-full_Accruals": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Accruals", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/TradeandOtherPayablesAdditionalInformationDetails", "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses", "label": "Accruals" } }, "en": { "role": { "documentation": "The amount of liabilities to pay for goods or services that have been received or supplied but have not been paid, invoiced or formally agreed with the supplier, including amounts due to employees." } } }, "auth_ref": [ "r335" ] }, "ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails", "http://www.genfit.com/role/EmployeeBenefitsSummaryofChangesinPresentValueofDefinedBenefitObligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income", "label": "Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income" } }, "en": { "role": { "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from the remeasurement of that net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r82" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "presentation": [ "http://www.genfit.com/role/Equity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity", "label": "Disclosure of share capital, reserves and other equity interest [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for share capital, reserves and other equity interest." } } }, "auth_ref": [ "r39" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r314" ] }, "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensation" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of share-based payment arrangements [text block]", "label": "Disclosure of share-based payment arrangements [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for share-based payment arrangements." } } }, "auth_ref": [ "r208" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r314" ] }, "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate", "label": "Risk free interest rate, share options granted" } }, "en": { "role": { "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]" } } }, "auth_ref": [ "r216" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r314" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Ex Transition Period", "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r322" ] }, "gnft_DisclosureOfOperatingExpenseLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DisclosureOfOperatingExpenseLineItems", "presentation": [ "http://www.genfit.com/role/OperatingExpenseAdditionalInformationDetails", "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Operating Expense [Line Items]", "label": "Disclosure Of Operating Expense [Line Items]", "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with operating expenses." } } }, "auth_ref": [] }, "gnft_PriceOfSharesAtAllocation": { "xbrltype": "perShareItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "PriceOfSharesAtAllocation", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Price of the share at the time of allocation", "label": "Price Of Shares At Allocation", "documentation": "Price of shares at allocation." } } }, "auth_ref": [] }, "ifrs-full_FinanceIncomeCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinanceIncomeCost", "crdr": "credit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofOperations": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/ConsolidatedStatementsofOperations", "http://www.genfit.com/role/FinancialIncomeandExpensesSummaryofFinancialIncomeandExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance income (cost)", "totalLabel": "Financial profit (loss)", "label": "Finance income (cost)" } }, "en": { "role": { "documentation": "The amount of income or cost associated with interest and other financing activities of the entity." } } }, "auth_ref": [ "r337" ] }, "gnft_DisclosureOfCashCashEquivalentsAndFinancialAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DisclosureOfCashCashEquivalentsAndFinancialAssetsLineItems", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagementSummaryofCashCashEquivalentsandFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Cash Cash Equivalents And Financial Assets [Line Items]", "label": "Disclosure Of Cash Cash Equivalents And Financial Assets [Line Items]", "documentation": "Disclosure of cash, cash equivalents and financial assets." } } }, "auth_ref": [] }, "gnft_AGAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "AGAMember", "presentation": [ "http://www.genfit.com/role/EarningsLossPerShareSummaryofEarningsLossPerShareDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "A G A", "label": "A G A [Member]", "documentation": "A G A" } } }, "auth_ref": [] }, "ifrs-full_FinanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinanceCosts", "crdr": "debit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofOperations": { "parentTag": "ifrs-full_FinanceIncomeCost", "weight": -1.0, "order": 2.0 }, "http://www.genfit.com/role/FinancialIncomeandExpensesSummaryofFinancialIncomeandExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/ConsolidatedStatementsofOperations", "http://www.genfit.com/role/FinancialIncomeandExpensesSummaryofFinancialIncomeandExpensesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Finance costs", "negatedLabel": "Financial expenses", "negatedTotalLabel": "Finance costs", "label": "Finance costs" } }, "en": { "role": { "documentation": "The amount of costs associated with financing activities of the entity." } } }, "auth_ref": [ "r48" ] }, "ifrs-full_ImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ImpairmentLoss", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment loss", "label": "Impairment loss" } }, "en": { "role": { "documentation": "The amount recognised as a reduction of the carrying amount of an asset or cash-generating unit to its recoverable amount. [Refer: Carrying amount [member]]" } } }, "auth_ref": [ "r118", "r119" ] }, "gnft_Installments": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "Installments", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Installments", "label": "Installments", "documentation": "Installments." } } }, "auth_ref": [] }, "gnft_NumberOfSharesRecordedAsDeductionFromEquity": { "xbrltype": "sharesItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "NumberOfSharesRecordedAsDeductionFromEquity", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares recorded as deduction from equity (in shares)", "label": "Number Of Shares Recorded As Deduction From Equity", "documentation": "Number of shares recorded as deduction from equity." } } }, "auth_ref": [] }, "ifrs-full_FinanceIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinanceIncome", "crdr": "credit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofOperations": { "parentTag": "ifrs-full_FinanceIncomeCost", "weight": 1.0, "order": 1.0 }, "http://www.genfit.com/role/FinancialIncomeandExpensesSummaryofFinancialIncomeandExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/ConsolidatedStatementsofOperations", "http://www.genfit.com/role/FinancialIncomeandExpensesSummaryofFinancialIncomeandExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial income", "totalLabel": "Finance income", "label": "Finance income" } }, "en": { "role": { "documentation": "The amount of income associated with interest and other financing activities of the entity." } } }, "auth_ref": [ "r337" ] }, "gnft_SocialSecurityCostsReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "SocialSecurityCostsReceivables", "crdr": "debit", "calculation": { "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails": { "parentTag": "ifrs-full_TradeAndOtherReceivables", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Social Security Costs Receivables", "label": "Social Security Costs Receivables", "documentation": "Social security costs receivables." } } }, "auth_ref": [] }, "gnft_CICFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "CICFourMember", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "C I C Four [Member]", "label": "C I C Four [Member]", "documentation": "CIC 4." } } }, "auth_ref": [] }, "gnft_DiscontinuanceOfStudyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DiscontinuanceOfStudyMember", "presentation": [ "http://www.genfit.com/role/ProvisionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discontinuance of Study", "label": "Discontinuance Of Study [Member]", "documentation": "Discontinuance Of Study" } } }, "auth_ref": [] }, "gnft_SOSU2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "SOSU2022Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SO SU 2022", "label": "SO SU 2022 [Member]", "documentation": "SO SU 2022" } } }, "auth_ref": [] }, "gnft_ShareWarrantsExercisePeriod": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ShareWarrantsExercisePeriod", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "End of exercise period", "label": "Share Warrants Exercise Period", "documentation": "Share warrants exercise period." } } }, "auth_ref": [] }, "gnft_RetirementAge": { "xbrltype": "integerItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "RetirementAge", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement age", "label": "Retirement age", "documentation": "Retirement age" } } }, "auth_ref": [] }, "gnft_UndertakingForCollectiveInvestmentInTransferableSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "UndertakingForCollectiveInvestmentInTransferableSecuritiesMember", "presentation": [ "http://www.genfit.com/role/CashandCashEquivalentsSummaryofCashandCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Undertaking For Collective Investment In Transferable Securities [Member]", "label": "Undertaking For Collective Investment In Transferable Securities [Member]", "documentation": "Undertaking for collective investment in transferable securities." } } }, "auth_ref": [] }, "ifrs-full_FinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialAssets", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails", "http://www.genfit.com/role/FinancialRisksManagementSummaryofCashCashEquivalentsandFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current and non current financial assets", "label": "Financial assets" } }, "en": { "role": { "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]" } } }, "auth_ref": [ "r230", "r234", "r235", "r238", "r302" ] }, "ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment", "presentation": [ "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment loss", "label": "Impairment loss recognised in profit or loss, property, plant and equipment" } }, "en": { "role": { "documentation": "The amount of impairment loss recognised in profit or loss for property, plant and equipment. [Refer: Impairment loss recognised in profit or loss; Property, plant and equipment]" } } }, "auth_ref": [ "r53", "r72" ] }, "gnft_A2026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "A2026Member", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "2026 [Member]", "documentation": "2026" } } }, "auth_ref": [] }, "gnft_SeniorStaffMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "SeniorStaffMember", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Staff [Member]", "label": "Senior Staff [Member]", "documentation": "Senior staff." } } }, "auth_ref": [] }, "gnft_BSA2015AMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "BSA2015AMember", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSA 2015-A", "verboseLabel": "B S A2015 A [Member]", "label": "B S A2015 A [Member]", "documentation": "BSA 2015-A." } } }, "auth_ref": [] }, "gnft_DisclosureOfTradeAndOtherReceivablesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DisclosureOfTradeAndOtherReceivablesTable", "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of trade and other receivables [Table]", "label": "Disclosure of trade and other receivables [Table]", "documentation": "Disclosure of trade and other receivables [Table]" } } }, "auth_ref": [] }, "gnft_SOD2020Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "SOD2020Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "S O D2020 [Member]", "label": "S O D2020 [Member]", "documentation": "SO D 2020." } } }, "auth_ref": [] }, "gnft_SO2021Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "SO2021Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "S O 2021", "label": "S O 2021 [Member]", "documentation": "S O 2021" } } }, "auth_ref": [] }, "ifrs-full_LossesOnDisposalsOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LossesOnDisposalsOfPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriod", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodTerminationofRESOLVEITandthedevelopmentprogramofelafibranorinNASHDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Losses on disposals of property, plant and equipment", "label": "Losses on disposals of property, plant and equipment" } }, "en": { "role": { "documentation": "The losses on the disposal of property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r55" ] }, "gnft_OtherInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "OtherInvestmentsMember", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other investments", "label": "Other investments [Member]", "documentation": "Other investments" } } }, "auth_ref": [] }, "ifrs-full_FinancialAssetsAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialAssetsAtFairValue", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of financial assets", "label": "Financial assets, at fair value" } }, "en": { "role": { "documentation": "The fair value of financial assets. [Refer: At fair value [member]; Financial assets]" } } }, "auth_ref": [ "r230" ] }, "gnft_AGAD20172Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "AGAD20172Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "A G A D20172 [Member]", "label": "A G A D20172 [Member]", "documentation": "AGA D 2017-2." } } }, "auth_ref": [] }, "gnft_AttendanceFeesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "AttendanceFeesMember", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersScheduleofDirectorsFeesandOtherCompensationDueandPaidtoNonExecutiveDirectorsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Attendance Fees", "label": "Attendance Fees [Member]", "documentation": "Attendance fees." } } }, "auth_ref": [] }, "gnft_DecreaseUnusedInProvisionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DecreaseUnusedInProvisionsMember", "presentation": [ "http://www.genfit.com/role/ProvisionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease (unused) in Provisions [Member]", "label": "Decrease (unused) in Provisions [Member]", "documentation": "Decrease (unused) in Provisions" } } }, "auth_ref": [] }, "gnft_SOC2020Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "SOC2020Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "S O C2020 [Member]", "label": "S O C2020 [Member]", "documentation": "SO C 2020." } } }, "auth_ref": [] }, "gnft_SOUS2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "SOUS2Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SO US 2", "label": "S O U S2 [Member]", "documentation": "SO US 2." } } }, "auth_ref": [] }, "gnft_RevenueRemainingPerformanceObligationVariableConsiderationAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "RevenueRemainingPerformanceObligationVariableConsiderationAmount", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/CommitmentsAdditionalInformationDetails", "http://www.genfit.com/role/DeferredIncomeandRevenueDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone payments", "label": "Revenue, Remaining Performance Obligation, Variable Consideration Amount", "documentation": "Revenue, Remaining Performance Obligation, Variable Consideration Amount" } } }, "auth_ref": [] }, "ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "- Acquisition of financial instruments", "label": "Purchase of financial instruments, classified as investing activities" } }, "en": { "role": { "documentation": "The cash outflow for the purchase of financial instruments. [Refer: Financial instruments, class [member]]" } } }, "auth_ref": [ "r355" ] }, "gnft_PercentageOfExercisableInstrumentsRelatingToCompanysRDProgramPortfolio": { "xbrltype": "percentItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "PercentageOfExercisableInstrumentsRelatingToCompanysRDProgramPortfolio", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of exercisable instruments relating to the development of elafibranor in pbc and elative clinical", "label": "Percentage Of Exercisable Instruments Relating To Company's R&D program portfolio", "documentation": "Percentage Of Exercisable Instruments Relating To Company's R&D program portfolio" } } }, "auth_ref": [] }, "gnft_OtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "OtherMember", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other [Member]", "label": "Other [Member]", "documentation": "Other." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfInformationAboutAmountsRecognisedInRelationToRegulatoryDeferralAccountBalancesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfInformationAboutAmountsRecognisedInRelationToRegulatoryDeferralAccountBalancesLineItems", "presentation": [ "http://www.genfit.com/role/DeferredIncomeandRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of information about amounts recognised in relation to regulatory deferral account balances [line items]", "label": "Disclosure of information about amounts recognised in relation to regulatory deferral account balances [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfInformationAboutAmountsRecognisedInRelationToRegulatoryDeferralAccountBalancesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfInformationAboutAmountsRecognisedInRelationToRegulatoryDeferralAccountBalancesTable", "presentation": [ "http://www.genfit.com/role/DeferredIncomeandRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of information about amounts recognised in relation to regulatory deferral account balances [table]", "label": "Disclosure of information about amounts recognised in relation to regulatory deferral account balances [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to amounts recognised in relation to regulatory deferral account balances." } } }, "auth_ref": [ "r183" ] }, "gnft_SharebasedCompensationAnnualExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "SharebasedCompensationAnnualExpense", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/OperatingExpenseAdditionalInformationDetails", "http://www.genfit.com/role/ShareBasedCompensationAdditionalInformationDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation annual expense", "label": "Sharebased Compensation Annual Expense", "documentation": "The amount of share-based compensation annual expense." } } }, "auth_ref": [] }, "ifrs-full_PurchaseOfInterestsInAssociates": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PurchaseOfInterestsInAssociates", "crdr": "credit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase of interests in associates", "label": "Purchase of interests in associates" } }, "en": { "role": { "documentation": "The cash outflow for the purchase of interests in associates. [Refer: Associates [member]]" } } }, "auth_ref": [ "r355" ] }, "gnft_ProportionOfLoanGuaranteedByTheFrenchGovernment": { "xbrltype": "percentItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ProportionOfLoanGuaranteedByTheFrenchGovernment", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proportion of loan guaranteed by the French government (in percent)", "label": "Proportion Of Loan Guaranteed By The French Government", "documentation": "Proportion Of Loan Guaranteed By The French Government" } } }, "auth_ref": [] }, "gnft_NumberOfCoFoundersHoldShareCapitalOfRelatedParty": { "xbrltype": "integerItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "NumberOfCoFoundersHoldShareCapitalOfRelatedParty", "presentation": [ "http://www.genfit.com/role/RelatedPartiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of co-founders hold share capital of related party", "label": "Number Of Co Founders Hold Share Capital Of Related Party", "documentation": "Number of co-founders hold share capital of related party." } } }, "auth_ref": [] }, "ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subscription of new ordinary shares", "label": "Purchase of interests in investments accounted for using equity method" } }, "en": { "role": { "documentation": "The cash outflow for the purchase of interests in investments accounted for using the equity method. [Refer: Investments accounted for using equity method]" } } }, "auth_ref": [ "r355" ] }, "gnft_IncreaseDecreaseDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "IncreaseDecreaseDomain", "presentation": [ "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase Decrease [Domain]", "label": "Increase Decrease [Domain]", "documentation": "Increase Decrease [Domain]" } } }, "auth_ref": [] }, "gnft_GovernmentGrantsAndSubsidiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "GovernmentGrantsAndSubsidiesMember", "presentation": [ "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails", "http://www.genfit.com/role/OperatingIncomeScheduleofOtherIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Government Grants And Subsidies [Member]", "label": "Government Grants And Subsidies [Member]", "documentation": "Government grants and subsidies." } } }, "auth_ref": [] }, "gnft_DecreaseInBorrowingsThroughConversionOfConvertibleInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DecreaseInBorrowingsThroughConversionOfConvertibleInstruments", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reduction in financial debt", "label": "Decrease In Borrowings Through Conversion Of Convertible Instruments", "documentation": "Reduction in financial debt." } } }, "auth_ref": [] }, "gnft_AGAS2021Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "AGAS2021Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA S 2021 [Member]", "label": "AGA S 2021 [Member]", "documentation": "AGA S 2021" } } }, "auth_ref": [] }, "gnft_TurnoverRateShareWarrantsGranted": { "xbrltype": "percentItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "TurnoverRateShareWarrantsGranted", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Turnover rate", "label": "Turnover Rate Share Warrants Granted", "documentation": "Turnover rate share warrants granted." } } }, "auth_ref": [] }, "gnft_DescriptionOfAccountingPolicyForOtherIncomeExplanatoryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DescriptionOfAccountingPolicyForOtherIncomeExplanatoryTextBlock", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Other income", "label": "Description Of Accounting Policy For Other Income Explanatory [Text Block]", "documentation": "The description of the entity's accounting policy for other income." } } }, "auth_ref": [] }, "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "- Acquisition of intangible assets", "label": "Purchase of property, plant and equipment, classified as investing activities" } }, "en": { "role": { "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r290" ] }, "gnft_FixedAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "FixedAssetsMember", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed Assets", "label": "Fixed Assets [Member]", "documentation": "Fixed Assets." } } }, "auth_ref": [] }, "gnft_KeyManagementPersonnelCompensationemployerContributions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "KeyManagementPersonnelCompensationemployerContributions", "crdr": "debit", "calculation": { "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Key management personnel compensation,employer contributions", "label": "Key management personnel compensation,employer contributions", "documentation": "Key management personnel compensation,employer contributions" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfInformationAboutDefinedBenefitPlansAbstract", "lang": { "en-us": { "role": { "terseLabel": "Disclosure of information about defined benefit plans [abstract]", "label": "Disclosure of information about defined benefit plans [abstract]" } } }, "auth_ref": [] }, "gnft_DebtInstrumentIncreaseInConversionRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DebtInstrumentIncreaseInConversionRatio", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion ratio (Shares per bond)", "label": "Debt Instrument Increase In Conversion Ratio", "documentation": "Debt Instrument increase in conversion ratio." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfInformationAboutEmployeesExplanatory", "presentation": [ "http://www.genfit.com/role/OperatingExpenseTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Employee Expenses and Number of Employees", "label": "Disclosure of information about employees [text block]" } }, "en": { "role": { "documentation": "The disclosure of information about employees." } } }, "auth_ref": [ "r323" ] }, "gnft_CollaborationAndLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "CollaborationAndLicenseAgreementMember", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodSignatureofaLicensingandPartnershipAgreementwithIpsenDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration and License Agreement", "label": "Collaboration and License Agreement [Member]", "documentation": "Collaboration and License Agreement" } } }, "auth_ref": [] }, "gnft_DisclosureOfCashCashEquivalentsAndFinancialAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DisclosureOfCashCashEquivalentsAndFinancialAssetsTable", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagementSummaryofCashCashEquivalentsandFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Cash Cash Equivalents And Financial Assets [Table]", "label": "Disclosure Of Cash Cash Equivalents And Financial Assets [Table]", "documentation": "Disclosure of cash, cash equivalents and financial assets." } } }, "auth_ref": [] }, "gnft_RevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "RevenueMember", "presentation": [ "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenue [Member]", "documentation": "Revenue" } } }, "auth_ref": [] }, "gnft_ClosingForeignExchangeRateCHFEuro": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ClosingForeignExchangeRateCHFEuro", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofApplicableExchangeRatesUsedtoTranslateFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ClosingForeignExchangeRateCHFEuro", "label": "ClosingForeignExchangeRateCHFEuro", "documentation": "ClosingForeignExchangeRateCHFEuro" } } }, "auth_ref": [] }, "gnft_ProvisionPension": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ProvisionPension", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pension provision", "label": "Provision, Pension", "documentation": "Provision, Pension" } } }, "auth_ref": [] }, "gnft_SubsidizedLoanBpifranceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "SubsidizedLoanBpifranceMember", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsidized Loan", "label": "Subsidized Loan, Bpifrance [Member]", "documentation": "Subsidized Loan, Bpifrance" } } }, "auth_ref": [] }, "gnft_AGAD2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "AGAD2022Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA D 2022", "label": "AGA D 2022 [Member]", "documentation": "AGA D 2022" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Director's Fees and Other Compensation Due and Paid to Non Executive Directors", "label": "Disclosure of information about key management personnel [text block]" } }, "en": { "role": { "documentation": "The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]" } } }, "auth_ref": [ "r323" ] }, "gnft_BorrowingsInterestRateStateGuaranteePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "BorrowingsInterestRateStateGuaranteePercentage", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate, including state guarantee (in percent)", "label": "Borrowings, Interest Rate, State Guarantee Percentage", "documentation": "Borrowings, Interest Rate, State Guarantee Percentage" } } }, "auth_ref": [] }, "gnft_CDNFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "CDNFiveMember", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "C D N Five [Member]", "label": "C D N Five [Member]", "documentation": "CDN 5." } } }, "auth_ref": [] }, "gnft_BSAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "BSAMember", "presentation": [ "http://www.genfit.com/role/EarningsLossPerShareSummaryofEarningsLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "B S A", "label": "B S A [Member]", "documentation": "B S A" } } }, "auth_ref": [] }, "ifrs-full_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RangeAxis", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Range [axis]", "label": "Range [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r182", "r200", "r214", "r298", "r299", "r362" ] }, "gnft_EndowmentFundBalance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "EndowmentFundBalance", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/RelatedPartiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Endowment fund balance", "label": "Endowment Fund Balance", "documentation": "Endowment fund balance." } } }, "auth_ref": [] }, "ifrs-full_RangesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RangesMember", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ranges [member]", "label": "Ranges [member]" } }, "en": { "role": { "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used." } } }, "auth_ref": [ "r182", "r200", "r214", "r298", "r299", "r362" ] }, "gnft_DisclosureOfOtherIncomeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DisclosureOfOtherIncomeLineItems", "presentation": [ "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails", "http://www.genfit.com/role/OperatingIncomeScheduleofOtherIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Other Income [Line Items]", "label": "Disclosure Of Other Income [Line Items]", "documentation": "Disclosure of other income." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "gnft_NoncurrentProvisionClosingCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "NoncurrentProvisionClosingCost", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current provision closing cost", "label": "Noncurrent Provision Closing Cost", "documentation": "Noncurrent provision closing cost." } } }, "auth_ref": [] }, "gnft_NetCashAdjustmentPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "NetCashAdjustmentPayment", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net cash adjustment payment", "label": "Net cash adjustment payment", "documentation": "Net cash adjustment payment" } } }, "auth_ref": [] }, "ifrs-full_OtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherIncome", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/DeferredIncomeandRevenueDetails", "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails", "http://www.genfit.com/role/OperatingIncomeScheduleofOtherIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other income", "verboseLabel": "Research tax credit (CIR)", "label": "Other income" } }, "en": { "role": { "documentation": "The amount of operating income that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r104", "r269", "r270" ] }, "gnft_ProbabilityOfContinuedPresenceDescription": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ProbabilityOfContinuedPresenceDescription", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails", "http://www.genfit.com/role/EmployeeBenefitsSummaryofAssumptionsUsedforEmployeesfortheMeasurementofRetirementIndemnitytoEmployeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Probability of continued presence in the company at retirement age", "label": "Probability Of Continued Presence Description", "documentation": "Probability of continued presence description." } } }, "auth_ref": [] }, "gnft_CEODecisionDate": { "xbrltype": "dateItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "CEODecisionDate", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Date of the CEO decision", "label": "C E O Decision Date", "documentation": "CEO decision date." } } }, "auth_ref": [] }, "ifrs-full_CurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentContractLiabilities", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/DeferredIncomeandRevenueDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income", "label": "Current contract liabilities" } }, "en": { "role": { "documentation": "The amount of current contract liabilities. [Refer: Contract liabilities]" } } }, "auth_ref": [ "r184" ] }, "ifrs-full_NotLaterThanOneYearMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NotLaterThanOneYearMember", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails", "http://www.genfit.com/role/EmployeeBenefitsSummaryofAssumptionsUsedforEmployeesfortheMeasurementofRetirementIndemnitytoEmployeesDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofMaturitiesofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Within 1 Year", "label": "Not later than one year [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of not later than one year." } } }, "auth_ref": [ "r26", "r194", "r196", "r206", "r304", "r308" ] }, "gnft_AGAS20172Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "AGAS20172Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "A G A S20172 [Member]", "label": "A G A S20172 [Member]", "documentation": "AGA S 2017-2." } } }, "auth_ref": [] }, "ifrs-full_CurrentContractLiabilitiesForPerformanceObligationsSatisfiedOverTime": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentContractLiabilitiesForPerformanceObligationsSatisfiedOverTime", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/DeferredIncomeandRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Upfront payment received", "label": "Current contract liabilities for performance obligations satisfied over time" } }, "en": { "role": { "documentation": "The amount of current contract liabilities for performance obligations satisfied over time. [Refer: Contract liabilities for performance obligations satisfied over time]" } } }, "auth_ref": [ "r332", "r335" ] }, "gnft_SO2019Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "SO2019Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "S O2019 [Member]", "label": "S O2019 [Member]", "documentation": "SO 2019." } } }, "auth_ref": [] }, "gnft_AccruedInterestsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "AccruedInterestsMember", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofMaturitiesofFinancialLiabilitiesDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofOtherLoansandBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued Interests [Member]", "label": "Accrued Interests [Member]", "documentation": "Accrued interests." } } }, "auth_ref": [] }, "gnft_SensitivityOfCashAndCashEquivalentsAndExpensesToVariationOfTenPercentOfTheUSDollarsAgainstTheEuroExplanatoryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "SensitivityOfCashAndCashEquivalentsAndExpensesToVariationOfTenPercentOfTheUSDollarsAgainstTheEuroExplanatoryTextBlock", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagementTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Sensitivity of Cash and Cash Equivalents and Expenses to Variation of Ten Percent of the US Dollars Against the Euro", "label": "Sensitivity Of Cash And Cash Equivalents And Expenses To Variation Of Ten Percent Of The U S Dollars Against The Euro Explanatory [Text Block]", "documentation": "Sensitivity of cash and cash equivalents and expenses to variation of ten percent of the US dollars against the euro explanatory." } } }, "auth_ref": [] }, "ifrs-full_OtherIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherIntangibleAssetsMember", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Intangibles", "label": "Other intangible assets [member]" } }, "en": { "role": { "documentation": "This member stands for a class of intangible assets that the entity does not separately disclose in the same statement or note. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r351" ] }, "ifrs-full_NotesAndDebenturesIssued": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NotesAndDebenturesIssued", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofConvertibleBondsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notes and debentures issued", "verboseLabel": "Notes and debentures issued", "label": "Notes and debentures issued" } }, "en": { "role": { "documentation": "The amount of notes and debentures issued by the entity." } } }, "auth_ref": [ "r328" ] }, "gnft_KeyManagementPersonnelCompensationAttendanceFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "KeyManagementPersonnelCompensationAttendanceFees", "crdr": "debit", "calculation": { "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Key management personnel compensation, attendance fees", "label": "Key management personnel compensation, attendance fees", "documentation": "Key management personnel compensation, attendance fees" } } }, "auth_ref": [] }, "gnft_DepositsAndGuarantees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DepositsAndGuarantees", "crdr": "debit", "calculation": { "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails_1": { "parentTag": "ifrs-full_OtherFinancialAssets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deposits And Guarantees", "label": "Deposits And Guarantees", "documentation": "Deposits and guarantees." } } }, "auth_ref": [] }, "ifrs-full_NotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NotionalAmount", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBondsDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notional amount", "label": "Notional amount" } }, "en": { "role": { "documentation": "The nominal or face amount of a financial instrument, used to calculate payments made on that instrument." } } }, "auth_ref": [ "r328" ] }, "ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentDeferredIncomeIncludingCurrentContractLiabilities", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/DeferredIncomeandRevenueDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred income current", "label": "Current deferred income including current contract liabilities" } }, "en": { "role": { "documentation": "The amount of current deferred income including current contract liabilities. [Refer: Deferred income including contract liabilities]" } } }, "auth_ref": [ "r332", "r335" ] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Table]", "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "gnft_OtherOperatingIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "OtherOperatingIncomeMember", "presentation": [ "http://www.genfit.com/role/DeferredIncomeandRevenueDetails", "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails", "http://www.genfit.com/role/OperatingIncomeScheduleofOtherIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Operating Income [Member]", "label": "Other Operating Income [Member]", "documentation": "Other Operating Income" } } }, "auth_ref": [] }, "ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentDeferredIncomeOtherThanCurrentContractLiabilities", "crdr": "credit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Current deferred income and revenue", "label": "Current deferred income other than current contract liabilities" } }, "en": { "role": { "documentation": "The amount of current deferred income other than current contract liabilities. [Refer: Deferred income other than contract liabilities]" } } }, "auth_ref": [ "r332", "r335" ] }, "ifrs-full_NumberOfEmployees": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfEmployees", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of employees", "label": "Number of employees" } }, "en": { "role": { "documentation": "The number of personnel employed by the entity at a date." } } }, "auth_ref": [ "r328" ] }, "gnft_KeyManagementPersonnelCompensationContributionInKind": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "KeyManagementPersonnelCompensationContributionInKind", "crdr": "debit", "calculation": { "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Key management personnel compensation, contribution in kind", "label": "Key management personnel compensation, contribution in kind", "documentation": "Key management personnel compensation, contribution in kind" } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Line Items]", "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "ifrs-full_CurrentExciseTaxPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentExciseTaxPayables", "crdr": "credit", "calculation": { "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentPayables", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.genfit.com/role/TradeandOtherPayablesAdditionalInformationDetails", "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current excise tax payables", "label": "Current excise tax payables" } }, "en": { "role": { "documentation": "The amount of current excise tax payables. [Refer: Excise tax payables]" } } }, "auth_ref": [ "r335" ] }, "gnft_RenegotiationCostsEstimated": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "RenegotiationCostsEstimated", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Renegotiation costs estimated", "label": "Renegotiation Costs Estimated", "documentation": "Renegotiation costs estimated." } } }, "auth_ref": [] }, "gnft_IncreaseInTheDebts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "IncreaseInTheDebts", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in the debts", "label": "Increase in the debts", "documentation": "Increase in the debts" } } }, "auth_ref": [] }, "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of other equity instruments granted in share-based payment arrangement", "label": "Number of other equity instruments granted in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement." } } }, "auth_ref": [ "r217", "r360" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Annual Report", "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r316", "r317", "r318" ] }, "gnft_AGADAndS20161And20162Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "AGADAndS20161And20162Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA D and S 2016-1 and 2016-2", "label": "A G A D And S20161 And20162 [Member]", "documentation": "AGA D and S 2016-1 and 2016-2." } } }, "auth_ref": [] }, "gnft_ObligationsUnderFinanceLeasesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ObligationsUnderFinanceLeasesMember", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Obligations Under Finance Leases [Member]", "label": "Obligations Under Finance Leases [Member]", "documentation": "Obligations under finance leases." } } }, "auth_ref": [] }, "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationAdditionalInformationDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of instruments exercised (in shares)", "verboseLabel": "Total number of AGA definitively vested (in shares)", "label": "Number of other equity instruments exercised or vested in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement." } } }, "auth_ref": [ "r360" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of other equity instruments exercisable in share-based payment arrangement", "label": "Number of other equity instruments exercisable in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement." } } }, "auth_ref": [ "r360" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total number of BSAAR voided (in shares)", "totalLabel": "Total number of BSAAR voided", "label": "Number of other equity instruments forfeited in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement." } } }, "auth_ref": [ "r360" ] }, "gnft_PCASGroupMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "PCASGroupMember", "presentation": [ "http://www.genfit.com/role/RelatedPartiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PCAS Group", "label": "P C A S Group [Member]", "documentation": "PCAS Group." } } }, "auth_ref": [] }, "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total number of BSAAR subscribed (in shares)", "label": "Number of other equity instruments outstanding in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement." } } }, "auth_ref": [ "r360" ] }, "ifrs-full_OtherNoncurrentFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherNoncurrentFinancialAssets", "crdr": "debit", "calculation": { "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails": { "parentTag": "gnft_TotalAcquiredAssets", "weight": 1.0, "order": 1.0 }, "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails": { "parentTag": "ifrs-full_OtherFinancialAssets", "weight": 1.0, "order": 2.0 }, "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails", "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current financial assets", "label": "Other non-current financial assets" } }, "en": { "role": { "documentation": "The amount of non-current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets]" } } }, "auth_ref": [ "r13" ] }, "gnft_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTextBlock", "presentation": [ "http://www.genfit.com/role/TradeandOtherPayablesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Trade and Other Payables", "label": "Disclosure Of Detailed Information About Trade And Other Payables Explanatory [Text Block]", "documentation": "Disclosure of detailed information about trade and other payables." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r319" ] }, "gnft_EvaluationDateForPerformanceConditions": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "EvaluationDateForPerformanceConditions", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Evaluation date for performance conditions", "label": "Evaluation Date For Performance Conditions", "documentation": "Evaluation date for performance conditions." } } }, "auth_ref": [] }, "ifrs-full_NumberOfOutstandingShareOptions": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfOutstandingShareOptions", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total number of SO remaining", "label": "Number of share options outstanding in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of share options outstanding in a share-based payment arrangement." } } }, "auth_ref": [ "r210", "r212", "r214" ] }, "gnft_AGAS20171Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "AGAS20171Member", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "A G A S20171 [Member]", "label": "A G A S20171 [Member]", "documentation": "AGA S 2017-1." } } }, "auth_ref": [] }, "ifrs-full_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails": { "parentTag": "gnft_ResearchAndDevelopmentExpenseGeneralAndAdministrativeExpenseMarketingAndMarketAccessExpenseAndOtherOperatingIncomeAndExpense", "weight": -1.0, "order": 2.0 }, "http://www.genfit.com/role/ConsolidatedStatementsofOperations": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofOperations", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails", "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "General and administrative expenses", "terseLabel": "General and administrative expense", "label": "General and administrative expense" } }, "en": { "role": { "documentation": "The amount of expense relating to general and administrative activities of the entity." } } }, "auth_ref": [ "r328" ] }, "gnft_PerformanceConditionsPlanTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "PerformanceConditionsPlanTwoMember", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance Conditions Plan Two", "label": "Performance Conditions Plan Two [Member]", "documentation": "Performance conditions plan two." } } }, "auth_ref": [] }, "gnft_BuildingsOnNonFreeholdLandMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "BuildingsOnNonFreeholdLandMember", "presentation": [ "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentSummaryofVariationsinTangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Buildings On Non Freehold Land [Member]", "label": "Buildings On Non Freehold Land [Member]", "documentation": "Buildings on non-freehold land." } } }, "auth_ref": [] }, "ifrs-full_InterestRateRiskMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InterestRateRiskMember", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Risk", "label": "Interest rate risk [member]" } }, "en": { "role": { "documentation": "This member stands for the type of risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. [Refer: Financial instruments, class [member]]" } } }, "auth_ref": [ "r201", "r202", "r203", "r204", "r249" ] }, "gnft_PercentageOfProfitExceedingLimitOffsettingTaxableProfit": { "xbrltype": "percentItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "PercentageOfProfitExceedingLimitOffsettingTaxableProfit", "presentation": [ "http://www.genfit.com/role/IncomeTaxNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of profit exceeding limit offsetting taxable profit", "label": "Percentage Of Profit Exceeding Limit Offsetting Taxable Profit", "documentation": "Percentage of profit exceeding limit offsetting taxable profit." } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseInNumberOfSharesOutstanding", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Capital increase (shares)", "label": "Increase (decrease) in number of shares outstanding" } }, "en": { "role": { "documentation": "The increase (decrease) in the number of shares outstanding. [Refer: Number of shares outstanding]" } } }, "auth_ref": [ "r37" ] }, "gnft_PercentageOfExercisableInstrumentsRelatingToDevelopmentOfTheProductPipelineOfTheCompanyEvaluationDate31March2024": { "xbrltype": "percentItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "PercentageOfExercisableInstrumentsRelatingToDevelopmentOfTheProductPipelineOfTheCompanyEvaluationDate31March2024", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsParentheticalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of exercisable instruments relating to development of the product pipeline of the company", "label": "Percentage Of Exercisable Instruments Relating To Development Of The Product Pipeline Of The Company Evaluation date 31 march 2024", "documentation": "Percentage Of Exercisable Instruments Relating To Development Of The Product Pipeline Of The Company Evaluation date 31 march 2024" } } }, "auth_ref": [] }, "gnft_PercentageOfExercisableInstrumentsRelatingToDevelopmentOfTheProductPipelineOfTheCompanyEvaluationDate20October2024": { "xbrltype": "percentItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "PercentageOfExercisableInstrumentsRelatingToDevelopmentOfTheProductPipelineOfTheCompanyEvaluationDate20October2024", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsParentheticalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage Of Exercisable Instruments Relating To Development Of The Product Pipeline Of The Company Evaluation date 20 october 2024", "label": "Percentage Of Exercisable Instruments Relating To Development Of The Product Pipeline Of The Company Evaluation date 20 october 2024", "documentation": "Percentage Of Exercisable Instruments Relating To Development Of The Product Pipeline Of The Company Evaluation date 20 october 2024" } } }, "auth_ref": [] }, "gnft_PaymentForBuybackOfDebtInstrument": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "PaymentForBuybackOfDebtInstrument", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payment for partial buyback", "label": "Payment For Buyback Of Debt Instrument", "documentation": "Payment for partial buy back of debt instrument." } } }, "auth_ref": [] }, "gnft_InterestExpensesForLeases": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "InterestExpensesForLeases", "crdr": "debit", "calculation": { "http://www.genfit.com/role/FinancialIncomeandExpensesSummaryofFinancialIncomeandExpensesDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/FinancialIncomeandExpensesSummaryofFinancialIncomeandExpensesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest Expenses For Leases", "negatedLabel": "Interest Expenses For Leases", "label": "Interest Expenses For Leases", "documentation": "Interest expenses for leases." } } }, "auth_ref": [] }, "ifrs-full_InterestRateTypesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InterestRateTypesMember", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate types [member]", "label": "Interest rate types [member]" } }, "en": { "role": { "documentation": "This member stands for all types of interest rates. It also represents the standard value for the 'Types of interest rates' axis if no other member is used. [Refer: Interest rate risk [member]]" } } }, "auth_ref": [ "r361" ] }, "gnft_NumberOfSegmentInformation": { "xbrltype": "fileNumberItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "NumberOfSegmentInformation", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofApplicableExchangeRatesUsedtoTranslateFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number Of Segment Information", "label": "Number Of Segment Information", "documentation": "Number Of Segment Information" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseInWorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseInWorkingCapital", "crdr": "credit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Change in working capital", "terseLabel": "Increase in capital", "label": "Increase (decrease) in working capital" } }, "en": { "role": { "documentation": "The increase (decrease) in working capital." } } }, "auth_ref": [ "r358" ] }, "gnft_PremisesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "PremisesMember", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodTerminationofRESOLVEITandthedevelopmentprogramofelafibranorinNASHDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Premises", "label": "Premises [Member]", "documentation": "Premises." } } }, "auth_ref": [] }, "ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisposalsIntangibleAssetsOtherThanGoodwill", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Decrease", "label": "Disposals, intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The decrease in intangible assets other than goodwill resulting from disposals. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r129" ] }, "gnft_TermsOfRetirementDescription": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "TermsOfRetirementDescription", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails", "http://www.genfit.com/role/EmployeeBenefitsSummaryofAssumptionsUsedforEmployeesfortheMeasurementofRetirementIndemnitytoEmployeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Terms of retirement", "label": "Terms Of Retirement Description", "documentation": "Terms of retirement description." } } }, "auth_ref": [] }, "gnft_CurrentSocialSecurityCostsReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "CurrentSocialSecurityCostsReceivables", "crdr": "debit", "calculation": { "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current Social Security Costs Receivables", "label": "Current Social Security Costs Receivables", "documentation": "Current social security costs receivables." } } }, "auth_ref": [] }, "ifrs-full_DilutedEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DilutedEarningsLossPerShare", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofOperations", "http://www.genfit.com/role/EarningsLossPerShareSummaryofEarningsLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted earnings (loss) per share (\u20ac/share)", "verboseLabel": "Diluted earnings (loss) per share", "label": "Diluted earnings (loss) per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r112", "r113" ] }, "ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughAppropriationOfRetainedEarnings", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) through appropriation of retained earnings, equity", "label": "Increase (decrease) through appropriation of retained earnings, equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the appropriation of retained earnings. [Refer: Retained earnings]" } } }, "auth_ref": [ "r325" ] }, "ifrs-full_DisposalsPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisposalsPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentSummaryofVariationsinTangibleAssetsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Decrease", "negatedTerseLabel": "Disposals, property, plant and equipment", "label": "Disposals, property, plant and equipment" } }, "en": { "role": { "documentation": "The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r70" ] }, "gnft_CashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "CashAndCashEquivalentsMember", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash And Cash Equivalents [Member]", "label": "Cash And Cash Equivalents [Member]" } } }, "auth_ref": [] }, "gnft_RevenueAndOtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "RevenueAndOtherIncome", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue and other income", "label": "Revenue and other income", "documentation": "Revenue and other income" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfFinancialAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfFinancialAssetsAxis", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofUSDollaragainstEuroDetails", "http://www.genfit.com/role/FinancialRisksManagementSummaryofCashCashEquivalentsandFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of financial assets [axis]", "label": "Classes of financial assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r207", "r243", "r244", "r265", "r266" ] }, "ifrs-full_ClassesOfFinancialInstrumentsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfFinancialInstrumentsMember", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBondsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial instruments, class [member]", "label": "Financial instruments, class [member]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]" } } }, "auth_ref": [ "r234", "r236", "r238", "r239" ] }, "ifrs-full_ClassesOfFinancialInstrumentsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfFinancialInstrumentsAxis", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBondsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of financial instruments [axis]", "label": "Classes of financial instruments [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r234", "r236", "r238", "r239" ] }, "gnft_NatixisPGEMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "NatixisPGEMember", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Natixis PGE [Member]", "label": "Natixis PGE [Member]", "documentation": "Natixis PGE" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfIntangibleAssetsAndGoodwillAxis", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of intangible assets and goodwill [axis]", "label": "Classes of intangible assets and goodwill [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r350" ] }, "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of intangible assets other than goodwill [axis]", "label": "Classes of intangible assets other than goodwill [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r132" ] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioForecastMember", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forecast", "label": "Forecast [Member]" } } }, "auth_ref": [] }, "gnft_ContractCostsRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ContractCostsRecognized", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract costs recognized", "label": "Contract Costs Recognized", "documentation": "Contract costs recognized." } } }, "auth_ref": [] }, "ifrs-full_Inventories": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Inventories", "crdr": "debit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Current inventories" } }, "en": { "role": { "documentation": "The amount of current inventories. [Refer: Inventories]" } } }, "auth_ref": [ "r15", "r90", "r272" ] }, "gnft_SOUS2019Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "SOUS2019Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "S O U S2019 [Member]", "label": "S O U S2019 [Member]", "documentation": "SO US 2019." } } }, "auth_ref": [] }, "gnft_TaxEffectOfTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "TaxEffectOfTaxCredits", "crdr": "debit", "calculation": { "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Effect Of Tax Credits", "negatedTerseLabel": "Tax Effect Of Tax Credits", "label": "Tax Effect Of Tax Credits", "documentation": "Tax Effect Of Tax Credits" } } }, "auth_ref": [] }, "gnft_SOCH2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "SOCH2022Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SO CH 2022", "label": "SO CH 2022 [Member]", "documentation": "SO CH 2022" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementScenarioAxis", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario", "label": "Scenario [Axis]" } } }, "auth_ref": [] }, "gnft_DecreaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DecreaseMember", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease", "label": "Decrease [Member]", "documentation": "Decrease" } } }, "auth_ref": [] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario", "label": "Scenario [Domain]" } } }, "auth_ref": [] }, "gnft_DisclosureOfOperatingExpensesAndOtherOperatingIncomeExpensesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DisclosureOfOperatingExpensesAndOtherOperatingIncomeExpensesLineItems", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Operating Expenses And Other Operating Income Expenses [Line Items]", "label": "Disclosure Of Operating Expenses And Other Operating Income Expenses [Line Items]", "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with operating expenses and other operating income (expenses)." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "presentation": [ "http://www.genfit.com/role/Statementofcashflowsindirectmethod", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of estimates and judgments", "label": "Disclosure of accounting judgements and estimates [text block]" } }, "en": { "role": { "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]" } } }, "auth_ref": [ "r323" ] }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfPropertyPlantAndEquipmentAxis", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/OperatingExpenseAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentSummaryofVariationsinTangibleAssetsDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of property, plant and equipment [axis]", "label": "Classes of property, plant and equipment [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r74" ] }, "gnft_ProvisionForCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ProvisionForCharges", "crdr": "credit", "calculation": { "http://www.genfit.com/role/ProvisionsAdditionalInformationDetails": { "parentTag": "ifrs-full_CurrentProvisions", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.genfit.com/role/ProvisionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for charges [Line Items]", "label": "Provision for charges", "documentation": "Provision for charges" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfProvisionsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfProvisionsAxis", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/OperatingExpenseAdditionalInformationDetails", "http://www.genfit.com/role/ProvisionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of other provisions [axis]", "label": "Classes of other provisions [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r123" ] }, "gnft_DebtNominalUnitValue": { "xbrltype": "decimalItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DebtNominalUnitValue", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBondsDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nominal value per unit (in EUR per bond)", "label": "Debt Nominal Unit Value", "documentation": "Debt nominal unit value." } } }, "auth_ref": [] }, "ifrs-full_ClassesOfShareCapitalAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfShareCapitalAxis", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of share capital [axis]", "label": "Classes of share capital [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r38" ] }, "gnft_RevenueFromCollaborationUpFrontCashPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "RevenueFromCollaborationUpFrontCashPayment", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodSignatureofaLicensingandPartnershipAgreementwithIpsenDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from collaboration, up-front cash payment", "label": "Revenue from collaboration, up-front cash payment", "documentation": "Revenue from collaboration, up-front cash payment" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/DeferredIncomeandRevenueDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred income non-current", "label": "Non-current deferred income including non-current contract liabilities" } }, "en": { "role": { "documentation": "The amount of non-current deferred income including non-current contract liabilities. [Refer: Deferred income including contract liabilities]" } } }, "auth_ref": [ "r332", "r335" ] }, "gnft_AGASMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "AGASMember", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "AGA S", "terseLabel": "A G A S [Member]", "label": "A G A S [Member]", "documentation": "AGAS." } } }, "auth_ref": [] }, "ifrs-full_NoncurrentDeferredIncomeOtherThanNoncurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentDeferredIncomeOtherThanNoncurrentContractLiabilities", "crdr": "credit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current deferred income and revenue", "label": "Non-current deferred income other than non-current contract liabilities" } }, "en": { "role": { "documentation": "The amount of non-current deferred income other than non-current contract liabilities. [Refer: Deferred income other than contract liabilities]" } } }, "auth_ref": [ "r332", "r335" ] }, "gnft_AuditInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "AuditInformationAbstract", "lang": { "en-us": { "role": { "label": "Audit Information [Abstract]", "documentation": "Audit Information [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails": { "parentTag": "gnft_ResearchAndDevelopmentExpenseGeneralAndAdministrativeExpenseMarketingAndMarketAccessExpenseAndOtherOperatingIncomeAndExpense", "weight": -1.0, "order": 1.0 }, "http://www.genfit.com/role/ConsolidatedStatementsofOperations": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofOperations", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails", "http://www.genfit.com/role/OperatingExpenseAdditionalInformationDetails", "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Research and development expenses", "terseLabel": "Research and development expense", "label": "Research and development expense" } }, "en": { "role": { "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss." } } }, "auth_ref": [ "r134" ] }, "gnft_SOUS20171Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "SOUS20171Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "S O U S20171 [Member]", "label": "S O U S20171 [Member]", "documentation": "SO US 2017-1." } } }, "auth_ref": [] }, "ifrs-full_UnusedProvisionReversedOtherProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "UnusedProvisionReversedOtherProvisions", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/OperatingExpenseAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unused provision reversed, other provisions", "label": "Unused provision reversed, other provisions" } }, "en": { "role": { "documentation": "The amount reversed for unused other provisions. [Refer: Other provisions]" } } }, "auth_ref": [ "r122" ] }, "gnft_CIRTaxCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "CIRTaxCreditMember", "presentation": [ "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails", "http://www.genfit.com/role/OperatingIncomeScheduleofOtherIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "C I R Tax Credit [Member]", "label": "C I R Tax Credit [Member]", "documentation": "CIR tax credit." } } }, "auth_ref": [] }, "ifrs-full_NoncurrentExciseTaxPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentExciseTaxPayables", "crdr": "credit", "calculation": { "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails": { "parentTag": "ifrs-full_NoncurrentPayables", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.genfit.com/role/TradeandOtherPayablesAdditionalInformationDetails", "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current excise tax payables", "label": "Non-current excise tax payables" } }, "en": { "role": { "documentation": "The amount of non-current excise tax payables. [Refer: Excise tax payables]" } } }, "auth_ref": [ "r335" ] }, "ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised", "presentation": [ "http://www.genfit.com/role/IncomeTaxNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Tax loss carry forwards", "label": "Unused tax losses for which no deferred tax asset recognised" } }, "en": { "role": { "documentation": "The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]" } } }, "auth_ref": [ "r63" ] }, "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill": { "xbrltype": "durationItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated useful lives of software and license agreements", "label": "Useful life measured as period of time, intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r127" ] }, "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment": { "xbrltype": "durationItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated useful lives for property, plant and equipment", "label": "Useful life measured as period of time, property, plant and equipment" } }, "en": { "role": { "documentation": "The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r68" ] }, "ifrs-full_ReserveOfExchangeDifferencesOnTranslation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ReserveOfExchangeDifferencesOnTranslation", "crdr": "credit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Currency translation adjustment", "label": "Reserve of exchange differences on translation" } }, "en": { "role": { "documentation": "A component of equity representing exchange differences on translation of financial statements recognised in other comprehensive income and accumulated in equity. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r93" ] }, "ifrs-full_ValueAddedTaxPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ValueAddedTaxPayables", "crdr": "credit", "calculation": { "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails": { "parentTag": "ifrs-full_TradeAndOtherPayables", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.genfit.com/role/TradeandOtherPayablesAdditionalInformationDetails", "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Value added tax payables", "label": "Value added tax payables" } }, "en": { "role": { "documentation": "The amount of payables related to a value added tax." } } }, "auth_ref": [ "r335" ] }, "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ReserveOfExchangeDifferencesOnTranslationMember", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Currency translation adjustment", "label": "Reserve of exchange differences on translation [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r93", "r271" ] }, "currency_CHF": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "CHF", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Switzerland, Francs", "label": "Switzerland, Francs" } } }, "auth_ref": [] }, "ifrs-full_ValueAddedTaxReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ValueAddedTaxReceivables", "crdr": "debit", "calculation": { "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails": { "parentTag": "ifrs-full_TradeAndOtherReceivables", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesAdditionalInformationDetails", "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Value added tax receivables", "label": "Value added tax receivables" } }, "en": { "role": { "documentation": "The amount of receivables related to a value added tax." } } }, "auth_ref": [ "r333" ] }, "gnft_FacilitySize": { "xbrltype": "decimalItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "FacilitySize", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Facility size", "label": "Facility Size", "documentation": "Facility size." } } }, "auth_ref": [] }, "gnft_LicenceFeesDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "LicenceFeesDomain", "presentation": [ "http://www.genfit.com/role/DeferredIncomeandRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "licence fees [Domain]", "label": "licence fees [Domain]", "documentation": "licence fees [Domain]" } } }, "auth_ref": [] }, "gnft_AdministrationAndManagementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "AdministrationAndManagementMember", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Administration And Management [Member]", "label": "Administration And Management [Member]", "documentation": "Administration and management." } } }, "auth_ref": [] }, "gnft_ConvertibleLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ConvertibleLoansMember", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofMaturitiesofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Loans [Member]", "label": "Convertible Loans [Member]", "documentation": "Convertible loans." } } }, "auth_ref": [] }, "ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DeferredTaxExpenseIncomeRecognisedInProfitOrLoss", "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impact on the profit/loss", "negatedTerseLabel": "Impact on the profit/loss", "label": "Deferred tax expense (income) recognised in profit or loss" } }, "en": { "role": { "documentation": "The amount of tax expense or income relating to changes in deferred tax liabilities and deferred tax assets, recognised in profit or loss. [Refer: Deferred tax assets; Deferred tax expense (income); Deferred tax liabilities]" } } }, "auth_ref": [ "r65" ] }, "ifrs-full_RevenueFromRenderingOfServices": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RevenueFromRenderingOfServices", "crdr": "credit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofOperations": { "parentTag": "ifrs-full_Revenue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofOperations", "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "verboseLabel": "Industrial income recognized", "label": "Revenue from rendering of services" } }, "en": { "role": { "documentation": "The amount of revenue arising from the rendering of services. [Refer: Revenue]" } } }, "auth_ref": [ "r328" ] }, "ifrs-full_DeferredTaxExpenseIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DeferredTaxExpenseIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Deferred tax expense (income) [abstract]", "label": "Deferred tax expense (income) [abstract]" } } }, "auth_ref": [] }, "gnft_TemporaryDifferenceFromPostemploymentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "TemporaryDifferenceFromPostemploymentsMember", "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Temporary difference from postemployments", "label": "Temporary Difference From Postemployments [Member]", "documentation": "Temporary difference from postemployments." } } }, "auth_ref": [] }, "gnft_TenPercentIncreaseOfCHFVsEuroMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "TenPercentIncreaseOfCHFVsEuroMember", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofCHFagainstEuroDetails", "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofUSDollaragainstEuroDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ten Percent Increase Of C H F Vs Euro", "label": "Ten Percent Increase Of C H F Vs Euro [Member]", "documentation": "Ten Percent Increase Of C H F Vs Euro" } } }, "auth_ref": [] }, "gnft_ResearchTaxCreditLitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ResearchTaxCreditLitigationMember", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research tax credit litigation", "label": "Research Tax Credit Litigation [Member]", "documentation": "Research Tax Credit Litigation" } } }, "auth_ref": [] }, "gnft_NoncurrentLiquidityContractNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "NoncurrentLiquidityContractNet", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncurrent Liquidity Contract Net", "label": "Noncurrent Liquidity Contract Net", "documentation": "Noncurrent Liquidity Contract Net" } } }, "auth_ref": [] }, "ifrs-full_DeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails": { "parentTag": "ifrs-full_DeferredTaxLiabilityAsset", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedPeriodStartLabel": "Deferred tax liabilities", "negatedPeriodEndLabel": "Deferred tax liabilities", "terseLabel": "Deferred tax liabilities", "label": "Deferred tax liabilities" } }, "en": { "role": { "documentation": "The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]" } } }, "auth_ref": [ "r21", "r25", "r64" ] }, "ifrs-full_DeferredTaxLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DeferredTaxLiabilityAsset", "crdr": "credit", "calculation": { "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxNarrativeDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liability (asset)", "negatedPeriodStartLabel": "Deferred tax liability (asset)", "negatedPeriodEndLabel": "Deferred tax liability (asset)", "negatedTerseLabel": "Deferred tax liability (asset)", "label": "Deferred tax liability (asset)" } }, "en": { "role": { "documentation": "The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets]" } } }, "auth_ref": [ "r64" ] }, "gnft_OtherExpenseByNatureMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "OtherExpenseByNatureMember", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other expenses (maintenance, fees, travel, taxes)", "label": "Other Expense By Nature [Member]", "documentation": "Other expense by nature." } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables", "crdr": "debit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "(Decrease) increase in trade payables and other liabilities", "label": "Adjustments for increase (decrease) in trade and other payables" } }, "en": { "role": { "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]" } } }, "auth_ref": [ "r358" ] }, "ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity", "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impact on equity", "negatedTerseLabel": "Impact on equity", "label": "Deferred tax relating to items credited (charged) directly to equity" } }, "en": { "role": { "documentation": "The amount of deferred tax related to items credited (charged) directly to equity. [Refer: Deferred tax expense (income)]" } } }, "auth_ref": [ "r60" ] }, "gnft_BNPFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "BNPFourMember", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "B N P Four [Member]", "label": "B N P Four [Member]", "documentation": "BNP 4." } } }, "auth_ref": [] }, "ifrs-full_DefinedBenefitPlansAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DefinedBenefitPlansAxis", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersScheduleofDirectorsFeesandOtherCompensationDueandPaidtoNonExecutiveDirectorsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined benefit plans [axis]", "label": "Defined benefit plans [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r78" ] }, "gnft_RevisedTurnoverRateAssumption": { "xbrltype": "percentItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "RevisedTurnoverRateAssumption", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revised turnover rate", "label": "Revised Turnover Rate Assumption", "documentation": "Revised turnover rate assumption." } } }, "auth_ref": [] }, "gnft_ResearchTaxCreditCarryforwardPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ResearchTaxCreditCarryforwardPeriod", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research tax credit, carryforward period (in years)", "label": "Research Tax Credit, Carryforward Period", "documentation": "Research Tax Credit, Carryforward Period" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForProvisions", "crdr": "debit", "calculation": { "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Adjustments for provisions", "label": "Adjustments for provisions" } }, "en": { "role": { "documentation": "Adjustments for provisions to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Provisions; Profit (loss)]" } } }, "auth_ref": [ "r357" ] }, "ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets", "crdr": "debit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "- Gain on disposal of property, plant and equipment", "label": "Adjustments for losses (gains) on disposal of non-current assets" } }, "en": { "role": { "documentation": "Adjustments for losses (gains) on disposal of non-current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Non-current assets; Profit (loss)]" } } }, "auth_ref": [ "r354" ] }, "gnft_GenfitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "GenfitMember", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodSignatureofaLicensingandPartnershipAgreementwithIpsenDetails", "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails", "http://www.genfit.com/role/RelatedPartiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Genfit", "label": "Genfit [Member]", "documentation": "Genfit" } } }, "auth_ref": [] }, "ifrs-full_DefinedBenefitPlansMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DefinedBenefitPlansMember", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersScheduleofDirectorsFeesandOtherCompensationDueandPaidtoNonExecutiveDirectorsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined benefit plans [member]", "label": "Defined benefit plans [member]" } }, "en": { "role": { "documentation": "This member stands for post-employment benefit plans other than defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods. It also represents the standard value for the 'Defined benefit plans' axis if no other member is used." } } }, "auth_ref": [ "r78" ] }, "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForReconcileProfitLossAbstract", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile profit (loss) [abstract]", "label": "Adjustments to reconcile profit (loss) [abstract]" } } }, "auth_ref": [] }, "gnft_AdditionalPaymentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "AdditionalPaymentsMember", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Payments", "label": "Additional Payments [Member]", "documentation": "Additional payments." } } }, "auth_ref": [] }, "ifrs-full_DepartureFromRequirementOfIFRSAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DepartureFromRequirementOfIFRSAxis", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Departure from requirement of IFRS [axis]", "label": "Departure from requirement of IFRS [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r9" ] }, "ifrs-full_AdjustmentsForSharebasedPayments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForSharebasedPayments", "crdr": "debit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "+ Expenses related to share-based compensation", "label": "Adjustments for share-based payments" } }, "en": { "role": { "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r357" ] }, "gnft_OperatingExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "OperatingExpenseAbstract", "lang": { "en-us": { "role": { "terseLabel": "Operating Expense [Abstract]", "label": "Operating Expense [Abstract]", "documentation": "Operating expense." } } }, "auth_ref": [] }, "srt_LitigationCaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "LitigationCaseAxis", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Axis]", "label": "Litigation Case [Axis]" } } }, "auth_ref": [] }, "gnft_AGAS2019Member": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "AGAS2019Member", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "A G A S2019 [Member]", "label": "A G A S2019 [Member]", "documentation": "AG AS 2019 ." } } }, "auth_ref": [] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.genfit.com/role/DeferredIncomeandRevenueDetails", "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodSignatureofaLicensingandPartnershipAgreementwithIpsenDetails", "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails", "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails", "http://www.genfit.com/role/RelatedPartiesAdditionalInformationDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofApplicableExchangeRatesUsedtoTranslateFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [] }, "gnft_ValuationAssumptionNoRiskRate": { "xbrltype": "percentItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "ValuationAssumptionNoRiskRate", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "No-risk rate", "label": "Valuation Assumption, No-risk Rate", "documentation": "Valuation Assumption, No-risk Rate" } } }, "auth_ref": [] }, "gnft_DisclosureOfConvertibleLoansTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "DisclosureOfConvertibleLoansTableTextBlock", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Convertible Loans", "label": "Disclosure Of Convertible Loans [Table Text Block]", "documentation": "Disclosure Of Convertible Loans" } } }, "auth_ref": [] }, "gnft_EmployeeBenefitExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "EmployeeBenefitExpensesMember", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee expenses", "label": "Employee Benefit Expenses [Member]", "documentation": "Employee benefit expenses." } } }, "auth_ref": [] }, "ifrs-full_Advances": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Advances", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Advances received", "label": "Advances received, representing contract liabilities for performance obligations satisfied at point in time" } }, "en": { "role": { "documentation": "The amount of advances received representing contract liabilities for performance obligations satisfied at a point in time. [Refer: Contract liabilities; Performance obligations satisfied at point in time [member]]" } } }, "auth_ref": [ "r332", "r335" ] }, "ifrs-full_DepreciationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DepreciationExpense", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Depreciation", "label": "Depreciation expense" } }, "en": { "role": { "documentation": "The amount of depreciation expense. Depreciation is the systematic allocation of depreciable amounts of tangible assets over their useful lives." } } }, "auth_ref": [ "r328" ] }, "gnft_EquityComponentBondIssueOCEANE": { "xbrltype": "monetaryItemType", "nsuri": "http://www.genfit.com/20230630", "localname": "EquityComponentBondIssueOCEANE", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity component Bond issue OCEANE", "label": "Equity component Bond issue OCEANE", "documentation": "Equity component Bond issue OCEANE" } } }, "auth_ref": [] }, "ifrs-full_EquityAndLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EquityAndLiabilities", "crdr": "credit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "Total - Shareholders' equity & liabilities", "label": "Equity and liabilities" } }, "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } } }, "auth_ref": [ "r24" ] }, "ifrs-full_NameOfAcquiree": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NameOfAcquiree", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Name of acquiree", "label": "Name of acquiree" } }, "en": { "role": { "documentation": "The name of the business or businesses that the acquirer obtains control of in a business combination. [Refer: Business combinations [member]]" } } }, "auth_ref": [ "r218" ] }, "ifrs-full_EquityAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EquityAndLiabilitiesAbstract", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "SHAREHOLDERS' EQUITY AND LIABILITIES", "label": "Equity and liabilities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_EquityAttributableToOwnersOfParentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EquityAttributableToOwnersOfParentMember", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Total shareholders' equity Group share", "label": "Equity attributable to owners of parent [member]" } }, "en": { "role": { "documentation": "This member stands for equity attributable to the owners of the parent." } } }, "auth_ref": [ "r7" ] }, "ifrs-full_EquityAttributableToOwnersOfParent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EquityAttributableToOwnersOfParent", "crdr": "credit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "Total equity attributable to owners of parent", "label": "Equity attributable to owners of parent" } }, "en": { "role": { "documentation": "The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest." } } }, "auth_ref": [ "r23" ] }, "ifrs-full_EquityInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EquityInvestmentsMember", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity investments [member]", "label": "Equity investments [member]" } }, "en": { "role": { "documentation": "This member stands for investments in equity instruments." } } }, "auth_ref": [ "r303", "r309" ] }, "country_FR": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "FR", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofApplicableExchangeRatesUsedtoTranslateFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "FRANCE", "label": "FRANCE" } } }, "auth_ref": [] }, "ifrs-full_EquityMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EquityMember", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity [member]", "label": "Equity [member]" } }, "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } } }, "auth_ref": [ "r7" ] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressesAddressTypeAxis", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Addresses, Address Type", "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AddressTypeDomain", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Address Type", "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://www.genfit.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Location", "label": "Auditor Location" } } }, "auth_ref": [ "r316", "r317", "r318" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://www.genfit.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Name", "label": "Auditor Name" } } }, "auth_ref": [ "r316", "r317", "r318" ] }, "dei_BusinessContactMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "BusinessContactMember", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Business Contact", "label": "Business Contact [Member]", "documentation": "Business contact for the entity" } } }, "auth_ref": [ "r317", "r318" ] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://www.genfit.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Firm ID", "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r316", "r317", "r318" ] }, "ifrs-full_EstimatedFinancialEffectOfContingentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EstimatedFinancialEffectOfContingentAssets", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/CommitmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated financial effect of contingent assets", "label": "Estimated financial effect of contingent assets" } }, "en": { "role": { "documentation": "The amount of the estimated financial effect of possible assets that arise from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within control of the entity." } } }, "auth_ref": [ "r125" ] }, "ifrs-full_NetAssetsLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NetAssetsLiabilities", "crdr": "debit", "calculation": { "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Assets (liabilities)", "label": "Assets (liabilities)" } }, "en": { "role": { "documentation": "The amount of assets less the amount of liabilities." } } }, "auth_ref": [ "r296", "r328" ] }, "ifrs-full_EstimatedFinancialEffectOfContingentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EstimatedFinancialEffectOfContingentLiabilities", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/CommitmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated financial effect of contingent liabilities", "label": "Estimated financial effect of contingent liabilities" } }, "en": { "role": { "documentation": "The amount of the estimated financial effect of contingent liabilities. [Refer: Contingent liabilities [member]]" } } }, "auth_ref": [ "r124" ] }, "ifrs-full_DisclosureOfLoansAndAdvancesToBanksExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfLoansAndAdvancesToBanksExplanatory", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Bank Loans", "label": "Disclosure of loans and advances to banks [text block]" } }, "en": { "role": { "documentation": "The disclosure of loans and advances to banks. [Refer: Loans and advances to banks]" } } }, "auth_ref": [ "r323" ] }, "ifrs-full_NetDeferredTaxAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NetDeferredTaxAssets", "crdr": "debit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets", "label": "Net deferred tax assets" } }, "en": { "role": { "documentation": "The amount of deferred tax assets net of deferred tax liabilities, when the absolute amount of deferred tax assets is greater than the absolute amount of deferred tax liabilities. [Refer: Deferred tax assets; Deferred tax liabilities]" } } }, "auth_ref": [ "r338" ] }, "ifrs-full_TreasurySharesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TreasurySharesMember", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury shares", "label": "Treasury shares [member]" } }, "en": { "role": { "documentation": "This member stands for the entity\u2019s own equity instruments, held by the entity or other members of the consolidated group." } } }, "auth_ref": [ "r7" ] }, "ifrs-full_ExciseTaxPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ExciseTaxPayables", "crdr": "credit", "calculation": { "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails": { "parentTag": "ifrs-full_TradeAndOtherPayables", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.genfit.com/role/TradeandOtherPayablesAdditionalInformationDetails", "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Excise tax payables", "label": "Excise tax payables" } }, "en": { "role": { "documentation": "The amount of payables related to excise tax." } } }, "auth_ref": [ "r335" ] }, "ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense", "crdr": "credit", "calculation": { "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax benefit arising from previously unrecognised tax loss, tax credit or temporary difference of prior period used to reduce current tax expense", "label": "Tax benefit arising from previously unrecognised tax loss, tax credit or temporary difference of prior period used to reduce current tax expense" } }, "en": { "role": { "documentation": "The amount of benefit arising from a previously unrecognised tax loss, tax credit or temporary difference of a prior period that is used to reduce current tax expense. [Refer: Temporary differences [member]; Unused tax losses [member]; Unused tax credits [member]]" } } }, "auth_ref": [ "r280" ] }, "ifrs-full_PerformanceObligationsSatisfiedOverTimeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PerformanceObligationsSatisfiedOverTimeMember", "presentation": [ "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance obligations satisfied over time", "label": "Performance obligations satisfied over time [member]" } }, "en": { "role": { "documentation": "This member stands for performance obligations satisfied over time. An entity satisfies a performance obligation over time, if one of the following criteria is met: (a) the customer simultaneously receives and consumes the benefits provided by the entity\u2019s performance as the entity performs; (b) the entity\u2019s performance creates or enhances an asset (for example, work in progress) that the customer controls as the asset is created or enhanced; or (c) the entity\u2019s performance does not create an asset with an alternative use to the entity and the entity has an enforceable right to payment for performance completed to date. [Refer: Performance obligations [member]]" } } }, "auth_ref": [ "r190" ] }, "ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LaterThanThreeYearsAndNotLaterThanFourYearsMember", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofMaturitiesofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Later than three years and not later than four years", "label": "Later than three years and not later than four years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than three years and not later than four years." } } }, "auth_ref": [ "r194", "r196", "r206", "r304", "r308", "r328" ] }, "ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LaterThanTwoYearsAndNotLaterThanThreeYearsMember", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofMaturitiesofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Later than two years and not later than three years", "label": "Later than two years and not later than three years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than two years and not later than three years." } } }, "auth_ref": [ "r194", "r196", "r206", "r304", "r308", "r328" ] }, "ifrs-full_LeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LeaseLiabilities", "crdr": "credit", "calculation": { "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails": { "parentTag": "gnft_TotalAcquiredLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities", "label": "Lease liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration." } } }, "auth_ref": [ "r192" ] }, "ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PostemploymentBenefitExpenseDefinedContributionPlans", "crdr": "debit", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined contribution plan expense", "label": "Post-employment benefit expense, defined contribution plans" } }, "en": { "role": { "documentation": "The amount of post-employment benefit expense relating to defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods." } } }, "auth_ref": [ "r87" ] }, "ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Patents", "label": "Copyrights, patents and other industrial property rights, service and operating rights [member]" } }, "en": { "role": { "documentation": "This member stands for a class of intangible assets representing copyrights, patents and other industrial property rights, service and operating rights. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r288" ] }, "ifrs-full_PotentialOrdinaryShareTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PotentialOrdinaryShareTransactionsMember", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Potential ordinary share transactions [member]", "label": "Potential ordinary share transactions [member]" } }, "en": { "role": { "documentation": "This member stands for potential ordinary share transactions. [Refer: Ordinary shares [member]]" } } }, "auth_ref": [ "r278" ] }, "ifrs-full_AdjustmentsForFinanceIncomeCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForFinanceIncomeCost", "crdr": "credit", "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "+ Net finance expenses (revenue)", "label": "Adjustments for finance income (cost)" } }, "en": { "role": { "documentation": "Adjustments for net finance income or cost to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income (cost); Profit (loss)]" } } }, "auth_ref": [ "r358" ] }, "ifrs-full_PreferenceSharesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PreferenceSharesMember", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preference shares [member]", "label": "Preference shares [member]" } }, "en": { "role": { "documentation": "This member stands for equity instruments that are senior in some aspects to ordinary shares, but subordinate to debt instruments in terms of claim. [Refer: Ordinary shares [member]]" } } }, "auth_ref": [ "r336" ] }, "ifrs-full_BorrowingCostsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BorrowingCostsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Borrowing costs [abstract]", "label": "Borrowing costs [abstract]" } } }, "auth_ref": [] }, "ifrs-full_Borrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Borrowings", "crdr": "credit", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New debt recognized", "label": "Borrowings" } }, "en": { "role": { "documentation": "The amount of outstanding funds that the entity is obligated to repay." } } }, "auth_ref": [ "r332" ] }, "ifrs-full_BorrowingsByNameAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BorrowingsByNameAxis", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails", "http://www.genfit.com/role/FinancialIncomeandExpensesAdditionalInformationDetails", "http://www.genfit.com/role/FinancialRisksManagementAdditionalInformationDetails", "http://www.genfit.com/role/IncomeTaxNarrativeDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBondsDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofConvertibleBondsDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofMaturitiesofFinancialLiabilitiesDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofOtherLoansandBorrowingsDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings by name [axis]", "label": "Borrowings by name [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r362" ] }, "ifrs-full_BorrowingsAdjustmentToInterestRateBasis": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BorrowingsAdjustmentToInterestRateBasis", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings, adjustment to interest rate basis", "label": "Borrowings, adjustment to interest rate basis" } }, "en": { "role": { "documentation": "The adjustment to the basis (reference rate) used for calculation of the interest rate on borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r362" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_104&doctype=Standard", "URIDate": "2023-03-23" }, "r1": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_a&doctype=Standard", "URIDate": "2023-03-23" }, "r2": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_b&doctype=Standard", "URIDate": "2023-03-23" }, "r3": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_i&doctype=Standard", "URIDate": "2023-03-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r5": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r6": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d&doctype=Standard", "URIDate": "2023-03-23" }, "r7": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106&doctype=Standard", "URIDate": "2023-03-23" }, "r8": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "136", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_136&doctype=Standard", "URIDate": "2023-03-23" }, "r9": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "20", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_20_d&doctype=Standard", "URIDate": "2023-03-23" }, "r10": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_35&doctype=Standard", "URIDate": "2023-03-23" }, "r11": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_a&doctype=Standard", "URIDate": "2023-03-23" }, "r12": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_c&doctype=Standard", "URIDate": "2023-03-23" }, "r13": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_d&doctype=Standard", "URIDate": "2023-03-23" }, "r14": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_e&doctype=Standard", "URIDate": "2023-03-23" }, "r15": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_g&doctype=Standard", "URIDate": "2023-03-23" }, "r16": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_h&doctype=Standard", "URIDate": "2023-03-23" }, "r17": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_i&doctype=Standard", "URIDate": "2023-03-23" }, "r18": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "k", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_k&doctype=Standard", "URIDate": "2023-03-23" }, "r19": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "l", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_l&doctype=Standard", "URIDate": "2023-03-23" }, "r20": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "n", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_n&doctype=Standard", "URIDate": "2023-03-23" }, "r21": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "o", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_o&doctype=Standard", "URIDate": "2023-03-23" }, "r22": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "q", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_q&doctype=Standard", "URIDate": "2023-03-23" }, "r23": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "r", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_r&doctype=Standard", "URIDate": "2023-03-23" }, "r24": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard", "URIDate": "2023-03-23" }, "r25": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "56", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_56&doctype=Standard", "URIDate": "2023-03-23" }, "r26": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "61", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_61_a&doctype=Standard", "URIDate": "2023-03-23" }, "r27": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "61", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_61_b&doctype=Standard", "URIDate": "2023-03-23" }, "r28": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "61", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_61&doctype=Standard", "URIDate": "2023-03-23" }, "r29": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard", "URIDate": "2023-03-23" }, "r30": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "69", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_69&doctype=Standard", "URIDate": "2023-03-23" }, "r31": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard", "URIDate": "2023-03-23" }, "r32": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2023-03-23" }, "r33": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_d&doctype=Standard", "URIDate": "2023-03-23" }, "r34": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2023-03-23" }, "r35": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r36": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r37": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_iv&doctype=Standard", "URIDate": "2023-03-23" }, "r38": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2023-03-23" }, "r39": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79&doctype=Standard", "URIDate": "2023-03-23" }, "r40": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "81A", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_a&doctype=Standard", "URIDate": "2023-03-23" }, "r41": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "81A", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_b&doctype=Standard", "URIDate": "2023-03-23" }, "r42": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "81A", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_c&doctype=Standard", "URIDate": "2023-03-23" }, "r43": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "81B", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81B_a_i&doctype=Standard", "URIDate": "2023-03-23" }, "r44": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "81B", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81B_a_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r45": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "81B", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81B_b_i&doctype=Standard", "URIDate": "2023-03-23" }, "r46": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "81B", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81B_b_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r47": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "82", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_a&doctype=Standard", "URIDate": "2023-03-23" }, "r48": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "82", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_b&doctype=Standard", "URIDate": "2023-03-23" }, "r49": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "82", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_d&doctype=Standard", "URIDate": "2023-03-23" }, "r50": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "91", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_91_a&doctype=Standard", "URIDate": "2023-03-23" }, "r51": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "91", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_91_b&doctype=Standard", "URIDate": "2023-03-23" }, "r52": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "92", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_92&doctype=Standard", "URIDate": "2023-03-23" }, "r53": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "98", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_98_a&doctype=Standard", "URIDate": "2023-03-23" }, "r54": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "98", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_98_b&doctype=Standard", "URIDate": "2023-03-23" }, "r55": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "98", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_98_c&doctype=Standard", "URIDate": "2023-03-23" }, "r56": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "98", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_98_g&doctype=Standard", "URIDate": "2023-03-23" }, "r57": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "99", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_99&doctype=Standard", "URIDate": "2023-03-23" }, "r58": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "10", "IssueDate": "2023-01-01", "Paragraph": "21", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&anchor=para_21&doctype=Standard", "URIDate": "2023-03-23" }, "r59": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_79&doctype=Standard", "URIDate": "2023-03-23" }, "r60": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_a&doctype=Standard", "URIDate": "2023-03-23" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_i&doctype=Standard", "URIDate": "2023-03-23" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_e&doctype=Standard", "URIDate": "2023-03-23" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "g", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g_i&doctype=Standard", "URIDate": "2023-03-23" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "g", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g&doctype=Standard", "URIDate": "2023-03-23" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI", "URIDate": "2023-03-23" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_c&doctype=Standard", "URIDate": "2023-03-23" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2023-03-23" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_iv&doctype=Standard", "URIDate": "2023-03-23" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_v&doctype=Standard", "URIDate": "2023-03-23" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2023-03-23" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73&doctype=Standard", "URIDate": "2023-03-23" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "75", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_75_b&doctype=Standard", "URIDate": "2023-03-23" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "77", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_77_f&doctype=Standard", "URIDate": "2023-03-23" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI", "URIDate": "2023-03-23" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "138", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_138&doctype=Standard", "URIDate": "2023-03-23" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "140", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_140_a&doctype=Standard", "URIDate": "2023-03-23" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "141", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_141_a&doctype=Standard", "URIDate": "2023-03-23" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "141", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_141_b&doctype=Standard", "URIDate": "2023-03-23" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "141", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_141_c&doctype=Standard", "URIDate": "2023-03-23" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "141", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_141_d&doctype=Standard", "URIDate": "2023-03-23" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "142", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_142&doctype=Standard", "URIDate": "2023-03-23" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "145", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_145_a&doctype=Standard", "URIDate": "2023-03-23" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "145", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_145&doctype=Standard", "URIDate": "2023-03-23" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_53&doctype=Standard", "URIDate": "2023-03-23" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Section": "Scope", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS19_g2-7_TI", "URIDate": "2023-03-23" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "36", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_36_a&doctype=Standard", "URIDate": "2023-03-23" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "36", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_36_b&doctype=Standard", "URIDate": "2023-03-23" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2023-01-01", "Paragraph": "48", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&anchor=para_48&doctype=Standard", "URIDate": "2023-03-23" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2023-01-01", "Paragraph": "52", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2023-03-23" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2023-01-01", "Paragraph": "52", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&anchor=para_52_b&doctype=Standard", "URIDate": "2023-03-23" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS21_g51-57_TI", "URIDate": "2023-03-23" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2023-03-23" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2023-03-23" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2023-03-23" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17&doctype=Standard", "URIDate": "2023-03-23" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "18", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2023-03-23" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "19", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_19_d&doctype=Standard", "URIDate": "2023-03-23" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "19", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_19&doctype=Standard", "URIDate": "2023-03-23" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard", "URIDate": "2023-03-23" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Section": "Disclosures", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI", "URIDate": "2023-03-23" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2023-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2023-en-r&anchor=para_35_b_iv&doctype=Standard", "URIDate": "2023-03-23" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2023-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "ix", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2023-en-r&anchor=para_35_b_ix&doctype=Standard", "URIDate": "2023-03-23" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2023-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2023-en-r&anchor=para_35_b_v&doctype=Standard", "URIDate": "2023-03-23" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2023-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2023-en-r&anchor=para_35_b_viii&doctype=Standard", "URIDate": "2023-03-23" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2023-01-01", "Paragraph": "16", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2023-01-01", "Paragraph": "16", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b&doctype=Standard", "URIDate": "2023-03-23" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2023-03-23" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2023-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard", "URIDate": "2023-03-23" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2023-01-01", "Paragraph": "67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_67&doctype=Standard", "URIDate": "2023-03-23" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2023-01-01", "Paragraph": "70", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2023-03-23" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI", "URIDate": "2023-03-23" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2023-01-01", "Paragraph": "126", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_126_b&doctype=Standard", "URIDate": "2023-03-23" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2023-01-01", "Paragraph": "129", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_129_b&doctype=Standard", "URIDate": "2023-03-23" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2023-01-01", "Paragraph": "130", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_130_b&doctype=Standard", "URIDate": "2023-03-23" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2023-01-01", "Paragraph": "130", "Subparagraph": "d", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_130_d_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2023-01-01", "Paragraph": "84", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_84_a&doctype=Standard", "URIDate": "2023-03-23" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2023-01-01", "Paragraph": "84", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_84_c&doctype=Standard", "URIDate": "2023-03-23" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2023-01-01", "Paragraph": "84", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_84_d&doctype=Standard", "URIDate": "2023-03-23" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2023-01-01", "Paragraph": "84", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_84&doctype=Standard", "URIDate": "2023-03-23" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2023-01-01", "Paragraph": "86", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_86_a&doctype=Standard", "URIDate": "2023-03-23" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2023-01-01", "Paragraph": "89", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_89&doctype=Standard", "URIDate": "2023-03-23" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS37_g84-92_TI", "URIDate": "2023-03-23" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_a&doctype=Standard", "URIDate": "2023-03-23" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2023-03-23" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_vii&doctype=Standard", "URIDate": "2023-03-23" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2023-03-23" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118&doctype=Standard", "URIDate": "2023-03-23" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "122", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_122_a&doctype=Standard", "URIDate": "2023-03-23" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_126&doctype=Standard", "URIDate": "2023-03-23" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS38_g118-128_TI", "URIDate": "2023-03-23" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2023-01-01", "Paragraph": "32A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_32A&doctype=Standard", "URIDate": "2023-03-23" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2023-01-01", "Paragraph": "76", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_76&doctype=Standard", "URIDate": "2023-03-23" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2023-03-23" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_d&doctype=Standard", "URIDate": "2023-03-23" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2023-01-01", "Paragraph": "50", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_50&doctype=Standard", "URIDate": "2023-03-23" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2023-03-23" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_10&doctype=Standard", "URIDate": "2023-03-23" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "18", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2023-03-23" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_25&doctype=Standard", "URIDate": "2023-03-23" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_28&doctype=Standard", "URIDate": "2023-03-23" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_31&doctype=Standard", "URIDate": "2023-03-23" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35&doctype=Standard", "URIDate": "2023-03-23" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard", "URIDate": "2023-03-23" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "46", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_46&doctype=Standard", "URIDate": "2023-03-23" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "50", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2023-03-23" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Section": "Presentation of a statement of cash flows", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS07_g10-17_TI", "URIDate": "2023-03-23" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "f", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_f_i&doctype=Standard", "URIDate": "2023-03-23" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "29", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_29_c_i&doctype=Standard", "URIDate": "2023-03-23" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "29", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_29&doctype=Standard", "URIDate": "2023-03-23" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "30", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_30_b&doctype=Standard", "URIDate": "2023-03-23" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "49", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_49_b_i&doctype=Standard", "URIDate": "2023-03-23" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2023-03-23" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2023-03-23" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2023-03-23" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "10", "IssueDate": "2023-01-01", "Paragraph": "22", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=10&code=ifrs-tx-2023-en-r&anchor=para_22&doctype=Standard", "URIDate": "2023-03-23" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "12", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_12_e&doctype=Standard", "URIDate": "2023-03-23" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "12", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_12_f&doctype=Standard", "URIDate": "2023-03-23" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "21", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_21_a_iv&doctype=Standard", "URIDate": "2023-03-23" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ix", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B13", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B13", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_e&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B13", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_f&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B13", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B16&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B4", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B4_d&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2023-03-23" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2023-03-23" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2023-03-23" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS13_g91-99_TI", "URIDate": "2023-03-23" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "14", "IssueDate": "2023-01-01", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2023-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2023-03-23" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "14", "IssueDate": "2023-01-01", "Section": "Explanation of recognised amounts", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS14_g32-36_TI", "URIDate": "2023-03-23" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "105", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_105&doctype=Standard", "URIDate": "2023-03-23" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "113", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_113_a&doctype=Standard", "URIDate": "2023-03-23" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "114", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_114&doctype=Standard", "URIDate": "2023-03-23" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "116", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_116_a&doctype=Standard", "URIDate": "2023-03-23" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "119", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_119&doctype=Standard", "URIDate": "2023-03-23" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "120", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_120_b_i&doctype=Standard", "URIDate": "2023-03-23" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "124", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_124&doctype=Standard", "URIDate": "2023-03-23" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2023-03-23" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2023-03-23" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "53", "Subparagraph": "j", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_j&doctype=Standard", "URIDate": "2023-03-23" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "94", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_94&doctype=Standard", "URIDate": "2023-03-23" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "95", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_95&doctype=Standard", "URIDate": "2023-03-23" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "97", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_97&doctype=Standard", "URIDate": "2023-03-23" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "109", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_109&doctype=Standard", "URIDate": "2023-03-23" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "109A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_109A&doctype=Standard", "URIDate": "2023-03-23" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2023-03-23" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "120", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_120&doctype=Standard", "URIDate": "2023-03-23" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "124", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_124&doctype=Standard", "URIDate": "2023-03-23" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "125", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_125&doctype=Standard", "URIDate": "2023-03-23" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "127", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_127&doctype=Standard", "URIDate": "2023-03-23" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "128", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_128_a_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "128", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_128_a&doctype=Standard", "URIDate": "2023-03-23" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "132", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_132_b&doctype=Standard", "URIDate": "2023-03-23" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "C32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_C32&doctype=Appendix&subtype=C", "URIDate": "2023-03-23" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "44", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_44&doctype=Standard", "URIDate": "2023-03-23" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_a&doctype=Standard", "URIDate": "2023-03-23" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_i&doctype=Standard", "URIDate": "2023-03-23" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_vi&doctype=Standard", "URIDate": "2023-03-23" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_c&doctype=Standard", "URIDate": "2023-03-23" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2023-03-23" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard", "URIDate": "2023-03-23" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "47", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_47_a_i&doctype=Standard", "URIDate": "2023-03-23" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2023-03-23" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2023-01-01", "Paragraph": "B64", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_a&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2023-01-01", "Paragraph": "B64", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_b&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2023-01-01", "Paragraph": "B64", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_c&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2023-01-01", "Paragraph": "B64", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_d&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2023-01-01", "Paragraph": "B64", "Subparagraph": "f", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_f_i&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2023-01-01", "Paragraph": "B64", "Subparagraph": "j", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_j&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2023-01-01", "Paragraph": "B67", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67_c&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2023-01-01", "Paragraph": "B67", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2023-01-01", "Section": "Disclosures application of paragraphs 59 and 61", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&doctype=Appendix&subtype=B&dita_xref=IFRS03_gB64-B67_TI", "URIDate": "2023-03-23" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2023-01-01", "Paragraph": "33", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2023-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2023-03-23" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "21C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_21C&doctype=Standard", "URIDate": "2023-03-23" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "23B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_23B_a&doctype=Standard", "URIDate": "2023-03-23" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_25&doctype=Standard", "URIDate": "2023-03-23" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_33&doctype=Standard", "URIDate": "2023-03-23" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard", "URIDate": "2023-03-23" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35H", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35H_b_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35H", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2023-03-23" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35I&doctype=Standard", "URIDate": "2023-03-23" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35K", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35K&doctype=Standard", "URIDate": "2023-03-23" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35M", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35M_b_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35M", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2023-03-23" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "36", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_36&doctype=Standard", "URIDate": "2023-03-23" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "39", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_39_a&doctype=Standard", "URIDate": "2023-03-23" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "39", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_39_b&doctype=Standard", "URIDate": "2023-03-23" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "42E", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_42E_e&doctype=Standard", "URIDate": "2023-03-23" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "42I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_42I&doctype=Standard", "URIDate": "2023-03-23" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_6&doctype=Standard", "URIDate": "2023-03-23" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard", "URIDate": "2023-03-23" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "8", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8_a&doctype=Standard", "URIDate": "2023-03-23" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "8", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8_h&doctype=Standard", "URIDate": "2023-03-23" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "B52", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B52&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Section": "Defined terms", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA_TI", "URIDate": "2023-03-23" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "23", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_a&doctype=Standard", "URIDate": "2023-03-23" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "23", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_c&doctype=Standard", "URIDate": "2023-03-23" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "23", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_d&doctype=Standard", "URIDate": "2023-03-23" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "23", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_h&doctype=Standard", "URIDate": "2023-03-23" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard", "URIDate": "2023-03-23" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2023-03-23" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_a&doctype=Standard", "URIDate": "2023-03-23" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2023-03-23" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2023-03-23" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_e&doctype=Standard", "URIDate": "2023-03-23" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_32&doctype=Standard", "URIDate": "2023-03-23" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "33", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_33_a&doctype=Standard", "URIDate": "2023-03-23" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2023-03-23" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard", "URIDate": "2023-03-23" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS08_g20-24_TI", "URIDate": "2023-03-23" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "9", "IssueDate": "2023-01-01", "Paragraph": "7.2.34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2023-en-r&anchor=para_7.2.34&doctype=Standard", "URIDate": "2023-03-23" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "9", "IssueDate": "2023-01-01", "Paragraph": "7.2.42", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2023-en-r&anchor=para_7.2.42&doctype=Standard", "URIDate": "2023-03-23" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expired 2023-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "12", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_12&doctype=Standard&book=b", "URIDate": "2023-03-23" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expired 2023-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "8", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_8_c&doctype=Standard&book=b", "URIDate": "2023-03-23" }, "r269": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "102", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_102&doctype=Standard", "URIDate": "2023-03-23" }, "r270": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard", "URIDate": "2023-03-23" }, "r271": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_108&doctype=Standard", "URIDate": "2023-03-23" }, "r272": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "68", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_68&doctype=Standard", "URIDate": "2023-03-23" }, "r273": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_70&doctype=Standard", "URIDate": "2023-03-23" }, "r274": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2023-03-23" }, "r275": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2023-03-23" }, "r276": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "82A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82A&doctype=Standard", "URIDate": "2023-03-23" }, "r277": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "IG6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2023-03-23" }, "r278": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "10", "IssueDate": "2023-01-01", "Paragraph": "22", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&anchor=para_22_f&doctype=Standard", "URIDate": "2023-03-23" }, "r279": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "10", "IssueDate": "2023-01-01", "Paragraph": "22", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&anchor=para_22_i&doctype=Standard", "URIDate": "2023-03-23" }, "r280": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "80", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_80_e&doctype=Standard", "URIDate": "2023-03-23" }, "r281": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "37", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_37_g&doctype=Standard", "URIDate": "2023-03-23" }, "r282": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "37", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_37_h&doctype=Standard", "URIDate": "2023-03-23" }, "r283": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "147", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_147_c&doctype=Standard", "URIDate": "2023-03-23" }, "r284": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "32", "IssueDate": "2023-01-01", "Paragraph": "IE33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2023-en-r&anchor=para_IE33&doctype=Illustrative%20Examples", "URIDate": "2023-03-23" }, "r285": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "36", "IssueDate": "2023-01-01", "Paragraph": "127", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_127&doctype=Standard", "URIDate": "2023-03-23" }, "r286": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "37", "IssueDate": "2023-01-01", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_70&doctype=Standard", "URIDate": "2023-03-23" }, "r287": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "119", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_119_c&doctype=Standard", "URIDate": "2023-03-23" }, "r288": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "119", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_119_e&doctype=Standard", "URIDate": "2023-03-23" }, "r289": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "14", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_14_f&doctype=Standard", "URIDate": "2023-03-23" }, "r290": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "16", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_16_a&doctype=Standard", "URIDate": "2023-03-23" }, "r291": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "16", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_16_b&doctype=Standard", "URIDate": "2023-03-23" }, "r292": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2023-03-23" }, "r293": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_c&doctype=Standard", "URIDate": "2023-03-23" }, "r294": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2023-03-23" }, "r295": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Section": "A Statement of cash flows for an entity other than a financial institution", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI", "URIDate": "2023-03-23" }, "r296": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "IG63", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_IG63&doctype=Implementation%20Guidance", "URIDate": "2023-03-23" }, "r297": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B10", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r298": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "B6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_B6&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r299": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "IE63", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_IE63&doctype=Illustrative%20Examples", "URIDate": "2023-03-23" }, "r300": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53&doctype=Standard", "URIDate": "2023-03-23" }, "r301": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2023-03-23" }, "r302": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35N", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35N&doctype=Standard", "URIDate": "2023-03-23" }, "r303": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_6&doctype=Standard", "URIDate": "2023-03-23" }, "r304": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "B11", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r305": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "B35", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r306": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "B35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r307": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "IG20C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_IG20C&doctype=Implementation%20Guidance", "URIDate": "2023-03-23" }, "r308": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "IG31A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance", "URIDate": "2023-03-23" }, "r309": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "IG40B", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_IG40B&doctype=Implementation%20Guidance", "URIDate": "2023-03-23" }, "r310": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard", "URIDate": "2023-03-23" }, "r311": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2023-03-23" }, "r312": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r313": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r314": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r317": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r318": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r319": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r321": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r322": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r323": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "10", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_10_e&doctype=Standard", "URIDate": "2023-03-23" }, "r324": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_104&doctype=Standard", "URIDate": "2023-03-23" }, "r325": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d&doctype=Standard", "URIDate": "2023-03-23" }, "r326": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106&doctype=Standard", "URIDate": "2023-03-23" }, "r327": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_108&doctype=Standard", "URIDate": "2023-03-23" }, "r328": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "112", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard", "URIDate": "2023-03-23" }, "r329": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_117&doctype=Standard", "URIDate": "2023-03-23" }, "r330": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "20", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_20_d&doctype=Standard", "URIDate": "2023-03-23" }, "r331": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_35&doctype=Standard", "URIDate": "2023-03-23" }, "r332": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard", "URIDate": "2023-03-23" }, "r333": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2023-03-23" }, "r334": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2023-03-23" }, "r335": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78&doctype=Standard", "URIDate": "2023-03-23" }, "r336": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2023-03-23" }, "r337": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "85", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_85&doctype=Standard", "URIDate": "2023-03-23" }, "r338": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "g", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g_i&doctype=Standard", "URIDate": "2023-03-23" }, "r339": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_37&doctype=Standard", "URIDate": "2023-03-23" }, "r340": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2023-03-23" }, "r341": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "135", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_135_b&doctype=Standard", "URIDate": "2023-03-23" }, "r342": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "141", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_141&doctype=Standard", "URIDate": "2023-03-23" }, "r343": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "144", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_144&doctype=Standard", "URIDate": "2023-03-23" }, "r344": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "171", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_171&doctype=Standard", "URIDate": "2023-03-23" }, "r345": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "9", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_9&doctype=Standard", "URIDate": "2023-03-23" }, "r346": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "21", "IssueDate": "2023-01-01", "Paragraph": "52", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2023-03-23" }, "r347": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "37", "IssueDate": "2023-01-01", "Paragraph": "88", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_88&doctype=Standard", "URIDate": "2023-03-23" }, "r348": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2023-03-23" }, "r349": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2023-03-23" }, "r350": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118&doctype=Standard", "URIDate": "2023-03-23" }, "r351": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "119", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_119&doctype=Standard", "URIDate": "2023-03-23" }, "r352": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "40", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2023-03-23" }, "r353": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "41", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2023-03-23" }, "r354": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "14", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_14&doctype=Standard", "URIDate": "2023-03-23" }, "r355": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_16&doctype=Standard", "URIDate": "2023-03-23" }, "r356": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17&doctype=Standard", "URIDate": "2023-03-23" }, "r357": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "20", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2023-03-23" }, "r358": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard", "URIDate": "2023-03-23" }, "r359": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard", "URIDate": "2023-03-23" }, "r360": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard", "URIDate": "2023-03-23" }, "r361": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "39", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_39&doctype=Standard", "URIDate": "2023-03-23" }, "r362": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard", "URIDate": "2023-03-23" } } }